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Abstract 
Breast cancer is the most common cancer in the UK today, with incidence rates 
rising steadily. Prognosis is improving but patients with metastatic disease only 
have a 15% chance of surviving 5 years beyond prognosis. Therefore, factors 
influencing the metastatic spread of breast cancer require better understanding. 
 
The matrix metalloproteinases (MMPs) are a family of proteases thought to 
promote metastasis due to their matrix degradation capabilities. MMP-8 
however has been discovered to be anti-tumourigenic in many cancers, and 
anti-metastatic in breast cancer. This occurs through unknown mechanisms, so 
this work sought to gain further insight into the functional effects of MMP-8. In 
the literature it has been suggested that MMP-8 is tumour protective through its 
role in regulating innate immune responses and preventing chronic 
inflammation. This occurs through activational cleavage of a pro-inflammatory 
chemokine, Interleukin-8 (IL-8). 
 
Using an in vitro over-expression model it is shown in this thesis that MMP-8 
reduced 2D random migration and scratch wound closure. It also increased cell 
adhesion and reduced colony formation and prevented primary tumour growth 
in mice. These data indicate an anti-tumourigenic role for MMP-8. 
Biochemically, MMP-8 induced expression of IL-8 in mammary carcinoma cells, 
and also the expression of a pro-inflammatory cytokine IL-6, dependent on its 
catalytic activity. This required NFĸB signalling and IL-6 also required Protease 
Activated receptor-2. This occurred following transient expression of MMP-8, 
and also in rare stably transfected clones that expressed MMP-8 long-term. 
However, wild-type MMP-8 was not tolerated by breast cancer cells and was 
epigenetically silenced, potentially as a mechanism to overcome growth 
inhibitory effects exerted by wild-type MMP-8. In these rare “long-term” MMP-8 
expressing cells phenotypic alterations occurred, including elevated IL-6 and IL-
8 expression independent of MMP-8, and a self-reinforcing loop between MMP-
8, IL-6 and IL-8.  
 
3 
 
This pathway may contribute to the anti-tumourigenic and metastasis 
suppressive effects of MMP-8, or it may represent a cellular response to 
overcome the anti-tumour actions of the protease.   
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Chapter 1- Introduction 
1.1 Breast Cancer 
 
Breast cancer is largely a disease that affects Western Europe and the USA and 
is the most common cancer in the UK today, with women having a 1 in 8 lifetime 
risk of developing the disease, which is an increase from the 1 in 9 lifetime risk 
published until 2010 (Cancer Research UK). Incidence rates of breast cancer are 
increasing, with an increase of 6% over the last 10 years, presumably due to our 
aging population, environmental factors and life-style choices. However, 
survival rates in the UK have improved dramatically; with over three-quarters 
of women surviving at least 10 years post diagnosis and almost two-thirds of 
women surviving beyond 20 years of diagnosis. This is likely attributed to an 
increase in education through ‘breast awareness’ programmes and the 
introduction of wide-spread screening programmes, which have been estimated 
to save about 1300 lives a year. However, once a patient has aggressive, 
metastatic breast cancer which has spread to distant organs, survival is 
dramatically reduced to only 15% of patients surviving beyond 5 years from 
diagnosis (statistics from Cancer Research UK 22-03-13). Therefore, breast 
cancer progression, and especially factors influencing metastatic spread of the 
disease, need to be better understood in order to prevent cancers reaching this 
stage.   
 
The normal breast is primarily made out of fatty tissue which contains lymph 
nodes, milk glands and milk ducts (figure 1.1). Cancer can arise from cell types 
of any of these structures. Carcinomas are the most common form of breast 
tumours and arise from epithelial cells such as those lining the milk duct and 
lobules (milk glands) while sarcomas arise from fatty tissue. Ductal carcinoma 
arising from the milk ducts is by far the most commonly seen type of breast 
cancer. The duct is lined by the basement membrane (BM), followed by 
myoepithelial cells and then the secretory luminal epithelial cells.  The 
myoepithelial cells separate the luminal epithelial cells of the breast duct from 
Chapter 1- Introduction 
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the BM (see figure 1.9) surrounding the duct. Their main function in the breast 
is mediating interactions between the layers, which is necessary for maintaining 
normal breast function. They also have a structural role as they are contractile 
and are involved in ejaculation of milk from the ducts [6].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the clinic breast cancer is assessed according to the TNM system (Tumour 
size, Node status, Metastasis). This system takes into account the size of the 
tumour (T), whether it has spread to the lymph nodes (N) and whether it has 
colonised distant organs (M), with the lungs and lymph glands being most 
commonly affected organs in breast cancer.  Further classification comes from 
how fast the mass grows (stage), its differentiation status (grade) and its 
hormone receptor status. The first 3 stages of breast cancer are illustrated in 
figure 1.2, with stage 4 cancer involving metastatic spread to distant organs.  
Breast cancer subtypes are differentiated by the expression of the Estrogen 
Receptor (ER), Progesterone Receptor (PR) and Human Epidermal Growth 
Factor Receptor 2 (HER2) (table 1.1). Luminal breast cancers are the most 
common, and easiest to treat due to their responsiveness to hormone therapies 
such as Tamoxifen or aromatase inhibitors, and HER2 positive cancers can be 
treated by Herceptin or other neoadjuvents.  Basal type cancers on the other 
hand are non-responsive to such treatments so consequently patients with this 
sub-type have a worse prognosis.  
Figure 1.1: Normal breast structure. Cancer generally arises in the lobes 
and milk ducts (Cancer Research UK) 
Chapter 1- Introduction 
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Breast Cancer Subtype ER PR HER2 
Luminal A  +   +    - 
Luminal B  +   +    + 
HER2-enriched   -   -    + 
Basal   -   -     - 
Table 1.1:  Breast cancer subtypes according to hormone receptor status. 
Generated from [2].  
Figure 1.2: TNM grading system. Tumour is small with no lymph node 
involvement in stage 1 breast cancer, increasing through the 4 stages the 
tumour increases in size and spreads to the lymph nodes (stages 2 and 3) 
and to distant organs in stage 4. Adapted from Cancer Research UK 
(http://www.cancerresearchuk.org/cancer-help/type/breast 
cancer/treatment/tnm-breast-cancer-staging).  
Chapter 1- Introduction 
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Breast cancer occurs in a multi-step process from the original neoplasm to 
metastatic disease, (see figure 1.3), although it must be noted that not all 
cancers follow this strict progression. In the clinic, 75% of breast cancer cases 
diagnosed are at the Ductal Carcinoma In Situ (DCIS) stage which occurs when 
cells within the duct become hyperproliferative and take on an altered 
phenotype from the normal ductal cells due to genetic alterations.  At this stage 
the tumour is contained and non-invasive so in most cases can be easily treated 
by surgery (either a lumpectomy or total mastectomy). If DCIS goes undetected 
the cancer cells can invade through the basement membrane and metastasise to 
distant organs such as the lymph nodes, lungs, liver, bone and brain [8]. This is 
the stage when prognosis is very poor, and treatment is generally just palliative.  
 
 
 
 
 
 
 
 
 
  
Figure 1.3: Breast cancer progression. Histological cross section of 
a milk duct showing a model of the progression from normal breast 
tissue to DCIS and then to invasive carcinoma. The cells of the duct 
acquire genetic changes which result in the cells undergoing 
uncontrolled division. These cells can then become ‘atypical’ as their 
shape changes. Women with such cells in their breast are at a high 
risk of developing DCIS [7].  
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1.2. Matrix Metalloproteinases (MMPs) 
The matrix metalloproteinases form a 23 member subfamily of the metzincin 
superfamily of metalloproteinases. They are endopeptidases and are broadly 
classed according to their target substrate and domain structure: the 
collagenases (MMPs-1,-8,-13), cleaving collagen; the stromelysins (MMPs-3,-10) 
cleaving most extracellular proteins including collagens (not Type I), 
proteoglycans, laminin, fibronectin and elastin; the gelatinases (MMPs-2,-9) 
cleaving gelatin; the matrilysins (MMPs-7, -26) cleaving proteoglycans and 
fibronectin; and the membrane type (MT) MMPs cleaving range of substrates 
including collagens and Cadherins. All members are secreted and all are freely 
diffusible, with the exception of the MT-MMPs. The membrane-type MMPs 
(MMPs-14,-15,-16,-24, or MT-MMP -1,-2,-3,-5 respectively) have a 
transmembrane domain and an intracellular cytoplasmic tail, or a glycosyl 
phosphatidyl inositol (GPI) anchor (MMPs-17 and -25 and MT-4 and -6 MMPs). 
MMPs -23A and -23B are type II transmembrane proteases and have an IgG-like 
domain as opposed to a membrane spanning domain [9]. Structurally, all MMPs 
require a zinc ion at their catalytic site for activity, have a pro-peptide domain 
and a signal peptide but vary with respect to the other domains (figure 1.4). The 
majority of the MMPs are secreted as inactive zymogens (with the exception of 
MMP-11, -28 and the MT-MMPs), only being activated after removal of the 
propeptide domain through proteolytic cleavage. This releases the “cysteine 
switch” which is the inhibitory binding of the active-site zinc ion and a 
conserved cysteine residue that holds the MMP in an inactive conformation [1] . 
Activation is carried out by various proteases, such as the serine protease uPA 
and other MMPs (figure 1.5). They can also be activated artificially in the 
laboratory by amino-phenyl mercuric acetate (APMA) and trypsin.  
Collectively MMPs can degrade all components of the extracellular matrix, 
which is primarily composed of collagens, but also elastins, laminins, 
glycoproteins and proteoglycans so it is imperative that expression is under 
tight regulatory control. MMP expression is low in most normal tissues, but can 
increase under certain physiological (embryogenesis, ovulation) and 
pathological conditions. Excess MMP expression is associated with disease 
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states such as arthritis whereby increased MMP expression associated with the 
disease results in destruction of connective tissue and cartilage surrounding the 
joints [10]. Up-regulation of MMPs is however required in some pathological 
conditions. MMPs have a principal role in wound healing, with their expression 
levels being tightly regulated at different stages throughout the process. For 
example, MMP1 expression is increased during re-epithelialisation but switched 
off once the wound is repaired, whereas MMPs 7 and 9 are expressed at their 
highest levels during wound epithelial differentiation (reviewed in [11]), with 
some MMP knockout mice having wound healing defects (MMP3 [12], MMP7 
[13], and MMP8 [14]).  
 
MMP regulation is complex and occurs through a number of mechanisms on 
different levels. MMPs are regulated at  the transcriptional level, with MMP 
promoters having binding sites for transcription factors associated with growth 
factor activity and inflammatory pathways such as NFĸB, AP-1, p53 and SP-1 
[15]. Epigenetic regulation can also occur via histone acetylation and DNA 
methylation, with mRNA stability (possibly through the action of miRNAs) also 
being a factor [15]. In addition, some MMP promoters contain polymorphisms 
which can influence the level of the MMP expression [16]. Post-translational 
control is achieved by spatial and temporal control of pro-enzyme activation, 
and some MMPs are also inhibited by other proteins, such as plasma α-2 
macroglobulin [17, 18]. The chief regulators of active MMPs are the endogenous 
tissue inhibitors of metalloproteinases (TIMPs). There are four human TIMPs (-
1, -2, -3 and -4). TIMPs -1, -2 and -4 are secreted, and -2 and -3 are able to 
associate with the MT-MMPs at the cell membrane [18], where TIMP-3 is 
anchored [19]. Collectively, all the TIMPs can inhibit all the active MMPs, along 
with some members of related metalloproteases families such as the ADAMS 
and  ADAMTSs (a disintegrin and metalloproteinase with a thrombospondin 
type 1 motif). The only exception is TIMP-1 which does not effectively inhibit 
the MT-MMPs. TIMP-2 is interesting as it has a dual role in both inhibition and 
activation of MMPs in that it is actually involved in the activation of proMMP2 
by binding to it at the cell surface bringing it in close proximity to MT1-MMP, for 
activation [20].   
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Figure 1.4: Domain structures and classification of the MMPs. 
MMPs are categorised according to their structure and function. 
Adapted from [1].  
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1.2.1 MMPs in Cancer 
 
It was first postulated that MMPs were heavily involved in the promotion of 
metastasis, due to their collective ability to degrade the extracellular matrix 
surrounding the primary tumour and thus clearing a path for tumour cells to 
migrate through and disseminate to distant organs. However, more recently 
MMPs have been found to have roles in the entire process of tumourigenesis, 
from initial tumour promotion, to tumour survival and growth, angiogenesis, to 
the metastatic spread of the disease and the associated inflammation [4, 21] 
(figure 1.6). This is through manipulation of the tumour microenvironment in 
addition to matrix remodelling, as despite their complex involvement in cancer, 
MMPs are mainly produced by cells within the stroma and not the cancer cells 
themselves [22]. The only exceptions are MMP-7 which is predominantly 
expressed by cancer cells but can also be expressed by host inflammatory cells 
[22] and MT4-MMP,  which in human breast cancers is seen in tumour epithelial 
cells as opposed to normal epithelial cells. Interestingly this is at the protein 
level only as mRNA levels between the two cell types is comparable [23].  The 
tumour stroma consists of a variety of cell types, such as fibroblasts, neutrophils 
and macrophages and endothelial cells, all of which produce MMPs. Many result 
Figure 1.5: MMP cross-activation [1].  MMPs can activate each 
other through proteolytic cleavage to release the cysteine  switch.  
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in acceleration of tumour growth [22], and can induce the epithelial to 
mesenchymal transition (EMT) [24, 25], a key event that occurs within cancer 
cells as they progress to malignancy. As a consequence MMPs were the target of 
cancer therapeutic drug trials. 
 
Clinical trials with synthetic broad spectrum MMP inhibitors were fraught with 
complications and were generally unsuccessful, resulting in the trials being 
abandoned [21]. Promising results were seen in animals treated with BB94, a 
broad spectrum MMP inhibitor, and was found to exert its most prominent 
effects in early stage cancer, reducing the angiogenic switch by 50% [11]. 
However, the human phase III trials were carried out on patients with advanced 
cancer. This was for both ethical considerations and at this time MMPs were 
only thought to influence the later stages of cancer, at which point the inhibitors 
appeared to be significantly less effective [21].  
 
A highly probable additional reason for the failure of the clinical trials is that 
MMPs have subsequently been found to have differential roles in cancer 
progression. Some MMPs have been found to have protective effects against 
cancer (figure 1.7), making them anti-targets for MMP inhibitors, whereas some 
have both anti-and pro-tumourgenic effects [22, 26]. For example, expression of 
MMP3 has been found to be protective against squamous cell carcinoma [27] 
following chemical carcinogen treatment of Mmp3 knockout and wild-type mice, 
but can also induce angiogenesis [28] . Mmp9 knockout mice exhibit reduced 
incidence of tumours compared to wild-type mice, but the tumours are more 
aggressive [29] suggesting that it exerts different effects at late and early stages 
of tumourigenesis. For a comprehensive review of MMPs with anti-
tumourigenic functions see Decock et al (2011) [3]. The first MMP discovered to 
predominantly exert protective effects in cancer, and thus making it an anti-
target for cancer treatment, was MMP-8.  
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Figure 1.6: The multiple roles of MMPs in cancer progression. Recently 
MMPs have been discovered to be involved in all aspects of tumourigenesis 
from invasion, angiogenesis, regulation of inflammation, and the 
development of a metastatic niche [4].   
Figure 1.7: Anti-tumourigenic actions of some MMPs. The stage 
in tumour progression at which the MMP is acting to counteract 
tumour progression. Generated from data presented in a review on 
ani-tumourigenic MMPs by Decock et al., (2011) [3]. 
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1.3 MMP-8 
 
MMP-8, also known as collagenase 2 or neutrophil collagenase, was first cloned 
in 1990 [30, 31]. Its main source is the neutrophils but has been shown to be 
expressed widely in different cell types such as epithelial and endothelial cells, 
fibroblasts, keratinocytes, smooth muscle cells and chondrocytes [32]. MMP-8 is 
secreted as an inactive zymogen. In the neutrophils, pro-MMP-8 is stored in the 
granules, due to its high level of glycosolation [30-32], and co-localises with 
lactoferrin [33] until required. It is activated extracellularly either by 
autocatalytic cleavage,  chemical modification,  reactive oxygen species,   
stromelysins 1 (MMP-3) and 2 (MMP-10) which release the cysteine switch 
(reviewed in [32]), and Cathepsin G and chromotrypsin [34]. A membrane-
bound form of MMP-8 that is resistant to TIMP inhibition has also been reported 
[35, 36]. As for all MMPs, regulation of MMP-8 expression at both the protein 
and RNA level is under tight control,  but has been shown to be upregulated by 
physiological factors such as hypoxia [37] and cytokines [38, 39]. Clinically, 
MMP-8 has mainly been implicated in a host of inflammatory conditions 
including atheroma [40], asthma [41], arthritis [42, 43] among many others 
(reviewed in [44]), and also in  association with pathologies such as wound 
healing [14, 45-48], peridontitis  [49, 50] and arterial disease [51]. Such 
research was primarily carried out using Mmp8 knockout mouse models and in 
vitro model systems. The Mmp8 knockout mouse provided the first evidence of 
MMP-8 having anti-tumourigenic properties, which has sparked further 
research into the anti-cancer functions of MMP-8.  
 
1.3.1 MMP-8 in the normal breast 
 
It has previously been discovered (Edwards Lab) that in the normal, non-
cancerous breast, MMP8 is expressed in the myoepithelial cells ([52] and Simon 
Pilgrim, Edwards Lab, UEA, unpublished) (figure 1.8A), which are a cellular 
layer in the ducts and lobules of the breast that lay between the luminal 
epithelial cells and the basement membrane (figure 1.8B). The myoepithelial 
cells express a number of key markers (see table 1.2) including alpha-Smooth 
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Muscle Actin (α-SMA) which is essential for their role in milk ejaculation. They 
also express integrins indicating that they are able to propagate and receive 
cellular signals and are involved in maintaining cell polarity.  There is evidence 
that the myoepithelial cells are able to synthesise the ductal basement 
membrane [53], although this comes from rat rather than human models. 
Importantly, myoepithelial cells have a role in breast tumour suppression, 
giving out paracrine signals that result in the down-regulation of tumourigenic 
MMPs in surrounding cells. For example, when primary myoepithelial cells were 
grown with various invasive breast cancer cell lines in a co-culture invasion 
assay system there was up to a 2.5-fold decrease in invasion of the breast cancer 
cell lines. MMP expression analysis in the breast cell lines showed a reduction in 
the RNA levels of pro-tumourgenic MMP-2 and MT-1 MMPs. This reduction was 
not a result of TIMP up-regulation as there was no significant change in TIMP 
expression between cancer cells in  mono-culture or co-culture with 
myoepithelial cells,  suggesting paracrine regulation [54]. As further support for 
this paracrine signalling, another study has shown that conditioned media from 
cultured myoepithelial cells exerts anti-proliferative effects on epithelial breast 
cancer cell lines [55]. Interestingly, as breast cancer progresses past the DCIS 
stage the myoepithelial cells disappear or de-differentiate, through unknown 
processes [54]. It is only very occasionally that the myoepithelial cells 
themselves become malignant in the first instance, and these tumours may be 
more aggressive clinically [56]. There is evidence to suggest that although it is 
not the myoepithelial cells that initially become malignant they do exhibit 
genetic alterations  in  DCIS breast tissue compared to unaffected breast tissue 
[57] resulting in a loss of their ability to maintain the cellular organisation of the 
duct and thus facilitating  tumour progression. It has been reported that 
changes in cytokine expression in myoepithelial cells during tumourigenesis 
alter proliferative and invasive capabilities of the cancerous luminal epithelial 
cells, enhancing the tumourigenic process [58].  
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Figure 1.8: MMP8 is expressed in the myoepithelial cells of the normal 
breast. A) Gene expression analysis of MMP8 by Taqman RT-PCR in laser-
dissected cell populations (Simon Pilgrim, Edwards Lab, UEA, 
unpublished). B) Cross section of duct in normal breast [6]. 
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Marker Function Reference 
α1β1 integrin Cell-matrix interactions at focal contacts  [56] 
α2β1 integrin Cell-matrix interactions at focal contacts  [56] 
α3β1 integrin Cell-matrix interactions at focal contacts  [56] 
α6β1 integrin Cell-matrix interactions at focal contacts  [56] 
α6β4 integrin Cell-matrix interactions at hemi-desmosomes with β6 integrin [56] 
CK5 Epithelial cytokeratin [59] 
CK14 Epithelial cytokeratin [56] 
CK17 Epithelial cytokeratin [60] 
Vimentin Cytoskeletal intermediate filament [56] 
E-Cadherin Component of adherns junction in epithelial cells [56] 
P-Cadherin 
 
Placental Cadherin- component of adherens junction in 
myoepithelial cells [61] 
α-SMA Contractile filament [56] 
Laminin Basement membrane glycoproteins [62] 
Maspin Serpin protease expressed in normal breast epithelial cells [63] 
      
 
  Table 1.2: Key markers expressed by myoepithelial cells 
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1.3.2 Protective roles in Cancer 
 
The earliest study showing the anti-tumourigenic effects of MMP-8 utilised 
Mmp8 knock-out mice and found that mmp8 deficiency in male nude mice 
caused more skin tumours when exposed to  chemical carcinogens, DMBA and 
TPA, with a faster initiation rate compared to wild-type males [64]. This effect 
was reversed by injection of bone marrow from wild-type mice into the Mmp8 
knockouts, presumably because of the high levels of MMP-8 in the neutrophils.  
Interestingly, Mmp8 reduced initial tumour progression, providing evidence 
that MMP-8 influences the early stages of tumour formation as well as later, 
metastatic stages, which is the stage at which  research has shown most 
extensively where MMP8 has an impact [52, 65-67]. Montel et al. (2004) 
experimented on two breast cancer cell lines, M-4A4 and NM-2C5, from the 
same parental cell line (MDA-MB-435), that had different metastatic potentials 
in athymic mice [67]. The M-4A4 line is highly metastatic whereas the NM-2C5 
line showed non-metastatic potential. Expression of MMP8 mRNA is 20 times 
greater in the NM-2C5, low metastatic line, than in the metastatic line (M-4A4). 
This is in contrast to MMPs 2 and 9 which were found to be expressed at the 
same levels in both cells lines [68], showing that MMP8 expression correlates 
with reduced metastatic capability of cells expressing it.  Over-expression of 
MMP-8 in the highly metastatic M-4A4 line and ribozyme-mediated MMP8 
knockdown in the NM-2C5 line reversed the phenotypes of the two cell lines, 
again showing the capability of MMP8 for reducing metastasis [67]. Caution 
must be taken when interpreting these findings however as since this study it 
has been shown that that MDA-MB-435 cell line is actually a melanoma cell line 
rather than breast [69]. 
 
Further evidence for MMP-8 as a metastasis suppressor comes from Gutiérrez-
Fernádez et al., (2008) [52]. Mice injected with B16F10 melanoma cells 
developed multiple lung metastasis, which were reduced in number when the 
B16F10 melanoma cells were transfected with murine Mmp8 cDNA. An inactive 
mutant form of Mmp8 did not have this effect, showing that proteolytic activity 
is required for MMP8 to exert its anti-metastatic properties [52]. MMP8 did not 
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actually slow down the growth of melanoma cells but it did reduce the invasive 
ability of cells expressing it, and also increased cell adhesion to collagen-1 and 
laminin-1 [52], through presently unknown mechanisms. These studies 
contribute knowledge to the hypothesis that MMP8 is active at different stages 
of breast cancer progression, and can act through proteolytic processing of 
potentially, many different substrates, currently which are largely unknown.  
 
In breast cancer, human studies involving the correlation of MMP8 expression 
with clinical diagnosis and prognosis show that cancer patients whose tumours 
express MMP8 are less likely to have lymph node metastasis [52]. Also, plasma 
MMP-8 levels have been found to be positively correlated with lymph node 
involvement, but negatively with distant metastasis [65]. It has been 
hypothesised that the more MMP-8 present in the plasma, the less there is 
contained within the tissue and vice versa, meaning that MMP-8 expression in 
the tumour may actually have a protective effect against lymph node metastasis.   
The DNA sequence of MMP8 has also has been shown to have an impact on 
prognosis. For example,  Decock et al. (2007)  found that four single nucleotide 
polymorphisms (SNPs) within the MMP8 gene had a link to metastatic spread to 
the lymph nodes, especially striking in patients with the minor, T allele of the 
SNP rs11225395 showing reduced spread of breast cancer to the lymph nodes, 
along with increased survival and a reduction in relapse, as determined through 
10 years of follow up [70]. This SNP, in the MMP8 promoter, affected DNA 
binding, with the T allele resulting in higher promoter activity, so MMP8 gene 
variation may exert some protective effects through changes in gene expression 
[70].  In a Korean study on gastric cancer however, this SNP was found to show 
no association with disease development and lymph node metastasis [71]. 
Further evidence for MMP8 promoter SNPs affecting gene expression comes 
from studies into preterm premature rupture of membranes (PPROM) during 
pregnancy which showed reduced transcription factor binding to the minor 
allele of -799C/T SNP [72], with the C allele of the same SNP appearing to be 
protective against arterial disease [51]. 
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Further, MMP-8 has been investigated in squamous cell carcinomas [73, 74] 
whereby expression of MMP8 in the tumour cells was found to have protective 
effects [73]. Korpi et al (2008) found a positive correlation between MMP-8 
protein expression in squamous cell carcinomas (SCC) cells and improved 
survival in female patients. On treatment with a chemical carcinogen, 4-
Nitroquinoline-N-oxide (4NQO), female Mmp8 knockout mice developed 
tumours whereas none of the wild-type female, or male, mice did [73]. The 
gender differences between the effects of MMP-8 are likely due to the influence 
of oestrogen in females, as data suggest that MMP-8 and oestrogen may impact 
on the expression of each other [64, 73, 75, 76].  MMP-8 has also been studied in 
melanoma, with Palavalli et al (2009), identifying 6 MMP8 mutants in 
melanoma cells from patients. Growth of human melanocyte Mel-STR cells 
stably transfected with wild-type MMP8 and 5 of the mutated versions 
identified was not affected, but wild-type MMP-8 inhibited colony formation in 
soft agar and reduced migration compared to the mutants. In vivo, injection of 
these same cells into NOD/SCID mice showed that wild-type MMP-8 protected 
against ulcerating lesions, and lung metastasis [77].  
More recently, MMP-8 has been examined in osteosarcoma (OS) [78] and in 
colorectal cancer (CRC) [66]. Korpi et al (2011) looked at MMP-8 levels in OS 
biopsy, surgery samples and lung metastases. MMP-8 was detectable by 
immunohistological staining in the sections and biopsy samples but not in the 
lung metastases, whereas the other MMPs examined (-2, -13 and -26) were 
found in metastases as well as the primary specimens. Nothing can be 
concluded from this so far, as further research on a larger patient pool is 
required, but it may point to MMP-8 being involved in prevention of metastatic 
spread of OS.  Also, single variable analysis did not uncover any correlation 
between MMP8 and survival, which may also be due to a limited sample size of 
only 25 patients [78].  Vayrynen et al (2011) carried out a larger scale study of 
148 CRC patients and 83 healthy controls with 2-year patient follow-up, looking 
at MMP8 levels in the serum of patients with CRC and healthy controls. They 
found a greater than 3-fold increase in serum-MMP-8 (sMMP-8) levels in 
patients compared to controls, with highest levels in patients with stage IV, 
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metastatic, disease and an association between higher levels of sMMP-8 and 
depth of primary tumour invasion. Their short patient follow-up did find a 
correlation between sMMP-8 levels and recurrence, but they did hypothesise 
that because they did not see much sMMP-8 in patients with stage III disease, 
which is where patients would have lymph node spread, that MMP-8 may be 
protecting against lymph node metastasis in CRC [66], which is concurrent with 
research on MMP-8 in breast cancer [65].  
In conjunction, all these studies point to MMP-8 being tumour protective, and 
specifically in preventing metastatic spread of the disease. However, the actions 
of individual proteins can differ wildly depending on their cellular environment, 
the type of cancer involved and the mechanism of study.  
 
1.3.3 Conflicting roles of MMP-8 in cancer 
 
As summarised above, the majority of studies into MMP-8 in cancer in the last 8 
years provide very convincing evidence for it being tumour-protective. 
However, there have also been conflicting reports suggesting that MMP-8 
accelerates tumour growth in other cancers. For example, in ovarian cancer, 
patient survival rates have been found to be higher in patients who express 
MMP-8 protein and mRNA at a low/non-existent level, with high levels of MMP8 
expression being associated with a more aggressive cancer [38]. However, in 
this case MMP8 levels could not be used as an independent factor for prognosis.   
Higher MMP8 levels in ovarian cysts were also found to be associated with 
higher rates of malignancy [79]. In squamous cell carcinoma MMP-8 has been 
found to be expressed in cell lines derived from patient tumours, and also in 
islands of malignant cells in vivo as determined by histological staining and in 
situ hybridization. This could potentially indicate that MMP8 may have a role in 
the metastatic spread of the disease. However, MMP-8 was only expressed 
sporadically at low levels and no conclusions could be drawn with regards to 
patient outcome [74]. 
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The observed differences in the effects of MMP-8 may be attributed to the type 
and stage of tumour. Also, there is likely variation between the different in vitro 
models and whether RNA or protein levels of MMP8 were the focus of the study. 
Despite these conflicting reports, in breast cancer, the consensus is a reduction 
in metastatic disease and increased survival with MMP-8 expression.  Therefore 
it is appropriate to harness the protective properties of MMP-8 to prevent 
metastatic spread of the disease in patients with breast cancer. As yet however 
the molecular mechanism and mode of action of MMP8 is largely unknown and 
this needs to be elucidated in order to determine potential therapeutic targets. 
 
1.3.4 MMP-8- modulator of the immune response 
 
The mechanism through which MMP8 exerts its anti-tumourigenic properties is 
largely unknown. There is however evidence that MMP8 is involved in 
modulating the acute immune response, and this alternative, but major role, 
may in part result in cancer protection.  
 
Murine lipopolysaccharide (LPS)-induced CXC chemokine (LIX) has been found, 
by incubation of an array of chemokines with recombinant MMP-8, to be 
proteolytically cleaved by MMP-8.  MMP-8 was found to be necessary for the 
initiation of the normal acute immune response to cell lesions and invading 
bacteria [80]. The human orthologues of LIX, CXCL8/IL-8 and CXCL5/ENA-78 
have also been found to be cleaved by MMP-8. This cleavage, in both mice and 
humans is part of a ‘feed-forward’ mechanism that recruits neutrophils to the 
site of a wound or lesion. LIX, like human IL-8 is a potent neutrophil 
chemoattractant. Initiation of the innate immune response using the endotoxin 
LPS results in the release of LIX (from an unknown binding partner), resulting 
in migration of neutrophils to the affected site. Here, they de-granulate, 
releasing MMP-8 among other proteins. MMP-8 cleaves LIX, converting to its 
more hyperactive form which recruits and activates yet more neutrophils, 
resulting eventually in the resolution of the immune response, and a return to 
tissue homeostasis [80]. This does not occur efficiently in Mmp8 null mice and 
they exhibit abnormal immune responses due to a heavily reduced number of 
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neutrophils as LIX is not fully activated. This results in chronic inflammation, 
and this contributes to a microenvironment highly conducive to tumour 
development [81, 82].  
 
Further evidence for a pro-inflammatory role of MMP-8 in immune responses 
comes from Mmp8 knockout mice in an experimental model of peridontitis and 
TNF-induced lethal hepatitis.  Hernández et al (2011) induced periodontitis in 
Mmp8 knockout mice using the pathogen Porphyromonas gingivalis and 
observed that protein levels of LIX were significantly higher in the wild-type 
infected mice than the Mmp8 knockout mice [49]. Van Lint et al (2005) showed 
a reduction in neutrophil influx to the liver and a reduction in apoptosis in 
Mmp8 knockout mice with hepatitis [83]. Like Hernández et al (2011), they also 
found a reduction in LIX in the absence of MMP-8.   Previous studies found an 
activational cleavage of LIX by MMP-8 [64, 80], but Hernández et al (2011) and 
Van Lint et al (2005) actually report a change in expression levels, possibly due 
to up-regulation at the RNA level or a release of LIX from ECM stores. Although 
the precise mechanism was not studied, it further complexity to the possible 
mechanistic actions of MMP-8.  
 
Wound healing is delayed in Mmp8 null mice compared to wild-type littermates, 
strongly indicating that MMP-8 is required for effective wound healing. The 
authors also report a delay of neutrophils migrating to the wound site, 
presumably as LIX is not cleaved resulting in a delayed immune response [14], 
or due to reduced collagen breakdown, obstructing the path of neutrophils 
through the ECM [84]. Interestingly, when the immune response was eventually 
initiated there was a greater accumulation of neutrophils which were more 
diffused around the wound site. Also, the immune response was sustained for 
up to 7 days post wounding [14, 64]. Normally the neutrophils would have 
undergone apoptosis at this point to reduce inflammation for healing to 
proceed. This delay in neutrophil apoptosis has been linked to reduced caspase 
11 expression in Mmp8 knockout mice in a model of autoimmune arthritis [42]. 
Vandenbrouke et al., (2012) also report the consequences of the pro-
inflammatory functions of MMP-8 in a murine model of systemic inflammatory 
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response syndrome (SIRS). However, in their study expression of MMP-8 was 
found to be detrimental to mouse survival. Using the same Mmp8 knockout mice 
as [64], Vandenbrouke et al., (2012) induced SIRS experimentally using LPS 
administration to induce TLR4 dependent inflammation. Using this model they 
showed that Mmp8 knockout mice were protected from hypothermia and death, 
with prior exposure to an Mmp8-specific inhibitor having the same effects. The 
brain is an early target of the syndrome, and MMP8 was found to distrupt the 
brain-CSF-barrier (BCSFB), after LPS administration, through degradation of 
Type I collagen of the basement membrane underlying the choroid plexus. Cells 
comprising this epithelial layer secrete CSF and form the BCSFB. A local 
inflammatory resposnse was observed in the CSF as observed by higher levels of 
pro-inflammatory cytokines IL-6, MIP-1α, MIP-1β, MIP-2 and MCP-1 in wild-
type MMP-8 mice. Although this cytokine up-regulation was not mirrored in the 
choroid plexus cells, systemic inflammation as determined by examination of 
cytokine levels in blood sera, was present in the Mmp8 wild-type mouse. This 
systemic inflammation resulted in organ damage and multiple organ failure in 
wild-type mice compared to Mmp8 knockout mice. Interestingly, using this 
model they do not report any differences in neutrophil migration between wild-
type and MMP8 knockout mice on LPS administration [85], a difference that was 
observed in other studies that used LPS to initiate inflammation [80], but this 
could be due to the difference in organs studied.  
 
Predominantly in the literature, MMP-8 has been shown to have an effect on LIX 
(IL-8), but it has also been shown that MMP-8 can cleave both murine and 
human IL-10 (which in contrast to LIX and IL-8 is an anti-inflammatory 
cytokine), and that MMP-8 deficient mice show decreased levels of processed 
IL-10 [86]. Similarly, MMP-8 has  been shown to solubilise IL-13 receptor α2, 
which is involved in allergy-induced asthma [87] There is also a link with IL-1β 
where addition of the cytokine to ovarian cancer cells increases MMP-8 protein 
secretion by 5.6 fold compared to controls [38], as does IL-6, which increases 
MMP-8 mRNA and protein levels in RPMI 8226 myeloma cells on exogenous 
addition for 24 hours [39]. Conversely, Transforming Growth Factor beta 
(TGFβ), which is heavily involved in immune responses, has been shown to 
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inhibit MMP-8 protein production in tumour and dermal fibroblasts from 
squamous cell carcinomas [74],  and both MMP-8 mRNA and protein levels in 
human odontoblasts and dental pulp cells [88] (summarised in figure 1.9). 
 
As aforementioned, MMP-8 is capable of cleaving CXC chemokines -8 and -5 [80] 
but recent evidence has shown that MMP-8 is also capable of cleaving 
chemokines of the CC family, which unlike CXC chemokines do not regulate 
neutrophils but act on monocytes, lymphocytes, basophils and eosinophils [89]. 
Through addition of recombinant MMP-8 to synthetic full length CCL 
chemokines Starr et al., (2012) have shown that MMP-8 can  cleave CCL15 (1-
92) to either CCL15 (25-92) or CCL15(28-92), and CCL23(1-99) to CCL23(26-
99) to generate products active for calcium mobilisation on transfection into 
murine pre-B B200-19 cells, and chemoattraction of human acute monocytic 
leukemia THP-1 cells. MMP-8 was also shown to cleave CCL16(1-97) to 
CCL16(8-85), although the generated cleavage fragment was inactive as a 
chemoattractant,  as shown by looking at transwell migration of THP-1 
monocytes. Increased glycosaminoglycan (GAG) binding was observed with the 
cleavage fragment however, which is a common requirement for the activity of 
chemokines, and CCL16 cleavage fragments were found to have modest 
chemoattractive activity at very high concentrations, when high levels of GAG 
were bound. It was also predicted from previous known cleavage sites and/or 
known cleavage sites generated by other MMPs that MMP-8 could be capable of 
cleaving CCL2-4, CCL-8, -13, and -17, although further investigation is required 
to confirm this [90]. 
 
MMP-8 has also been shown to have an anti-inflammatory role. Unexpectedly, 
intratracheal injection of LPS into Mmp8 knockout mice resulted in a two-fold 
increase in neutrophil influx into the alveolar space compared to wild-type 
mice, thus MMP8 presence reduces the number of neutrophils within the lungs 
in this system, reducing acute inflammation [35, 91]. Similarly, in a mouse 
asthma model, on allergen stimulation Mmp8 knockout mice showed a 10 fold 
increase in neutrophils, along with reduced neutrophil apoptosis [41], again 
indicating an anti-inflammatory role for MMP-8. Studies by Garcia-Prieto et al., 
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(2010) and Quintero et al., (2010) add further evidence to this. Garcia-Prieto et 
al., (2010)  link MMP-8 expression to increased activational cleavage of the anti-
inflammatory cytokine IL-10, resulting in reduced neutrophil influx to the lungs 
[86].  Quintero et al., (2012), like Herman et al., (2001) [40] and Owen et al., 
(2004) [35], show that Mmp8 knockout mice exhibit increased neutrophil and 
macrophage accumulation after LPS and bleomycin-induced Acute Lung Injury 
(ALI) compared to wild-type mice. They also show that the presence of MMP-8 
reduces alveolar capillary barrier injury, with the knockout mice showing a 
higher severity of inflammation and haemorrhage. These phenotypes were 
attributed to the inactivational cleavage of Macrophage Inflammatory Protein- 
1α (MIP-1α), a potent pro-inflammatory CC chemokine (alternatively known as 
CCL-3), that acts to recruit neutrophils to wound sites via binding to its receptor 
CCR-1 [36]. Further evidence has come from a more recent study by González-
Lopéz (2012) that attributes anti-inflammatory properties in the lung to MMP8-
mediated regulation of two alarmins, S100A8 and S100A9, in an endotoxemia 
mouse model after LPS stimulation. Both S100A8 and S100A9 are constitutively 
expressed in the neutrophils and are ligands for toll-like receptor 4 (TLR4) and 
Receptor for Advanced Glycation End-products (RAGE), but are increased in the 
lungs of Mmp8 deficient mice in this model, resulting in an inflammatory 
response [91].    
 
 Collectively, these studies highlight the complexity of involvement of MMP-8 in 
the immune response in that it appears to be required for a normal immune 
response to prevent chronic inflammation [14, 64, 80], but in other cases may 
act to reduce acute inflammation in the first instance [35, 41]. The studies used 
different methods to stimulate an immune response, so this could be a possible 
explanation for the observed differences, but reactions could also be dependent 
on the tissue studied, the immune cells examined and the mouse model used. 
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Figure 1.9: Summary of the inflammatory cytokine networks 
MMP8 is involved in. Key: directional arrow = activation, blunt 
ended arrow = inhibition.    
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1.4 Inflammation and Cancer 
 
As briefly mentioned in section 1.2 (MMPs in tumour progression), the tumour 
microenvironment is instrumental to the initiation and development of cancer, 
with the tumour microenvironment hosting numerous inflammatory cells. 
During acute inflammation, in response to tissue wounding or an aberrant cell, 
the immune response is beneficial by removing and repairing the cause of the 
immune reaction, so plays an anti-tumourigenic role. However, a sustained, 
chronic  inflammation, can drive cancer initiation and progression [92].  
 
Neutrophils are the ‘first response’ immune cells to a wound site whereby they 
initiate the response. Guided by chemotactic factors (chemokines) macrophages 
emerge, secreting growth factors and cytokines to repair the wound. In a normal 
situation the inflammatory response would then be resolved; the inflammatory 
cells would undergo apoptosis and would be cleared by phagocytosis. If this 
does not occur effectively, or the cause of the immune response is not resolved, 
the inflammatory response is sustained chronically, resulting in tissue damage 
and an abundance of growth factors and mutagenizing reactive oxygen species 
(ROS) [81, 93].  
 
Inflammation is driven by small signalling molecules, chemokines and 
cytokines, that are produced by inflammatory cells and also tumour cells. The 
balance of pro- and anti-inflammatory cytokines in the tumour 
microenvironment determine the outcome of tumour growth. Large amounts of 
pro-inflammatory cytokines result in chronic inflammation, and consequently in 
increased tumour growth, and angiogenesis. In  contrast, tumours producing 
fewer pro-inflammatory cytokines than anti-inflammatory cytokines cannot use 
them to growth advantage [81]. 
 
Chronic inflammation not only accelerates tumourigenesis but can also initiate 
it. This is because the reactive oxygen and nitrogen species produced by 
inflammatory cells during an immune response can induce DNA mutagenesis. In 
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addition, an increasing number of cancers are associated with infections, for 
example cervical cancers caused by the human papilloma virus (HPV) [94, 95].  
 
Parallels have been drawn between tumours and wound healing, in that both 
growth of new cells following wounding and tumourigenesis require cytokine 
signalling, up-regulation of growth factors, cell proliferation and survival. In the 
1980’s Dvorak described cancers as ‘wounds that do not heal’ [96]. A study by 
Chang et al., (2005) showed that overall and metastasis-free survival of breast 
cancer patients is reduced if tumours express a “wound-response” gene 
signature [97], and more recently a study by Riss et al., (2006) used microarray 
technologies to quantify the gene expression changes associated with renal 
regeneration and repair and renal cell carcinoma [98]. They showed that 77% of 
the genes expressed under both pathologies were regulated concordantly. Of 
the pathways investigated, the NFĸB pathway significantly contained a high 
number of these concordant genes [98]. NFĸB has been described as the key 
mediator between inflammation and tumourigenesis [92, 99]. This is due to its 
role in promotion of cell proliferation and inhibition of apoptosis [100], its 
central role as a transcription factor for pro-inflammatory cytokines (e.g. 
Interleukin 6 (IL-6) and its downstream effector STAT3) promoting cellular 
growth, and expression of tissue destructing MMPs such as MMPs 1,9 and 13 
promoting invasion [99, 101]. NFᴋB is constitutively active in the majority of 
cancers, emphasising its pivotal role in both inflammation and tumourigenesis.  
 
1.4.1 Inflammation in breast cancer 
 
Inflammatory breast cancer is a rare type of breast cancer whereby cancer cells 
block lymphatic vessels, resulting in inflammation, but the cancer itself is not 
actually caused by inflammation [102]. The core inflammatory mediator, NFĸB, 
however has been implicated in breast cancer progression through its role in 
the regulation of E-Cadherin, a marker of an epithelial, differentiated state of 
cancers and its role in the metastatic spread of the disease. Increased activity of 
some NFĸB subunits have been found to be present at higher levels in breast 
cancer cells compared to adjacent non carcinoma cells [103], and is seen at 
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higher levels in Estrogen Receptor (ER) negative tumours and breast cancer cell 
lines than in ER positive lines [104, 105]. This indicates that NFĸB expression is 
involved in aggressiveness of cancer. Moreover, there is evidence that it has a 
role in the epithelial to mesenchymal transition (EMT) of breast cancer cells, 
thus propelling the cancer further in the direction of aggressive, metastatic 
disease. This has been shown in MCF10A breast cells through the repression of 
E-Cadherin, an epithelial marker and the induction of vimentin, a mesenchymal 
marker with the over-expression of the p65 NFĸB subunit [106] and also in Ras-
transformed mammary epithelial cells, whereby blockade of NFĸB activity 
prevented EMT [107]. With regards to metastatic spread of breast cancer, NFĸB 
has been shown to be crucial in metastasis of breast cancer cells to the bone 
[108] so consequently, it is a prime target in breast cancer therapies. As 
aforementioned there are numerous down-stream targets of NFĸB that are 
involved in a whole host of cellular processes. A cytokine and a chemokine, IL-6 
and IL-8 respectively, are such targets that have been discovered to be affected 
by over-expression of MMP-8 in the breast cancer cell model utilised in this 
thesis. The subsequent and concluding section of this chapter will investigate 
their roles in inflammation and cancer in general.  
 
1.4.2 IL- 6 and IL-8- Introduction and Regulation 
 
IL-6 and -8 are proteins involved in immune responses. IL-6 is a 21-28kDa 
cytokine [109], which has a pivotal role in the immune response but can also act 
on multiple cells in a range of organs and tissue systems. Due to these wide 
functions IL-6 is known as a ‘pleotropic’ cytokine [110]. IL-6 has two signalling 
pathways, classical and trans. IL-6 actually signals through two receptors which 
aggregate to form the complete receptor, the first is an 80kDa protein, IL-6Rα, 
and the second in a 130kDa protein, gp130. If both of the receptors are bound to 
the membrane of the target cell this is ‘classical’ signalling. However, soluble IL-
6Rα (sIL-6Rα) can be generated from differential splicing at the mRNA level or 
from shedding of the bound receptor [111, 112]. IL-6 can bind sIL-6Rα forming 
a heterodimeric complex which can bind to the membrane-bound gp130 on the 
target cell [113]. This ‘trans’ signalling occurs when the target cell does not have 
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an endogenous IL-6Rα. The IL-6Rα is mainly expressed on cells of the immune 
system but also on neural and skeletal tissue [110], whereas the gp130 receptor 
is expressed by most cell types [114]. Signalling through the sIL-6Rα has been 
implicated in many disease states such as arthritis, asthma, inflammatory bowel 
disease and cancers [112].  IL-6 downstream signalling is widespread and 
complex (summarised in figure 1.10). The main downstream signalling effector 
discussed in the literature is STAT3, which propagates pro-survival signals, and 
has been described as a ‘multifaceted oncogene’ through its ability to both 
promote cell survival and protect cells from immune surveillance [115] . IL-6 
has been described as having both pro- and anti-inflammatory roles. It is anti-
inflammatory in acute inflammation [116, 117] but pro-inflammatory in chronic 
inflammatory disease [118, 119]. Therefore, IL-6 is involved in the generation of 
an environment of chronic inflammation which is conducive to tumour 
initiation and progression. 
 
IL-8, otherwise known as CXCL8, is a pro-inflammatory CXC-type 8kDa 
chemokine, with a predominant role as chemo-attractant for, and activator of 
neutrophils, thus playing a strong role in acute inflammation [120]. It signals 
through two cell-surface G-Protein Coupled Receptors, CXCR1 and CXCR2 
resulting in mobilisation of calcium and downstream signalling [121, 122]. 
These receptors have different specificities; CXCR1 is only activated by IL-8 and 
GCP-2, whereas CXCR2 can be activated by multiple growth factors and 
cytokines [5]. Like IL-6, IL-8 downstream signalling is broad and complex, but 
can be summarised in figure 1.11. IL-8 does not solely regulate neutrophil 
chemotaxis but can regulate many other cellular pathways in a range of cell 
types.  
 
As can be seen from figures 1.10 and 1.11 the majority of the down-stream 
signalling of both IL-6 and IL-8 is pro-inflammatory and pro-cell survival, and as 
a consequence the majority of studies on the roles of IL-6 and -8 in cancer 
points to both cytokines being pro-tumourigenic.  
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Figure 1.10: The IL-6 pathway in Cancer. On binding its receptor IL-6 
initiates a cascade of kinase phosphorylation resulting in the activation of 
the transcription factor STAT3 which regulates genes involved in cell 
survival. Adapted from a publically available figure from Qiagen.  
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Figure 1.11: IL-8 downstream signalling in cancer. IL-8 initiates a 
kinase phosphorylation cascade resulting in activation of transcription 
factors involved in tumourigenesis [5].   
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1.4.3 IL-6 in Cancer 
 
 
IL-6 has been implicated in a range of cancers and is predominantly described 
as a target for cancer treatment. In vitro studies have shown that exogenous 
addition of rhIL-6 to a range of human breast cancer cell lines induces the 
epithelial to mesenchymal transition which was characterised by a reduction in 
E-Cadherin expression (Sullivan 2009). In addition, MCF-7 cells over-expressing 
IL-6 exhibited an enhanced invasive capacity, induced vimentin expression and 
showed a lack of E-Cadherin expression showing IL-6 expression could reverse 
the phenotype of these cells. Similar results have been published in prostate 
cancer, with exogenous addition of IL-6 to a non-tumourigenic prostate cancer 
cell line, SV40T, resulting in morphological changes, loss of E-Cadherin 
expression and gain of vimentin expression [123]. In bilary tract cancer cell 
lines exogenous addition of rhIL-6 could induce EMT and cellular invasion 
[124]. Despite these pro-tumourigenic roles of IL-6 in vitro, in contrast Chiu et 
al., (1996) showed that addition of rhIL-6 to some ER+ cells (but not MCF-7 
cells) reduced proliferation. IL-6 produced by ER- cells such as MDA-MB-231 
cells could exert this effect showing that IL-6 can act as a paracrine growth 
factor [125]. The high levels of IL-6 produced by ER- cells, which are 
predominantly cells which have come from a highly aggressive tumour however 
suggests that IL-6 may be involved in the high tumourigenicity of these cell 
lines.   
 
IL-6 has also been implicated in ovarian cancer, for example, elevated IL-6 levels 
in ovarian cancer ascites was found to be an independent predictor of reduced 
progression free survival [126]. High IL-6 expression in ovarian tumours, with 
higher levels found in malignant cells compared to the tumour stroma, was 
found to be positively associated with shorter overall patient survival [127]. 
Studies have also described a dynamic cytokine network in ovarian cancer, in 
which IL-6 has been found to play a dominant role [127-129]. IL-6 has also been 
found to be a key driver in malignant progression of squamous cell carcinoma 
where it initiates a complex self-reinforcing cytokine-MMP network [130, 131]. 
It has also been found to be higher in the serum of lung cancer patients 
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compared to healthy controls [132]. Additionally, tumour IL-6 mRNA levels 
have been found to be reduced in non-tumour cells compared to tumour cells, 
presumed to be due to promoter methylation in the non-tumour cells [133]. In 
nonsmall cell lung cancer  IL-6 has been shown to be a predictor of poor 
survival in [134].  
 
Within breast cancer tissue itself IL-6 protein and RNA has been detected 
(reviewed in [135]) but whether IL-6 can be used as a prognostic factor, or 
whether the IL-6 present in the tumours was actually produced by the tumour 
cells has led to great discussion and controversy [135]. However, serum IL-6 
levels have been consistently shown to be higher in breast cancer patients 
[136], especially patients with higher grade tumours [137, 138], and in patients 
with re-current breast cancer [139, 140]. Serum IL-6 levels have also been 
linked to reduced relapse free survival and overall survival [138, 141] and so 
therefore has been described as a predictor of breast cancer survival.  
 
To summarise, IL-6 has been implicated in a range of cancers, predominantly 
having a tumour promoting role. IL-8 plays slightly different roles in cancer, but 
is just as implicitly involved.  
 
1.4.4 IL-8 in cancer 
 
Like IL-6, IL-8 has been implicated in tumour growth and EMT but has also been 
heavily described as a promoter of angiogenesis via up-regulation of VEGF. 
Firstly the in vitro effects of IL-8 will be described, followed by results of human 
studies. IL-8 (and its receptors, CXCR1 and 2) has been found to be elevated in 
epithelial cells that have undergone EMT [142]. Endogenous expression of IL-8 
in mammary carcinoma cell lines appears to correlate with metastatic potential, 
with high levels secreted by the metastatic MDA-MB-231 cells and low/non-
existent levels secreted by the non-metastatic MCF-7 and T47D cell lines [143-
145].  In addition, IL-8 induction by ROS increased the invasiveness of MDA-MB-
231 cells [146] and  IL-8 signalling blockade resulted in a reduction of the 
ability of MCF-7 and MDA-MB-231 breast cancer cells to invade through 
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Matrigel in vitro [142]. Additionally, Lin et al., (2004) examined the cytokine 
profiles of a range of ER+ and ER- breast cancer cell lines, with IL-8 being found 
to be positively correlated with vimentin status (a marker of EMT) and the cell’s 
metastatic status. IL-8 expressing cells were more invasive through Matrigel 
which was reduced on exposure to IL-8 neutralising antibodies [144]. Knocking 
down IL-8 in MDA-MB-231 cells, which endogenously produce lots of IL-8, 
confirmed that in vitro invasion through Matrigel was reduced [147]. Both 
studies showed however that IL-8 had no effect on either cellular proliferation 
or cell cycle profile [144, 147]. Collectively these studies led to IL-8 being 
considered an important factor in breast cancer progression.  
 
Early studies provide evidence for a role of IL-8 in the tumour 
microenvironment. Youngs et al., (1997) showed that IL-8 induced migratory 
chemotaxis of MCF-7 cells through an 8µm-pored microchemotaxis chamber, 
even though the cells do not endogenously express it [148]. This 
chemoattractive activity of IL-8 on carcinoma cells, as well as its main role in 
neutrophil chemotaxis, suggests that IL-8 in the tumour microenvironments, 
may have a role in the metastatic spread of cancer. The most predominant role 
of IL-8 in the tumour microenvironment is in angiogenesis through its ability to 
activate the vascular endothelial growth factor receptor 2 (VEGFR-2) in 
endothelial cells, increasing the permeability of the endothelial barrier [149] 
and allowing for intravasion of tumour cells and neutrophils, and to induce 
angiogenesis through up-regulation of VEGF via CXCR2 [150] which can then co-
localise with VEGFR-2 [149].  
 
In vitro studies utilising Human Umbilical Vascular Endothelial Cells (HUVECS) 
as a model system for angiogenesis have shown that IL-8 can induce the 
migration of HUVECs through Matrigel, promote tube formation into vessel-like 
structures [144, 151, 152], and increase HUVEC proliferation [151, 152] while 
inhibiting apoptosis [152]. HUVECS express both IL-8 receptors, CXCR1 and 2, , 
suggesting that IL-8 propagates these actions through its traditional signalling 
pathways [152]. In vivo, subcutaneous injection of conditioned media 
(combined with Matrigel to form a plug) from IL-8 expressing cells induced 
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blood vessel formation (validated by a CD31 stain which is specific for vascular 
cells) compared to media from low IL-8 expressing cells [144], and tumours 
resulting from subcutaneous injection of MDA-MB-231 cells displayed a higher 
microvasculature density that tumours arising from injection of MDA-MB-231 
cells with suppressed IL-8 [147]. However, in this study, IL-8 suppression in 
MDA-MB-231 cells resulted in faster growth of tumours after subcutaneous 
injection, suggesting that IL-8 may have a tumour suppressive role in this model 
[147]. Additional support for the pro-angiogenic role of IL-8 comes from a nude 
mouse xenograft model in which Ras-induced IL-8 expressing HeLa cells form 
subcutaneous tumours. Tumours injected biweekly with an antibody to IL-8 
exhibited a reduction in tumour growth rate which was due to an increase in 
necrosis attributed to a reduction in angiogenesis. Tumours that were not 
injected with the IL-8 neutralising antibody had significantly more 
vascularisation than those where IL-8 was inhibited [153].  
 
There have not been many human studies looking into the prognostic 
significance of IL-8 in breast cancer. Generally IL-8 is associated with a more 
aggressive cancer subtype and therefore could potentially be used as a predictor 
of metastatic disease. A small scale study by Derin et al., (2007) showed a 
correlation between serum levels of IL-8 and metastatic breast cancer but did 
not observe any differences in patients compared to healthy controls, nor any 
correlation with prognosis [154]. A slightly larger study by Benoy et al., (2004) 
showed increased serum IL-8 levels in breast cancer patients compared to 
controls, with higher levels correlating with a more aggressive cancer and 
metastasis [155]. Higher IL-8 (and IL-6 and IL-10) serum concentrations have 
been found in patients with breast cancer compared to controls, with higher 
levels positively correlated to higher grade [137]. Therefore, although evidence 
is limited IL-8, like IL-6, appears to be associated with higher grade tumours, 
metastasis and a poorer prognosis.  
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Project Aims 
 
This chapter has described in detail the anti-tumourigenic effects of MMP8 in 
cancer and has touched on its tumour protective role in human breast cancer. 
However, apart from the knowledge that MMP8 is required for cognate immune 
responses, little is known mechanistically about how it exerts these effects. Its 
influence on the immune system during acute immune responses suggests that 
MMP8 may be tumour-protective via its immuno-modulatory functions.  
 
The aims of this project are to dissect the functions of MMP8 in mammary 
carcinoma cells through the generation of an MMP8 in vitro expression model. 
Using this model both the functional and molecular influence of MMP8 on the 
cells will be determined using a range of microscopic, biochemical and 
proteomic approaches.  
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Chapter 2- Materials and Methods 
2.1 General Reagents, antibodies, plasmids and cell lines 
2.1.1 General chemicals 
 
Table 2.1 lists general chemicals used to make widely used buffers (see table 2.2). 
More specific reagents are described within the appropriate method.  
 
  
Chemical/Reagent 
 
Source 
Calcium Phosphate 
Transfection 
Calcium Chloride dehydrate (CaCl2.2H2O) 
 
Fisher Scientific 
(C/1500/53) 
 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
 
Fisher Scientific 
(BPE310a) 
General Buffers Trisaminomethane (TRIS Base) 
 
Fisher Scientific (BP152) 
 Phosphate Buffered Saline (Dulbecco A) 
tablets 
 
Oxoid (BR0014G) 
 Glycerol 
 
Fisher Scientific 
(G/0650/17) 
 Sulphuric Acid (H2SO4) 
 
BDH Lab supplies 
 Hydrochloric Acid (HCl) 
 
Fisher Scientific 
(H/1200/PB17) 
 Sodium Hydroxide (NaOH) 
 
Fisher Scientific (S302) 
 Triton X-100 
 
Sigma (93443) 
 Polysorbate 20 (TWEEN 20) 
 
Sigma (P7949) 
 Sodium Chloride 
 
Fisher Scientific 
(S/3160/60) 
Plasmid propagation Agar 
 
Formedium Ltd. (AGA02) 
 Luria Broth (LB) 
 
Merck (VMO40685) 
 Tryptone Fisher Scientific 
(BPE1421) 
 
 
 
 
  
Table 2.1: Commonly used chemicals and reagents grouped according to their 
most common usage.  
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Chemical/Reagent 
Source 
Plasmid propagation Yeast extract 
Fisher Scientific 
(BP1422) 
 
Ampicillin 
 
Formedium (AMP25) 
 Agarose 
Fisher Scientific 
(BP1356) 
 Ethylenediaminetetraacetic acid (EDTA) 
Fisher Scientific 
(D/0700/53) 
 Glacial Acetic Acid 
Fisher Scientific 
(A/0400/BP17) 
Western Blotting 
Protogel- 30% (w/v) Acrylamide:0.8% 
(w/v) Bis-Acrylamide electrophoresis grade 
 
National Diagnostics (EC-
890) 
 
Tetramethylethylenediamine (TEMED) 
 
Invitrogen (15524-010) 
 
Sodium Dodecyl Sulfate 
 
Fisher  Scientific (BP166) 
 
Ammonium Persulfate (APS) 
 
Sigma (A3678) 
 
Bromophenol Blue 
 
Sigma (B8026) 
 
Ponceau S 
 
Electran (44083) 
 Bovine Serum Albumin 
Fisher Scientific 
(BPE9701) 
 
Skimmed Milk Powder 
 
Oxoid (LP0031) 
 
SimplyBlue
TM
 SafeStain 
 
Invitrogen (LC6060) 
 
Methylene Blue 
 
Sigma (M9140) 
 
 
  
Table 2.1: Commonly used chemicals and reagents grouped according to their 
most common usage.  
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Buffer 
 
Recipe 
 
Section used 
LB Broth 
5g yeast, 10g NaCl, 10g 
Tryptone in 1L dd H2O and 
sterilised by autoclave 
2.2.1 
LB Agar 
5g yeast, 10g NaCl, 10g 
Tryptone, 15g Agar  in 1L 
ddH2O and sterilised by 
autoclave 
2.2.1 
TAE (50x stock diluted in ddH2O 
when required) 
2M Tris-HCl and 1M glacial 
acetic acid with 100ml 0.5M 
EDTA made up to 1L with 
ddH2O 
2.2.1 
Calcium Chloride 
2M CaCl2 in ddH2O and filter 
sterilised using a 0.2µm filter 
2.3.2 
2x HEPES Buffered Saline (HBS) 
280mM NaCl, 1.5mM 
Na2HPO4, 50mM HEPES in 
ddH2O and filter sterilised 
using a 0.2µm filter 
2.3.2 
Methylene Blue 
2g Methylene Blue, 500ml 
ddH2O and 500ml methanol 
2.3.6 and 2.6.5 
Destain 
50% EtOH with 50% 0.1M 
HCl 
2.6.5 
PBS 
1 PBS tablet (see table 2.1) in 
100ml ddH2O 
multiple 
TBS (10x stock diluted in ddH2O 
when required) 
0.2M Tris-HCl and 1.4M NaCl 
made up to 1L ddH2O, pH 7.6 
2.4.4 
RIPA protein lysis buffer 
50mM TRIS-HCl, 150mM 
NaCl, 1% TRITON-X, pH7.8 
2.4.1 
SDS Sample buffer for western 
blotting 
125mM TRIS-HCl, 5% SDS, 
15% Glycerol, Bromophenol 
Blue pH 6.8 
2.4.3 and 2.3.4 
Ponceau S 
0.1% Ponceau in 0.5% Acetic 
Acid 
2.4.4 
Coating buffer for adhesion 
0.1M Sodium Carbonate, pH 
9.6 
2.6.5 
Acetate citrate buffer 
0.3M sodium citrate, 145mM 
tri-sodium citrate, 28mM citric 
acid, 385ml propan-2-ol made 
up to 1 litre with ddH2O and 
pH 6) 
2.6.6.2 
 
3,3'-Diaminobenzidine 
(DAB) 
 
3M DAB in  70% perchloric 
acid 
2.6.6.2 
 
  
Table 2.2: Buffers  
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2.1.2. Antibodies 
 
Table 2.3 lists the antibodies used throughout this project.  
 
 
Primary 
Antibody 
Supplier 
Concentration 
used (for 
Western Blot*) 
Secondary 
Antibody 
Cell line 
characterisation 
MMP8 
Abcam 
(ab81286) 
1:2000 Anti-Rabbit 
 V5 tag 
Invitrogen 
(46-0705) 
1:1000 Anti-Mouse 
 Cytokeratin 18 
Cell 
Signalling 
(#4548) 
1:1000 Anti-Mouse 
 β-Catenin 
Cell 
Signalling 
(#9587) 
1:1000 Anti-Rabbit 
 Integrin β1 NCA 1:1000 Anti-Mouse 
 E-Cadherin 
Cell 
Signalling 
(#4065) 
1:1000 Anti-Rabbit 
 Vimentin 
Cell 
Signalling 
(#3932) 
1:1000 Anti-Rabbit 
 MMP14 NCA [156] 1:1000 Anti-sheep 
 PAR2 (D61D5) 
Cell 
Signalling 
(#6976) 
1:1000 Anti-Rabbit 
Cell Signalling 
Total NFĸB p65 
(F-8) 
Santa Cruz 
(sc-8008) 
1:1000 Anti-mouse 
 
Phospho NFĸB 
p65 (ser536) 
Santa Cruz 
(sc-101752) 
1:1000 Anti-Rabbit 
 Total Iĸβα 
Santa Cruz 
(sc-371) 
1:1000 Anti-Rabbit 
 
Phospho Iĸβα 
(ser32)(14D4) 
Cell Signalling 
(#2859) 
1:1000 Anti-Rabbit 
 Total IKKα 
Cell Signalling 
(#2682) 
1:1000 Anti-Rabbit 
 
Phospho IKKα 
(ser176)/IKKβ 
(ser177) 
(C84E11) 
Cell Signalling 
(#2078) 
1:1000 Anti-Rabbit 
 
 
 
Table 2.3: Antibodies used throughout this project primarily for western 
blotting grouped according to usage.  NCA= not commercially available,  
* = with the exception of the functional blocking antibodies 
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Primary 
Antibody 
Supplier 
Concentration 
used (for 
Western Blot*) 
 
Secondary 
Antibody 
 p38 MAPK 
Cell Signalling 
(#9212) 
1:1000 Anti-Rabbit 
 
Phospho p38 
MAPK 
(Thr180/Tyr182) 
(28B10) 
Cell Signalling 
(#9216) 
1:1000 Anti-Rabbit 
 
p44/42 MAPK 
(Erk1/2) 
Cell Signalling 
(#9102) 
1:1000 Anti-Rabbit 
 
Phospho p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) 
Cell Signalling 
(#9101) 
1:1000 Anti-Rabbit 
Apoptosis and Cell 
Cycle 
Caspase 3 
Cell Signalling 
(#9662) 
1:1000 Anti-Rabbit 
 Caspase 7 
Cell Signalling 
(#9492) 
1:1000 Anti-Rabbit 
 Caspase 9 
Cell Signalling 
(#9502) 
1:1000 Anti-Rabbit 
 PARP 
Cell Signalling 
(#9542) 
1:1000 Anti-Rabbit 
 PDCD4 
Abcam 
(ab51495) 
1:2000 Anti-Rabbit 
 p53 (DO-1) 
Santa Cruz 
(sc-126) 
1:10 000 Anti-Mouse 
 
p21 
Waf1/Cip1 
(12D1) 
Cell Signalling 
(#2947) 
1:1000 Anti-Rabbit 
Mass Spectrometry 
Validation 
Annexin A1 
Abcam 
(ab33061) 
1.25µg/ml Anti-Rabbit 
 
MRP8 (S100A8) 
[EPR3554] 
Abcam 
(ab92331) 
1:1000 Anti-Rabbit 
Function-Blocking IL-8 
R&D Systems 
(MAB208) 
100ng/ml NA 
 IL-6 
R&D Systems 
(MAB2061) 
100ng/ml NA 
Loading Controls 
Heat Shock 
Protein 70 (hsc-
70) 
Santa Cruz 
(sc-7298) 
1:1000 Anti-mouse 
 GAPDH (14C10) 
Cell Signalling 
(#3683) 
1:1000 
HRP-
conjugated/anti-
rabbit 
Table 2.3: Antibodies used throughout this project primarily for western 
blotting grouped according to usage.  NCA= not commercially available,  
* = with the exception of the functional blocking antibodies 
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  Supplier 
Concentration 
used (for 
Western Blot*) 
Secondary 
Antibody 
Secondary 
Antibodies 
Mouse HRP 
conjugated 
DAKO 1:1000 NA 
 
Rabbit HRP 
conjugated 
DAKO 1:1000 NA 
 
Sheep HRP 
conjugated 
DAKO 1:1000 NA 
 
Donkey anti-
Rabbit  Infra-Red 
conjugated 
Licor 1:10000 NA 
 
Donkey anti-
Mouse Infra-Red 
conjugated 
Licor 1:10000 NA 
Table 2.3: Antibodies used throughout this project primarily for western 
blotting grouped according to usage.  NCA= not commercially available,  
* = with the exception of the functional blocking antibodies 
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Figure 2.1. Plasmid map of pcDNA4 V5-His A. Ampicillin and Zeocin 
resistance sites are highlighted along-side the multiple cloning site 
containing EcoRI and XhoI restriction sights which were used to clone 
MMP-8 into the vector and the unique XbaI site which was used to 
linearise the plasmid. The T7 forward and BGH Reverse Priming sites 
were used for sequencing to confirm the presence of MMP-8 in the 
plasmid by sequencing.  
2.1.3. Plasmid constructs 
 
Wild-type MMP8 has previously been cloned into the pcDNA4
TM
 V5-His A plasmid 
(Invitrogen) using the EcoRI and XhoI restriction sites (figure 2.1) by Dr. Julie 
Decock. The vector backbone alone was used as a negative control for transfection, 
and E198A, a catalytically inactive version of MMP8 was generated using site-
directed mutagenesis (section 2.1.3.1).  Zeocin resistance was used for generating 
stable cell lines (see section 2.2.2) and ampicillin resistance was used for bacterial 
propagation of the plasmid (see section 2.2). 
 
 
 
 
 
 
  
Chapter 2- Materials and Methods 
 
58 
 
2.1.3.1 Site-Directed Mutagenesis of MMP8 
 
A mutagenesis PCR was used to generate a catalytically inactive MMP8 
(5’- CTTGTTGCTGCTCATGAATTTGGC to 
5’- CTTGTTGCTGCTCATGCATTTGGC). 
This results in a switch from glutamic acid (E) to alanine (A) at position 198 
(E198A). The reaction is carried out in duplicate and the mix consists of 5µl 10x 
reaction buffer , 45ng pcDNA4-WT MMP8 DNA, 125ng forward primer (5’- 
CTTGTTGCTGCTCATGCATTTGGCCATTCTTTGG), 125ng reverse primer (5’- 
CCAAAGAATGGCCAAATGCATGAGCAGCAACAAG), 1µl dNTPs and made 
up to 50µl with water. Lastly, 1µl Pfu Turbo polymerase (2.5U/µl) was added. All 
reagents were from Stratagene with the exception of primers from Sigma. The PCR 
cycles in a thermocycler were as follows: 30 seconds at 95˚C, and 16 cycles of 95˚C 
for 30 seconds and 68˚C for 7 minutes (2 minutes per kilobase of plasmid). 
Following the PCR reaction the samples were incubated on ice for 2 minutes before 
the addition of 1µl DpnI (10U/µl)(Statagene) which causes the parental, methylated 
DNA to be digested. This is added to one of the reactions only, the other serves as a 
negative control. The reactions were centrifuged for one minute and then incubated 
at 37˚C for hour for the parental DNA digestion to occur. Transformation of 4µl of 
the reaction was carried out (using standard transformation protocol section 2.2.1 and 
2.2.2) and the entire transformation was plated out onto lysogeny broth (LB) agar 
plates containing ampicillin (100µg/ml) as a selection reagent. Following incubation 
at 37˚C overnight colonies from the DpnI treated reaction were picked and put into 
3ml LB broth (+ 100µg/ml ampicillin) and incubated at 37˚C and shaken at 180rpm 
overnight. DNA was isolated from these cultures using the QIAPrep Miniprep kit 
(QIAGEN), following manufactures instructions. The presence of the mutation was 
detected by sequencing at the BBSRC Genome Analysis Centre, Norwich Research 
Park.  
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2.1.4 Cell Culture 
 
2.1.4.1 Cell Lines 
 
MDA-MB-231 and MCF-7 breast cancer cell lines were cultured in Dulbecco’s 
Modified Eagle Medium containing high glucose + GLUTAMAX (GIBCO, 21885). 
SKBR3 cells were cultured in McCoys 5A (GIBCO, 16600-082), HMT-3522 S1 
human breast epithelial cells [157] were cultured in Minimum Essential Media, 
MEM (GIBCO, 41090-028), and T47D cells were were cultured in RPMI-1640 plus 
4.5g/L D-glucose, 2.383g/L HEPES, L-Glutamine, 1.5g/L Sodium Bicarbonate, and 
110mg/L Sodium Pyruvate (GIBCO, A10491). All culture medium was 
supplemented with 10% (v/v) Fetal Bovine Serum (HyClone, SV30160.03).  Cells 
were passaged once a week when they reached 80- 90% confluency with the use of 
0.25% (w/v) Trypsin and 1mM EDTA (GIBCO, 25200-072). All cells grown in 
75cm
2
 or 175cm
2
 tissue culture flasks (NUNC) at 37˚C and 5% (v/v) CO2 in a 95% 
humidity incubator.  
 
2.1.4.2 Routine Mycoplasma testing 
 
Cells were tested weekly to ensure they were mycoplasma free. This was carried out 
through PCR reaction on 3-day culture supernatant.  Culture supernatant was boiled 
for 5 minutes before spinning down for 1 minute at high speed. Each PCR reaction 
consisted of:  
5.0µl 5x Phusion Buffer, 2.5µl 2mM dNTPs, 2.5µl 10µM Myco1 primer 
(GGGAGCAAACAGGATTAGATACCCT), 2.5µl 10µM Myco2 primer 
(TGCACCATCTGTCACTCTGTTACCCTC), 2.0µl boiled culture supernatant, 
0.25µl Phusion high fidelity Taq Polymerase, 10.25µl Water (Finzymes). The 
samples were run for 30 seconds at 98˚C, 40 cycles of: 10 seconds at 98˚C, 20 
seconds at 52˚C, 30 seconds at 72˚C finished with 2 minutes at 72˚C.  Products were 
resolved on a 2% agarose gel. If positive, a band will be seen at 270 base pairs.  
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2.2 DNA Propagation 
 
2.2.1 Plasmid Transformation 
 
To amplify the plasmid constructs pcDNA4, pcDNA4-WT MMP8 and pcDNA4- 
E198A MMP8, 1µl of DNA at 1µg/ml was added to 50µl of DH5α Compentent 
E.coli (Invitrogen) and incubated on ice for 30 minutes. The E.coli was then heat-
shocked for 5 minutes at 37˚C and then cooled on ice for 2 minutes. To this, 250µl of 
room temperature LB broth (table 2.2 ) was added and the tubes incubated at 37˚C, 
180rpm for 1 hour. Either the entire transformation reaction, for the MMP8 
constructs, or half, for the empty vector control was spread onto LB agar plates (see 
table 2.2) containing 100µg/ml ampicillin as a selection reagent for successful 
transformation and incubated at 37˚C overnight.  
 
2.2.2 Colony Expansion and DNA Extraction 
 
A single colony was picked and put into 100ml LB containing 100µg/ml ampicillin 
and incubated at 37˚C, 180rpm overnight. DNA was extracted using either QIAGEN 
Plasmid Midi Kit (cat #12143) or QIAGEN Plasmid Maxi Kit (cat #12963), 
following manufactures instructions, depending on the amount of DNA required. To 
check the sequence of the plasmid it was sent to the BBSRC Genome Analysis 
Centre, Norwich Research Park, and sequenced using primers specific to regions in 
the pcDNA4 plasmid either side of the cloning site  
(T7-20mer, 5’-TAATACGACTCACTATAGGG-3’ and BGH reverse,  
5’- TAGAAGGCACAGTCGAGG-3’-)  
2.3 Transfections 
2.3.1 Transient Transfections 
 
MCF-7, MDA-MB-231, SKBR3 and HMT-2552 S1 cells were plated 24-48 hours 
prior to transfection (400,000 cells/well of a 6-well tissue culture plate and 6 x 10
6
 
cells for a 10cm
2
 tissue culture dish) and transfected at 80-90% confluency with 
pcDNA4, pcDNA4-WT MMP8 and pcDNA4- E198A MMP8 plasmid DNA.  Two 
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transfections mixes were initially made; the first containing 50µl serum-free DMEM 
(per well of a 6-well plate) or 250µl serum-free DMEM (per 10cm
2
 dish) and 3µl (6-
well plate) or 9µl (10cm
2
 dish) of the transfection reagent LipoD293 (SignaGen 
Laboratories). The second mix, the DNA mix, contains the same volume of serum-
free DMEM as for the first mix with 1µg (6-well plate) or 3µg (10cm
2
 dish) plasmid 
DNA. Each mix was first mixed thoroughly by vortex and then the contents of the 
tube containing the LipoD293 was transferred to the tube containing the DNA, which 
was then mixed by vortex. The mix was incubated at room temperature for 15 
minutes. During incubation the media is removed and the cells were washed twice 
with PBS and media replaced: 900µl of serum-free DMEM per well of a 6-well plate 
and 4.5ml in a 10cm
2
 dish. The transfection mix was added dropwise to the cells 
(100µl per well of a 6-well plate and 500µl per 10cm
2
 dish) and cells were incubated 
for 6 hours at 37˚C. The cells were washed twice with PBS and 1ml (6-well plate) or 
5ml (10cm
2
 dish) of serum-free media is then added.  Conditioned media and cell 
lysate is harvested at time-points from 24 hours post transfection onwards.  
 
2.3.2 Kill Curve 
 
The pcDNA4 plasmid containing the MMP8 constructs contains a Zeocin resistance 
gene that was used when generating stable transfected MDA-MB-231 cells (section 
2.3.3). Cells that had not transfected successfully would die after Zeocin treatment, 
leaving only the transfected cells. The amount of Zeocin used had to be optimised as 
too much would be toxic and too little would not kill the cells off fast enough.  
To determine the optimum concentration of Zeocin MDA-MB-231 cells (100,000 
cells per well of a 6 well plate) were treated with a range of Zeocin concentrations 
from 20-100µg/ml, with media containing Zeocin refreshed every 3 days over 2 
weeks. The concentration of 40µg/ml was decided upon as most of the cells had died 
after 2 weeks of treatment, whereas cell death had occurred much earlier with higher 
concentrations.  
 
2.3.3 Stable Transfection 
 
MDA-MD-231 cells were engineered to constitutively over-express pcDNA4 wild 
type MMP8 plasmid DNA, pcDNA4 E198A mutant MMP8 plasmid DNA and a 
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pcDNA4 vector control plasmid (empty vector). The calcium phosphate method of 
transfection was used. This method makes use of a co-precipitation reaction that 
occurs on the mixing of DNA together with Calcium Chloride and a HEPES-
buffered solution, which,  when introduced into the culture media adheres to the cells 
and is taken up by endocytosis or phagocytosis [158]. 
 
Cells (75,000 cells/well of a 6 well plate) were seeded 24 hours prior to transfection 
so that they were at 20-30% confluency.  An hour before transfection, 1.5ml of fresh 
medium (supplemented with FBS) was put on the cells, and the reagents, 2 x HBS 
buffer and CaCl2 (see table 2.2 for recipe) were brought to room temperature. In a 
sterile eppendorf tube a mix was made of 4µg plasmid DNA, 7.6µl 2M CaCl2 and 
made up to 62µl total volume with sterilised distilled water. This is the mix produced 
for one well of a six well plate, but as six wells were transfected with each construct 
a mastermix is made. In a separate tube 62µl (per well to be transfected) of 2x HBS 
was added. The HBS was bubbled using an automatic pipette pump attached to a 1ml 
serological pipette, with a sterile 200µl pipette tip attached to the end whilst the 
CaCl2-DNA mix was added dropwise into it. Once all the CaCl2-DNA mix had been 
completely transferred the mix was mixed briefly by vortex and left to precipitate for 
20 minutes at room temperature. Following incubation 124µl of the transfection mix 
was added to each well of the 6-well plate 1 drop/second whilst gently tilting the 
plate constantly. After 16 hours incubation at 37˚C the transfection media was 
removed from the cells, they were washed twice in PBS to remove all traces of the 
transfection mix and 3ml of complete medium added. The selection reagent, Zeocin 
(Invitrogen, R250) was added at 40µg/ml (see section 2.3.2) to the media 48 hours 
after transfection. The selection media was replaced every 3 days throughout all 
experiments. When appropriate (after approximately 1 month) cells were grown up 
into larger culture vessels as pooled stably transfected cells.  MMP8 expression was 
determined by western blotting and Taqman qRT-PCR. 
 
Clonal isolates were generated from the pooled cell lines expressing MMP8 at the 
protein level by diluting out cells in a 96-well plate. Wells containing single cells 
were maintained under selection and taken up into larger vessels when appropriate.   
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2.3.4 Transfection Monitoring Experiment 
 
MDA-MB-231 cells expressing wild-type MMP-8 and EA mutant MMP-8 six weeks 
post stable transfection were divided into two, with half of the cells maintained under 
Zeocin selection and the other half without. Every two weeks cells were plated 
(250,000 cells per well of a 6 well plate) and left to adhere for 24 hours, after which 
they were washed with PBS and 1ml serum-free media added. After 24 hours of 
culture in serum-free media the media was collected, centrifuged at 193xg to remove 
any cells, and tested for MMP-8 expression by western blot.  
 
2.3.5 siRNA transfection 
 
MDA-MB-231 cells over-expressing wild-type MMP8 were transfected at 60% 
confluency with 25nM of either IL-6 (siGENOME SMARTpool M-007993-02-0005, 
Dharmacon), IL-8 (siGENOME SMARTpool M-004756-00-0005, Dharmacon) or 
control siRNA (siGENOME Non-Targeting siRNA Pool #1 D-001206-13-05, 
Dharmacon) using DharmaFECT 1 Transfection Reagent (Dharmacon, T-2001-02). 
RNA was collected 48 hours later for analysis (for methodology for RNA collection 
see section 2.5.1-2.5.3). Cells transfected with MMP8 siRNA (siGENOME 
SMARTpool M-005969-00-0005, Dharmacon) or F2RL1 (PAR2) (siGENOME 
SMARTpool, M-005098-01-005, Dharmacon) were re-transfected 24 hours after the 
first transfection and serum free cell culture supernatant, RNA and cell lysate 
collected for analysis 48 hours after the second transfection.  
 
2.3.6 Colony Formation Assay 
 
MDA-MB-231 cells were transfected with pcDNA4 empty vector, wild-type MMP8 
and EA mutant MMP8 as for stable transfection (section 2.3.2). To prevent cells 
becoming confluent before they started dying off from the addition of Zeocin they 
were split, with 1/3 of the transfected cells continuing in a fresh 6 well plate. To 
speed up the rate of death of untransfected cells Zeocin was added at 200µg/ml and 
was replaced every 3 days. One well of cells was not transfected and was used as a 
control for cell death. When the control cells had all died and when individual 
colonies were visible by eye (approximately 20 days post transfection) cells were 
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washed with PBS and stained with methylene blue for thirty minutes at room 
temperature to fix the cells and visualise the colonies. Excess methylene blue was 
washed off with water and the plate imaged (Syngene, G:Box) and the number of 
colonies quantified by eye and ImageJ software.  
2.4 Protein Analysis 
2.4.1 Protein Extraction 
 
Serum-free conditioned media was removed from cells, spun down at 2152xg for 5 
minutes to clear it of any cells, and the supernatant stored at -20˚C.  The cells were 
washed twice in ice cold PBS (table 2.2) to ensure total removal of media. 
Depending on the size of the vessel, cells are either scraped directly into ice cold 
RIPA lysis buffer (table 2.2) containing Protease Inhibitor (1 Complete Mini, EDTA-
free tablet, Roche, per 10ml of lysis buffer) which inhibits a broad range of cysteine 
and serine proteases, but not metallo or aspartic proteases. Alternatively, cells were 
scraped into a larger volume of PBS which was centrifuged at 193xg for 5 minutes 
and the cell pellet resuspended in lysis buffer (plus protease inhibitor). This is then 
incubated on ice for 30 minutes to allow cell lysis. Following this cell debris is 
removed by centrifugation at high speed for 10 minutes and the pellet discarded. 
Lysate is stored at -20˚C until required.  
 
2.4.2 Protein Quantification- Bicinchoninic acid (BCA) Assay 
 
Protein quantification was carried out using a BCA Protein Assay Kit (Thermo 
Scientific #23227) as this kit is compatible with the TRITON-X in the cell lysis 
buffer. It is a colorimetric assay consisting of two- reactions. The first reaction 
involves chelation of copper by protein in the sample, resulting in a blue colour. 
The second step is the reaction of the chelated copper with the BCA, forming a 
deep purple colour of which the absorbance when determined at 550nm is 
linear to the amount of protein present. Experimental samples are measure 
against a standard curve which is generated using bovine serum albumin (BSA) 
at known concentrations (0, 0.125, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0 mg/ml). 
Standards and experimental samples were put in a 96-well plate (10µl) and 
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200µl of working solution was added to each well. This solution consists of 
reagent B (containing 4% cupric sulphate) and reagent A (containing 
bicinchoninic acid) from the kit mixed in a 1:50 ratio. The plate was incubated at 
37˚C for 30 minutes before allowing it to cool at room temperature and reading 
the absorbance at 550nm on a plate reader (BMG labtech Fluostar). The 
absorbance value of the lysis buffer was deducted from the absorbance values of 
the standards and samples to correct for background signal. The concentration 
of protein in the sample was determined from the BSA standard using linear 
regression to obtain a straight line curve. 
 
2.4.3 Conditioned Media Concentration- trichloroacetic acid (TCA) 
precipitation  
 
To concentrate the proteins in conditioned media samples in order to analyse 
them by western blotting 10% (w/v) TCA was added to the media at a volume of 
the equivalent of 1/3rd of the media to be concentrated. The sample was then 
incubated on ice for 5 minutes during which time the highly acidic TCA 
denatures and precipitates the proteins in the sample. The sample was 
centrifuged at high speed for 5 minutes to pellet the precipitated protein. After 
discarding the supernatant the pellet was washed twice in 400µl of ice-cold 
acetone, centrifuging at 14550xg for 5 minutes. The pellet was air-dried for 5 
minutes before being re-suspended in 50µl sample buffer (table 2.2). Unless 
otherwise stated the entire 50 µl sample was analysed by western blot.  
 
2.4.4 Western Blotting 
 
Denatured and reduced cell lysate (30ug of protein unless stated otherwise) and 
conditioned media samples (TCA precipitated) were boiled for 3 minutes with SDS 
sample buffer (table 2. ) and unless otherwise stated run on 10% resolving gel 
(resolving gel: 4ml dH20, 3.33ml Acrylamide, 2.5ml 1.5M TRIS pH 8.8, 100µl SDS, 
100µl APS, 5µl TEMED. Stacking top gel: 4ml dH20, 1ml acrylamide, 0.6M TRIS 
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pH 6.8, 60µl SDS, 75µl APS, 7µl TEMED). The samples were run at 200 volts for 1 
hour alongside a dual colour protein ladder (BioRad).  
 
The gel was transferred onto Immobilon-FL transfer membrane (Millipore, 
IPFL00010) or nitrocellulose (GE Healthcare, RPN203D) using a semi-dry transfer 
module at 15 volts for 1 ½ hours. To ensure consistent transfer of protein had 
occurred membranes were incubated for 5 minutes in Ponceau S red stain (table 2.1 
). The membranes were then blocked in 5% (w/v) Bovine Serum Albumin (BSA) in 
PBS or Tris Buffered Saline (TBS) containing 0.1% (v/v) TWEEN-20 for at least 
one hour at room temperature. Primary antibodies (see table 2.3) were diluted in 5% 
BSA or skimmed milk prepared in either PBS or TBS containing 0.1% (v/v) 
TWEEN depending on the specific requirements for the individual antibody, and 
were left on the membrane overnight at 4⁰ C under constant agitation. The 
membrane was washed 3 times for 10 minutes each in PBS or TBS containing 0.1% 
(v/v) TWEEN under constant agitation before addition of the secondary antibody 
(see table 2.3).  Unless otherwise stated the appropriate secondary antibody (see table 
2.2 for secondary antibodies used) was used at 1:10,000 in 5% BSA made in PBS or 
TBS  containing  0.1% (v/v) TWEEN for the Infra-Red conjugated antibodies and 
1:1000 for the HRP-conjugated ones and incubated for 2 hours at room temperature. 
This was followed by another 3 x 10 minute washes in PBS or TBS containing 0.1% 
TWEEN, and then a final 10 minute wash in PBS, under constant agitation. If using 
Horse Radish Peroxidase (HRP) conjugated secondary antibodies blots were treated 
for 5 minutes with ECL (Thermo Scientific, 32106) and then imaged using the 
FujiFilm Intelligent Darkbox LAS-3000. If using Infra-Red antibodies blots were 
images using the Odyssey Infra-Red scanner (Licor).  
 
2.4.5 Enzyme Linked Immunosorbent Assay (ELISA) 
 
Human Interleukin-6, Interleukin-8 and Tumour Necrosis Factor (TNF)-α 
ReadySET-Go! ELISAs were purchased from eBioscience (catalogue numbers 88-
7066-22, 88-7087-22 and 88-7346 respectively) and used to analyse serum free cell 
supernatant samples according to manufacturer’s instructions. Media was diluted 
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1:10 where appropriate to ensure samples fell within the predetermined range of the 
standard curve.  
 
2.4.6 Human Phospho-Kinase Array Kit 
 
The Proteome Profiler
TM 
Antibody array (R&D Systems, ARY003) utilises 
antibodies to an array of phospho-kinase proteins for detection pre-stamped on a 
nitrocellulose membrane. According to manufacturer’s instructions lysate from 
MDA-MB-231 wild-type and EA mutant MMP8 over-expressing and vector control 
clonal isolates that had been serum starved for 24 hours was applied to the 
membranes. The membrane was then incubated with a secondary, HRP-conjugated 
antibody that bound to a different part of the protein. The resulting membranes were 
treated with ECL (Thermo Scientific, 32106) for 5 minutes and then 
chemiluminescence imaged using a FujiFilm Intelligent Darkroom imager. Pixel 
intensity was quantified using the ‘gel analyser’ tool in Image J 
(http://rsweb.nih.gov/ij/).  
 
2.4.7 Cytometric Bead Array 
 
Cells were transiently transfected with pcDNA4 vector control, Wild Type MMP8 
and E198A Mutant MMP8 plasmid constructs (2.3.1) and transfection success 
confirmed by western blot of serum free cell culture media collected 48 hours post 
transfection (2.4.3 and 2.4.4). The commercially available Human Inflammatory 
Cytokine Kit was used (BD Bioscience, 551811) according to manufacturer’s 
guidelines and using a BDFACSAria
TM
II flow cytometer to determine the levels of 
IL-8, IL-1β , IL-10, TNF, IL-6, IL-12p70 in the conditioned media from the 
transiently transfected cells.  
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2.4.8 Immunoprecipitation of MMP8 and Mass Spectrometry to 
determine MMP8 binding partners 
 
2.4.8.1  Immunoprecipitation of MMP8 from conditioned cell culture media 
 
MDA-MB-231 stably over-expressing pcDNA4 vector control, wild-type MMP8 and 
E198A mutant MMP8 DNA were grown to 80% confluency in T175 cell culture 
flasks before being washed with PBS and 15mls serum free media added overnight. 
Media was centrifuged to pellet any cells and 14.5mls of media was incubated 
overnight at 4˚C under constant rotation with 150µl of anti-V5 Agarose beads 
(Sigma, A7345) that had been prewashed with RIPA lysis buffer (table 2.2). The 
bound beads were pelleted by centrifugation at 193xg for 5 minutes and washed 3 
times using RIPA buffer. Protein was stripped from the beads by the addition of 60µl 
SDS sample buffer (table 2.2) containing 4% (w/v) DTT and boiled for 5 minutes. 
Finally the beads were pelleted by centrifugation and 50µl of the 
immunoprecipitation reaction, IP, (the equivalent to 12mls of media precipitated) 
was loaded onto a 4-20% precast Tris-Glycine gradient gel (NuSep, Peqlab, NB10-
420) and run for 45 minutes at 200V. The gel was then stained using SimplyBlue
TM
 
SafeStain (Invitrogen, LC6060). Visible bands were then cut from the gel and sent 
for analysis at the Mass Spectrometry Services at the John Innes Centre, Norwich 
Research Park (see section 2.4.8.2). The remaining 10µl of the immunoprecipitation 
reaction was also run on a 4-20% precast Tris-Glycine gradient gel (NuSep, Peqlab, 
NB10-420) for 45 mins at 200V but the standard western blotting protocol (section 
2.4.4)  was followed and the blot probed with an anti-MMP8 antibody to confirm 
that the IP was successful.  
 
2.4.8.2 Mass Spectrometry  
 
With many thanks to Gerhard Saalbach, John Innes Centre, Norwich Research 
Park. 
The exised immunoprecipitation gel bands (procedure described in section 
2.4.8.1, above) were send to the Mass Spectrometry Services at the John Innes 
Centre, Norwich Research Park where they were washed, reduced and 
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alkylated, and treated with trypsin according to standard procedures. Peptides 
were extracted with 5% formic acid/50% acetonitrile, dried down, and re-
dissolved in 0.1% TFA. For LC-MS/MS analysis, a sample aliquot was applied via 
a nanoAcquityTM(Waters Ltd, Manchester, UK ) UPLCTM-system running at a flow 
rate of 250 nL min-1 to an LTQ-Orbitrap™ mass spectrometer (Thermo Fisher, 
Waltham, MA). Peptides were trapped using a pre-column (Symmetry ® C18, 
5µm, 180 µm x 20 mm, Waters Ltd) which was then switched in-line to an 
analytical column (BEH C18,1.7 µm, 75 µm x 250 mm, Waters Ltd) for 
separation. Peptides were eluted with a gradient of 3-37% acetonitrile in 
water/0.1% formic acid at a rate of 0.67% min-1. The column was connected to a 
10 µm SilicaTip™ nanospray emitter (New Objective, Woburn, MA, USA) 
attached to a nanospray interface (Proxeon, Odense, Denmark) for infusion into 
the mass spectrometer. The mass spectrometer was operated in positive ion 
mode at a capillary temperature of 200 °C. The source voltage and focusing 
voltages were tuned for the transmission of MRFA peptide (m/z 524) (Sigma-
Aldrich, St. Louis, MO). Data dependent analysis was carried out in oribtrap-IT 
parallel mode using CID fragmentation on the 5 most abundant ions in each 
cycle. The orbitrap was run with a resolution of 30,000 over the MS range from 
m/z 350 to m/z 1800 and an MS target of 106 and 1 s maximum scan time. 
Collision energy was 35, and an isolation width of 2 was used. Only mono-
isotopic 2+ and 3+ charged precursors were selected for MS2. The MS2 was 
triggered by a minimal signal of 1000 with an AGC target of 3x104 ions and 150 
ms scan time using the chromatography function for peak apex detection. 
Dynamic exclusion was set to 1 count and 30 s exclusion with an exclusion mass 
window of ±20 ppm. MS scans were saved in profile mode while MSMS scans 
were saved in centroid mode. 
Raw files were processed with MaxQuant version 1.3.0.3 ( http://maxquant.org) 
[159] to generate re-calibrated peaklist-files which were used for a database 
search using an in-house Mascot® 2.3 Server (Matrix Science Limited, London, 
UK). Mascot-mgf files were generated from MaxQuant apl-files using a suitable 
perl script. Mascot searches were performed on the 
Sprot_sptrembl20120711.fasta database with taxonomy set to human and a 
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common contaminants database using trypsin/P with 2 missed cleavages, 6 
ppm precursor tolerance, 0.8 Da fragment tolerance, carbamidomethylation (C) 
as fixed, and oxidation (M) and acetylation (protein N-terminus) as variable 
modifications. Mascot search results were imported and evaluated in Scaffold 3 
(proteomsoftware.com, Portland, OR, USA) resulting in a false discovery rate of 
0% for both peptides and proteins. 
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2.5 Gene Expression Analysis 
 
Depending on the amount of RNA required and whether conditioned media was also 
required from the same cells two different methods of RNA isolation were used. The 
predominent method used is described in sections 2.5.1 and 2.5.2  and was used 
when cells were cultured on 6 well plates or 10cm
2 
dishes when conditioned media 
was required for other assays. If there was no requirement to harvest any conditioned 
media from the experiment it was carried out on a much smaller scale as described in 
section 2.5.3.  
 
2.5.1 RNA Collection and Extraction 
 
Cells were washed twice in PBS before being scraped into 500µl RNA-Bee RNA 
isolation reagent (amsbio, CS-501B), transferred to a tube and stored at -80⁰ C until 
extraction. A chloroform extraction was performed in combination with the SV Total 
RNA Isolation System (Promega, Z3100). On ice, 100µl chloroform was added to 
the sample, mixed by inversion and returned to ice for 5 minutes. This was then 
centrifuged at high speed for 15 minutes at 4⁰ C. The upper clear layer was 
transferred to a fresh tube and the lower layer discarded. To the upper layer 200µl of 
95% ethanol was added. The mixture was added to the spin column provided with 
the SV Total RNA Isolation System. RNA quantification were checked using a nano-
drop (Thermo Scientific).  
 
2.5.2 Reverse Transcription 
 
RNA (1µg) was mixed with 2µl Random Primers(200 ng/ µl)  and 1µl of dNTP mix 
(10mM), and the volume made up to 11 µl with ddH20. The mixture was heated at 
70⁰ C for 10 minutes before being returned to ice. A was then made up for all 
samples consisting of 2µl 10 x MMLV buffer , 1µl Moloney Murine Leukemia Virus 
(MMLV) Reverse Transcriptase and 0.5µl RNAse OUT Ribonuclease Inhibitor (all 
reagents from Invitrogen) per sample, with 9µl added per sample to give a 20µl 
reaction. Samples were incubated at 37˚C for 1 hour, followed by deactivation of the 
MMLV by heating to 85˚C for 10 minutes. This results in a total of 20µl cDNA at 
50ng/µl.  
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2.5.3 Cells-to-cDNA 
 
A maximum of 100,000 cells were lysed in 30µl cells-to-cDNA lysis buffer 
(Ambion, AM8723) and incubated at 75˚C for 15 minutes. For each sample 1µl of 
DNAse I (2U/µl, Ambion, AM2222) and 3µl 10x DNAse buffer (AM8170G) was 
added and incubated at 37˚C for 15 minutes followed by 75˚C for 5 minutes. Of this 
mixture 8µl is transferred to a fresh tube along with 1µl dNTPs (10mM) and 2µl 
Random Primers (200ng/µl, both Invitrogen). Samples were incubated at 70˚C for 5 
minutes and then the remaining reverse transcription reagents were added: 4µl 5x 
Reverse Transcriptase buffer, 2µl 0.1M DTT, 1.5µl nuclease free water, 0.5µl 
MMLV reverse transcriptase and 1µl RNAse OUT (all Invitrogen). This final mix 
was incubated at 37˚C for 50 minutes followed by 75˚C for 15 minutes to deactivate 
the MMLV Reverse Transcriptase. To this, 30µl of nuclease free water was added. 
When analysing the samples by Taqman qRT-PCR (section 2.5.4) 5µl of the 
resulting cDNA was used to look for a gene of interest and 5µl of a 1:10 dilution was 
used when looking at 18S expression levels as a normaliser gene.  
 
2.5.4. Taqman Quantitative Real-Time PCR 
 
Taqman Quantatitative Real-Time PCR analysis was carried out to determine the 
level of expression of a gene of interest in RNA extracted from cells in culture.  A 
total of 5ng cDNA (10µl of 0.5ng/µl dilution), or 5µl if using the cell-to-cDNA 
method (section 2.5.3) was loaded per well in combination with 8.33µl of mastermix 
(Primer Design), the appropriate primer-probe (see table 2.4) and nuclease free water 
to make the reaction up to 25µl. 18S ribosomal RNA was used as a normalising 
marker, and had previously been shown to be expressed at a consistent level in the 
type of samples analysed,  into which 1ng is used due to it being highly abundant. 
When using a new primer-probe set samples were compared to a standard curve 
which assesses how well the probe is reacting to a variety of cDNA concentrations. 
Serial dilutions of a sample expected to show good levels of expression of the gene 
of interest were generated ranging from 20-0.625ng, and 1-0.03125ng for the 18S 
reference gene. The reaction was run on and ABI7500 machine (Applied 
Biosystems) using the following cycles:  2 mins at 50˚C, 10 mins at 95˚C followed 
Chapter 2- Materials and Methods 
 
73 
 
by 40 cycles of 15 secs at 90˚C and 1 min at 60˚C.  Data was analysed using the 2-ΔCt 
method comparing Ct values of the gene of interest to 18 values.  
 
Target  Sequence 
Timp 1 Forward Primer: 
Reverse Primer: 
Probe: 
5'- GACGGCCTTCTGCAATTCC -3' 
5'- GTATAAGGTGGTCTGGTTGACTTCTG -3' 
5'-FAM- ACCTCGTCATCAGGGCCAAGTTCGT -TAMRA-3' 
Timp 2 Forward Primer: 
Reverse Primer: 
Probe: 
5'- GAGCCTGAACCACAGGTACCA -3' 
5'- AGGAGATGTAGCACGGGATCA -3' 
5'-FAM- CTGCGAGTGCAAGATCACGCGC -TAMRA-3' 
Timp 3 Forward Primer: 
Reverse Primer: 
Probe: 
5'- CCAGGACGCCTTCTGCAA -3' 
5'- CCCCTCCTTTACCAGCTTCTTC -3' 
5'-FAM- CGACATCGTGATCCGGGCCA -TAMRA-3' 
Timp 4 Forward Primer: 
Reverse Primer: 
Probe: 
5'- CACCCTCAGCAGCACATCTG -3' 
5'- GGCCGGAACTACCTTCTCACT -3' 
5'-FAM- CACTCGGCACTTGTGATTCGGGC -TAMRA-3' 
MMP-1 Forward Primer: 
Reverse Primer: 
Probe: 
5’- AAGATGAAAGGTGGACCAACAATT -3’ 
5’ -CCAAGAGAATGGCCGAGTTC -3’ 
5’- FAM-CAGAGAGTACAACTTACATCGTGTTGCGGCTC-
TAMRA -3’ 
MMP-2 Forward Primer: 
Reverse Primer: 
Probe: 
5’- AACTACGATGACGACCGCAAGT -3’ 
5’- AGGTGTAAATGGGTGCCATCA -3’ 
5’- FAM-CTTCTGCCCTGACCAAGGGTACAGCC-TAMRA -3’ 
MMP-3 Forward Primer: 
Reverse Primer: 
Probe: 
5’- TTCCGCCTGTCTCAAGATGATAT -3’ 
5’- AAAGGACAAAGCAGGATCACAGTT -3’ 
5’- FAM-TCAGTCCCTCTATGGACCTCCCCCTGAC-TAMRA 
-3’ 
MMP-7 Forward Primer: 
Reverse Primer: 
Probe: 
5’-CTTTGCGCGAGGAGCTCA -3’ 
5’-CAGGCGCAAAGGCATGA -3’ 
5’- FAM-CCATTTGATGGGCCAGGAAACACG-TAMRA -3’ 
MMP-8 
 
 Primer-probe ready-made assay from Primer Design 
MMP-9 Forward Primer: 
Reverse Primer: 
Probe: 
5’- AGGCGCTCATGTACCCTATGTAC -3’ 
5’- GCCGTGGCTCAGGTTCA -3’ 
5’- FAM-CATCCGGCACCTCTATGGTCCTCG -TAMRA -3’ 
MMP-10 Forward Primer: 
Reverse Primer: 
Probe: 
5’- GGACCTGGGCTTTATGGAGATAT -3’ 
5’- CCCAGGGAGTGGCCAAGT -3’ 
5’- FAM- CATCAGGCACCAATTTATTCCTCGTTGCT-
TAMRA -3’ 
MMP-11 Forward Primer: 
Reverse Primer: 
Probe: 
5’-GGGTGCCCTCTGAGTCGA -3’ 
5’-TCACAGGGTCAAACTTCCAGTAGA -3’ 
5’- FAM-ATGCTGATGGCTATGCCTACTTCCTGCG -TAMRA 
-3’ 
MMP-12 Forward Primer: 
Reverse Primer: 
Probe: 
5’- CGCCTCTCTGCTGATGACATAC -3’ 
5’- GGTAGTGACAGCATCAAAACTCAAA -3’ 
5’- FAM-TCCCTGTATGGAGACCCAAAAGAGAACCA-
TAMRA -3’ 
MMP-13 Forward Primer: 
Reverse Primer: 
Probe: 
5’- AAATTATGGAGGAGATGCCCATT -3’ 
5’- TCCTTGGAGTGGTCAAGACCTAA -3’ 
5’- FAM-CTACAACTTGTTTCTTGTTGCTGCGCATGA-
TAMRA -3’ 
MMP-14 Forward Primer: 
Reverse Primer: 
Probe: 
5’-AAGGCCAATGTTCGAAGGAA -3’ 
5’-GGCCTCGTATGTGGCATACTC -3’ 
5’- FAM-
CAACATAATGAAATCACTTTCTGCATCCAGAATTACA -
TAMRA -3’ 
MMP-15 Forward Primer: 
Reverse Primer: 
Probe: 
5’- GCGCTTCAACGAGGAGACA -3’ 
5’- TCCAGTATTTGGTGCCCTTGT -3’ 
5’- FAM- CCTTCCTGAGCAATGACGCAGCCTAC -TAMRA -
3’ 
 
Table 2.4: Taqman primer-probes. All primers and probes were 
purchased from Sigma with the exception of those noted.  
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Target  Sequence 
MMP-16 Forward Primer: 
Reverse Primer: 
Probe: 
5’- ATGATTTACAGGGCATCCAGAAA -3’ 
5’- TGGAGGCCGAGGAGGTTT -3’ 
5’- FAM-CAAGATT 
CCTCCACCTACAAGACCTCTACCGAC-TAMRA -3’ 
MMP-17 Forward Primer: 
Reverse Primer: 
Probe: 
5’- FAM- GCGGGTATCCTTCCTCTACGT -3’ 
5’- CAGCGACCACAAGATCGTCTT -3’ 
5’- FAM- 
ATTGTCCTTGAACACCCAGTACCTGTCTCCTTTAA -
TAMRA -3’ 
MMP-19 Forward Primer: 
Reverse Primer: 
Probe: 
5’- GGCTACCGGCCCCACTT -3’ 
5’- TGTCTCTTCTTCTTCCTCATCCCTTA -3’ 
5’- FAM- ATCCAGGCTCTCTATGGCAAGAAGAGTCCA-
TAMRA -3’ 
MMP-20 Forward Primer: 
Reverse Primer: 
Probe: 
5’- CCTTTGACGCTGTGACAATGC -3’ 
5’- TCCTGTCCGCAAGTGAACCT -3’ 
5’- FAM-TCCTGCTCTTCAAGGACCGGATTTTCTG -
TAMRA -3’ 
MMP-21 Forward Primer: 
Reverse Primer: 
Probe: 
5’-CCAGTGACACGGGCATCA -3’ 
5’- ATTATGGATCCCGTCCTGTAGGT -3’ 
5’- FAM-CCTTCTCAAGGTGGCCGTCCATGA-TAMRA -3’ 
MMP-23 Forward Primer: 
Reverse Primer: 
Probe: 
5’- TCCACAAGAAAGGGAAAGTGTACTG -3’ 
5’- ACGGCGTTGGCGATGAT -3’ 
5’- FAM-TTCTCCTACCCCGGCTACCTGGCC -3’ 
MMP-24 Forward Primer: 
Reverse Primer: 
Probe: 
5’- CCAGTACATGGAGACGCACAA -3’ 
5’- TGCGGACGGGGAGTGT -3’ 
5’- FAM- CAGGGCATCCAGAAGATCTATGGACCC -
TAMRA -3’ 
MMP-25 Forward Primer: 
Reverse Primer: 
Probe: 
5’- GACGATGAGGAGACCTGGACTTT -3’ 
5’- CCTGGTAGAAGGGCCTCATAATG -3’ 
5’- FAM-CCGACCTGTTTGCCGTGGCTGTC -3’ 
MMP-26 Forward Primer: 
Reverse Primer: 
Probe: 
5’- AATTCTGGAAATCCTGGAGTTGTC -3’ 
5’- CAAAGAATGCCCAATCTCATGA -3’ 
5’- FAM-
CTGGTCAGCTTCAGACACTGGATATAATCTGTTCC-
TAMRA -3’ 
MMP-27 Forward Primer: 
Reverse Primer: 
Probe: 
5’- GTTTAGAAGTGTGGAGCAAAGTCACT -3’ 
5’- ATAGCGAGGACACCGACCAT -3’ 
5’- FAM- CATCATGATTGCCTTTAGGACTCGAGTCCA -
TAMRA -3’ 
MMP-28 Forward Primer: 
Reverse Primer: 
Probe: 
5’- TTTGAGACCTGGGACTCCTACAG -3’ 
5’- CCCAGAAATGGCTCCCTTTA -3’ 
5’- FAM- ACTCTTCCTTCGATGCCATCACTGTAGACAG -
TAMRA -3’ 
Interleukin-6  Primer-probe ready-made assay from Applied Biosystems 
catalogue # Hs00985639_m1 
Interleukin-8  Primer-probe ready-made assay from Applied Biosystems 
catalogue # Hs00174103_m1 
PAR2 (F2RL1) Forward Primer: 
Reverse Primer: 
Probe: 
5’- CGTCCAGTGGAGCTCTGAGT -3’ 
5’- GCAGGAGAGAGAGGCTGCTA -3’ 
Universal Probe#3 (Roche) 
Table 2.4: Taqman primer-probes. All primers and probes were 
purchased from Sigma with the exception of those noted.  
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2.6 Functional Cell Assays 
2.6.1 Proliferation 
 
Cells (20,000 cells per well of a 24 well plate) were seeded in triplicate and 
maintained in media supplemented with 10% FBS. Accurate cell counts using a 
haemocytometer were taken after 24, 48, 72 and 96 hours. 
 
2.6.2 2-D Time Lapse Microscopy 
 
Cells ( cells per well of a 24 well plate) were seeded in quadruplicate 24 hours prior 
to the experiment in media supplemented with 10% FBS. Cells were serum starved 
for 6 hours prior to imaging and throughout the course of the experiment. Using a 
Zeiss Axiovert with an inbuilt camera the same group of cells were imaged every 10 
minutes over a 15 hour time period. Ten individual cells were tracked per well of the 
plate using Image J software utilising the ‘Manual Tracking’ tool 
(http://rsweb.nih.gov/ij/plugins/track/track.html) and the distance accumulated and 
velocity of the cells was determined using the ‘Chemotaxis’ application 
(http://ibidi.de/applications/ap chemo.html). Three biological replicates were carried 
out. 
 
2.6.3 Scratch Wound Assay  
 
Cells (250,000 cells per well of a 12 well plate) were seeded in triplicate 24 hours 
prior to experiment in media supplemented with 10% FBS. By 24 hours post seeding 
the cells were 100% confluent. The media was removed from the cells and they were 
washed with serum-free media. The scratch was made through the centre of the well 
with a p10 pipette tip. The cells were then washed a further two times with serum-
free DMEM to remove any detached cells before replacing it with 1ml fresh serum-
free DMEM. Pictures were taken (x10 objective) immediately after the scratch 
wound was made and then 24 hours later. Cells were imaged at 9 hours and 24 hours 
post making the scratch wound. Wound closure was analysed using Axiovision 
software that enabled the scratch to be measured. Scratch wound closure was 
expressed as a percentage of the original scratch wound size.  Three biological 
replicates were carried out.  
Chapter 2- Materials and Methods 
 
76 
 
2.6.4 Inverted Invasion Assay 
 
Collagen type I gels were prepared by the mixing of Type I Collagen (Rat Tail Type 
I, First Link UK, 60-30-810) and 10X DMEM in a 1:10 ratio (10x DMEM: Type I 
Collagen) on ice. To polymerise the gels the pH was increased through the gradual 
addition of 10M NaOH until the gel maintains an orange/pink colour. This was put 
into the well of an 8.0µm Transwell (100µl per transwell), which was suspended in 
the well of a 24 well plate, and incubated at 37˚C for 30 minutes until set. Once set 
the transwells were inverted and MDA-MB-231 clonal isolates (pcDNA4 empty 
vector, wild-type MMP8 and E198A Mutant MMP8) were seeded at a density of 
50,000 cells in 100µl of complete media onto the underside of the transwell by 
reverse pipetting. Cells were allowed to adhere for 4 hours at 37˚C before being 
reverted back so that the gel is on the upper facing side of the transwell membrane 
and the cells are on the lower side. The transwells were washed twice in pre-
incubated serum-free media to remove any unattached cells and serum and left in 
1ml pre-warmed serum free media. As a chemoattractant for the cells through the gel 
100µl of complete media with 50ng/µl EGF was added on top of the gel in the 
transwell. The assay was then incubated for 48 hours at 37˚C for invasion to occur 
before imaging. To allow for cell imaging live cells were stained with 4µM Calcein 
AM (Invitrogen) in 1ml of serum free media to cover the gel for an hour before 
imaging. Invasion was measured using a laser-scanning confocal microscope (Leica) 
that took images at 15µm sections throughout the gel starting at the bottom on the gel 
where the cells were initially seeded. Analysis was carried out using the ‘Area 
Calculator’ PlugIn (http://rsb.info.nih.gov/ij/plugins/area.html) in ImageJ to calculate 
the total area of cells in each 15µm section. Results are expressed as the percentage 
of cells (by area) that migrate past 30µm into the type I collagen plug over the total 
area of cells in the gel.  
 
2.6.5 Adhesion Assay  
 
Type I Collagen, Fibronectin and Laminin (100µl per well of a 96 well plate) were 
coated at 5µg /µl in coating buffer (table 2.2) and left to coat overnight at 4˚C. Wells 
coated with coating buffer only were used as a control. Prior to seeding cells, the 
coating buffer was removed and the wells were washed twice with PBS. They were 
then blocked with 100µl of 1% BSA for 30 minutes at 37˚C. Cells were trypsinised, 
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quenched with complete media, centrifuged at 1000rpm for 5 mins, resuspended in 
serum free media and counted. This centrifugation step is to remove as much serum 
as possible from the cells. The number of cells required were centrifuged and 
resuspended in serum free media with a final concentration of 6000 MDA-MB-231 
cells per 100µl of serum free media. The wells were again washed twice with PBS. 
Cells were added (100µl serum free media containing 6000 cells per well) and 
allowed to adhere for 1 hour at 37˚C. The plate was then inverted to remove media 
and the wells were washed gently twice with PBS. Adhered cells were fixed and 
stained with methylene blue (table 2.2) for 30 minutes at room temperature. Excess 
stain was removed by holding the plate under running water until it ran clear. To 
quantify adhesion the stain was eluted by the addition of 100µl destain (50% EtOH, 
50% 0.1M HCl) for 10 minutes at room temperature and absorbance measured at 
630nm on a plate reader (BMG labtech Fluostar). For analysis the values obtained 
for the coating buffer only control were subtracted from the values obtained for the 
matrix coatings to eliminate any background readings arising from the coating 
buffer.  
 
2.6.6 MMP8 collagenase activity assay- Collagen Contraction Assay 
and Hydroxyproline Assay 
 
2.6.6.1 Collagen Digestion Assay 
 
Type I Collagen gels were made through the mixing of collagen type I (Rat Tail 
Type I, First Link UK, 60-30-810) and 10X DMEM in a 1:10 ratio (10x DMEM: 
Type I Collagen) on ice. To polymerise the gels the pH was increased through the 
gradual addition of 10M NaOH until the gel maintains an orange/pink colour. MDA-
MB-231 clonal isolates were trypsinised, neutralised with complete media, 
centrifuged, resuspended in serum free media and counted. Cells (300,000 in 250µl 
serum free media) were mixed with 250µl collagen gel, and 500µl collagen gel-cell 
mix added to a well of a 24 well plate, resulting in a collagen gel concentration of 
0.925mg/ml. The gel/cells were incubated at 37˚C for 30 minutes for the gels to set, 
after which 500µl serum free media is added so as the gels do not dry out. Twenty 
four hours later the gels were released from the edges and bottom of the cell culture 
well using a small spatula. Collagenases within the gel digest the gel. A further 24 
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hours later the media from the gels was collected and analysed for collagen 
breakdown using a hydroxyproline assay (next section, 2.6.6.2).  
2.6.6.2 Hydroxyproline Assay 
 
Determining hydroxyproline release is an indirect method to measure collagen 
breakdown. Concentrated HCl was used to hydrolise proteins and release 
hydroxyproline. The hydroxyproline is then oxidised to a pyrrole with Chloroamine 
T (7% Chloroamine T, BDH cat# 276704E) which can be detected at 560nm with the 
addition of 4-dimethylaminobenzaldehyde (DAB).  
 
In triplicate, 200µl of media sample from the collagen digestion assay (above) was 
taken and 200µl concentrated HCl was added. This was boiled overnight at 105˚C, 
resulting in a dark brown liquid if hydroxyproline is present. The HCl was then 
evaporated out of the sample by placing the samples in a speed vac heated to 60˚C 
for 3 hours. Once dried, 200µl water was added to the samples and pipetted to re-
dissolve the dried sample. Samples were loaded (40µl) onto a flat bottomed 96-well 
plate alongside a dilution standard from 0-30mg/ml of stock hydroxyproline. 
Samples and standards were oxidised for exactly 4 minutes through the addition of 
25µl of Solution A (2ml Chloroamine T and 8ml acetate citrate buffer (table 2.2) 
before the addition of 150µl Solution B (30ml propan-2-ol with 10ml DAB (table 
2.2). The plate was then sealed and incubated at 65˚C for 35 minutes before cooling 
and reading the absorbance. Quantification was carried out through the extrapolation 
of the concentration of the experimental samples from the known concentrations of 
the standard curve.  
 
2.6.7 Cell Cycle Analysis using Flow Cytometry 
 
This method utilises Propidium Iodide (PI) staining to determine the stage of the cell 
cycle cells are in. PI is a nucleic acid stain, with staining intensity being proportional 
to the amount of DNA present within a cell.  
 
Cells were grown to 70% confluency before all cells were collected (including any 
cells floating in the cell culture media), centrifuged at 193xg and washed with PBS 
and resuspended in 70% (v/v) EtOH to fix the cells. Cells were fixed overnight at -
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20˚C before being pelleted, washed twice with PBS and resuspended with a PI, 
RNAse (to remove and RNA which would bind the PI), TRITON X-100 solution.  
Per sample of approximately 200,000 cells the solution consisted of 200ul PBS, 8µl 
PI (1mg/ml stock- final concentration of 40µg/ml, Sigma, P 4170), 40 µl of RNase A 
stock (1mg/ml in PBS stock - final concentration 0.1mg/ml) (Sigma R6513)) and 
0.1% TRITON X-100. Samples were incubated at 37˚C for 30 minutes in the dark. 
They were then run at slow speed on the flow cytometer (Accuri C6), recording 
10,000 events per sample. Doublets were gated for and a final analysis was carried 
out using FlowJo software that calculated the percentage of cells in each phase of the 
cell cycle.  
 
2.6.8 MMP8-IL-6/IL-8 reciprocal activation  
 
Recombinant human IL-6 (R&D Systems# 206-IL/CF) and IL-8 (R&D Systems 
#208-IL/CF)  was added to serum-starved parental MDA-MB-231 cells at 0.3, 0.6 
and 100ng/ul IL-6 and 0.5, 1.5 and 100ng/ul IL-8 for 24 hours. Cells were harvested 
for RNA extraction and mRNA levels of MMP8, IL-6 and IL-8 were determined by 
Taqman qRT-PCR (section 2.4). APMA activated recombinant human MMP8 (R&D 
Systems #908-MP) was added to cells up to 10ng/ml for 24 hours.  
2.7 Molecular Pathway Inhibition  
 
Small molecule inhibition was utilised to dissect the mechanism of action of MMP8 
on the induction of IL-6 and IL-8. Cells were plated at 2.6 x 10
4
/cm
2
 in 6 well plates 
and allowed to settle for 24 hours. Inhibitors (Table 2.5) were added into serum-free 
DMEM. Cell supernatants were removed after 24 and 48 hours (inhibitor replenished 
at 24 hours), samples centrifuged to remove any cell debris and stored at -20˚C for 
analysis by ELISA (section 2.4.5). 
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2.8 In vivo 
 
MDA-MB-231 cells engineered to stably over-express wild-type and E198A 
mutant MMP8 and empty vector control transfected cells were injected 
subcutaneously into the left flank (1 million cells in 100µl PBS per mouse) of 
CD1 nu/nu mice. Six mice each were injected with wild-type MMP-8 and E198A 
mutant MMP-8 expressing cells and 8 mice were injected with cells transfected 
with the control empty vector. Primary tumour growth was measured by bi-
weekly palpation using digital calipers and mice were sacrificed at day 54. 
Target Inhibitor Concentration  
Used 
Source 
p38 SB203580  1µM Caymen Chemicals 
Cambridge Bioscience 
(CAY13067) 
 BIRB 0796  1µM Caymen Chemicals 
 Cambridge Bioscience 
(CAY10460) 
MKK1 PD0325901  0.1µM Caymen Chemicals 
 Cambridge Bioscience 
(CAY13034) 
 U0126  10µM Caymen Chemicals 
Cambridge Bioscience 
(CAY70970) 
PI3K Wortmannin  1µM Sigma (W1628-1MG) 
 PI-103  0.5µM Caymen Chemicals 
 Cambridge Bioscience 
(10009209) 
PKC Bisindolylmaleimide 
I  
360nm Calbiochem (203290) 
JNK SP600125  20µM Sigma (S5567) 
NF-KB BAY 11-7082  10µM Calbiochem (196871) 
TGFβR1 SB431542  10 µM Caymen Chemicals 
Cambridge Bioscience 
(CAY13031) 
MMPs CT1746 10 µM Gift from Gillian Murphy 
University of Cambridge 
 GM6001 10 µM UNK 
MMP8 DL111  1µM Gift from Vincent Dive 
 CEA Saclay, Gif- sur-Yvette 
Table 2.5. Pathway inhibitors 
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Chapter 3- Development and 
characterisation of mammary in 
vitro models for over-expressing 
MMP-8 
 
MMP8 has been shown to be protective against mammary carcinoma in human 
studies, specifically against metastatic spread of the disease [65, 70], but 
through unknown mechanisms. This chapter concerns the development and 
characterisation of an in vitro model to investigate the functions of MMP-8 in 
mammary carcinoma cells. This chapter outlines the development of an 
expression model and characterisation of the functional effects of MMP-8 on 
carcinoma cell migration, invasion, adhesion and growth.  
3.1 Generation of an MMP8 expression model 
3.1.1 Determination of an appropriate in vitro system  
 
MMP8 is produced by the myoepithelial cells in the normal breast, which are 
located between the epithelial cells and the basement membrane of the ductal 
lumen. The initial aim of this project was to elucidate the role of MMP8 in the 
normal breast using these cells and then transfer knowledge gained to 
cancerous breast cells. The 1089 immortalised myoepithelial cell line was going 
to be used (gift from Dr. Louise Jones, Queen Mary University of London), of 
which there are two forms, the original 1089 cell and one which was engineered 
to  over-expresses  β6 integrin (denoted 1089β6), making the cell line more 
DCIS-like. Myoepithelial cells express a number of protein markers that enable 
them to be distinguished from the luminal epithelial cells. For example, 
myoepithelial cells express β4 integrin, cytokeratin 14 (CK14), vimentin, 
tenascin, and α-smooth muscle actin, whereas luminal epithelial cells do not. 
Conversely, luminal epithelial cells express cytokeratin 18 (CK18), whereas 
myoepithelial cells do not. Both cell types however express E-Cadherin in the 
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normal, non-cancerous, breast [56]. The 1089 and 1089β6 cell lines proved to 
be very difficult to culture, in that their phenotypes drifted very rapidly. Cells 
that were originally expressing E-Cadherin and not CK18 (figure 3.1A), soon lost 
E-Cadherin expression and gained CK18 expression (figure 3.1B). Morphological 
differences also emerged in parallel to this alteration in expression markers. 
Cells in early culture exhibited a cobble-stone morphology and were round with 
large areas of cytoplasm. Once expression markers had altered cells became 
very elongated and visually more fibroblastic (figure 3.1C).  This transition 
occurred within a week or two of culture making these cells highly impractical 
for long-term experiments as one could not be certain that phenotypic drifts 
were not occurring during experiments. In addition, the aim of this project was 
to over-express MMP8 permanently in a mammary cell line and then look at any 
changes in cellular characteristics. Firstly the generation of stable transfectants 
is time-consuming and cells would likely have drifted in phenotype during this 
time, and secondly, it would be impossible to examine the effect of MMP-8 on 
cellular markers such as markers of the epithelial-to-mesenchymal transition 
(EMT) which include E-Cadherin and CK18, as the phenotypic drift of cells 
would mask any MMP-8 dependent effects.  As a result the non-metastatic, more 
epithelial-like, MCF-7 and the highly metastatic, more mesenchymal-like,  MDA-
MB-231 breast cancer cell lines were used, as these have been well 
characterised in the literature, have been shown to be representative of cancer 
cells from breast cancer patients [160, 161], and are less susceptible to 
phenotypic drifts. As can be seen from figure 3.2 the cells express key protein 
markers that distinguish their different subtypes. For example, vimentin, a 
mesenchymal marker is expressed by the MDA-MB-231 cells only, and E-
Cadherin, an epithelial marker [162] is expressed in the MCF-7 cells only.  
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Figure 3.1: Characterisation of 1089 and 1089β6 myoepithelial 
cells. Western blot analysis of expression markers E-Cadherin 
(epithelial and myoepithelial) and CK18 (epithelial only) in (A) cells 
pre- phenotypic drift and (B) cells post-phenotypic drift. MCF-7 and 
MDA-MB-231 cell lines used as positive controls (+) for the markers 
and GAPDH as a loading control. C) Light microscopy of 1089 and 
1089β6 cells in culture highlighting morphological changes.  
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Figure 3.2: Characterisation of MCF-7 and MDA-MB-231 
mammary carcinoma cells. Western blot analysis of markers of 
expression of epithelial cells (E-Cadherin, CK18) and mesenchymal 
cells (vimentin, β4 integrin) using GAPDH as a loading control.  
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3.1.2 Generation and validation of MMP8 expression constructs 
 
Wild-type MMP8 had previously been cloned into the pcDNA4TM V5-His plasmid 
in our lab prior to the start of this project. The V5 tag was used as at the time of 
construction there was no MMP-8 antibody for western blot commercially 
available. Using PCR a mutant version of MMP8 was generated within the same 
plasmid whereby a glutamic acid (E) residue at position 198 is substituted for 
an alanine (A) residue at the zinc binding site of the catalytic domain, rendering 
the protein catalytically inactive. This mutant is termed E198A in all subsequent 
experiments. The mutation was initially confirmed by sequencing (Appendix 1) 
and later by examination of the collagen-degrading ability of the cells that have 
been generated to over-express both wild-type MMP8 and the EA mutant MMP8 
(figure 3.6). Prior to use in any experiments, plasmids were checked to be 
comparable to each other with regards to levels of linear, circular and 
supercoiled DNA. This was achieved by linearization and separation of the 
digest products on an agarose gel (figure 3.3).  
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Figure 3.3: Restriction digest of pcDN4TM V5-His and MMP8 
constructs. 500ng pcDNA4 digested with: 1 – XbaI to linearise, 2-
EcoRI and XhoI to cut out MMP8 (as seen at approximately 1500bp) 
and 3 - uncut , showing circularised and supercoiled DNA in equal 
amounts across the 3 plasmid constructs.   
Chapter 3- Development and characterisation of mammary in vitro models 
 
87 
 
3.1.3 Transfection of MMP8 constructs into mammary carcinoma 
cells 
 
To ensure that the plasmid constructs could be expressed in cells all constructs 
were transiently transfected into SK-BR-3, MCF-7 and MDA-MB-231 cells and 
MMP-8 protein detected by western blot. As can be seen in figure 3.4 a high 
level of expression was achieved, with both wild-type and E198A mutant MMP-
8 observed in the cell lysate and secreted into the conditioned media at 
equivalent levels between the two constructs. MMP-8 is a secreted protease so 
high levels in the media was expected, plus this showed that the constructs were 
expressed effectively. Both pro (75kDa) and active MMP-8 (approximately 
50kDa) was observed in the cell lysate. It is unclear whether secreted MMP-8 is 
active as when extending the exposure of the western blot to visualise and 
active band the pro-MMP-8 band became so over-exposed that is would have 
eclipsed any active-MMP-8 band.  
 
Despite successful transient transfection of MMP8 into mammary carcinoma 
cells, generation of cells stably over-expressing MMP8 proved problematic. 
Three different protocols were followed in an attempt to make stable 
transfectants. Previously in the lab it was attempted using the Fugene 6 
transfection reagent (Roche), which was unsuccessful as none of the resulting 
clones expressed MMP8 protein. Despite achieving a high level of expression of 
MMP8 on transient transfection into SK-BR-3, MCF-7 and MDA-MB-231 cells 
(figure 3.4) with LipoD293 transfection reagent (SignaGen Laboratories), on 
stable transfection the reagent appeared to be toxic and once under selection 
cells died within a week. 
 
Stable transfection was eventually achieved using the well-established calcium 
phosphate method of transfection. Both pooled stably transfected cells and 
isolated clones were generated for all three constructs in the MDA-MB-231 cell 
line (figure 3.5).  Western blot analysis showed that MMP8 is only detected in 
the serum free conditioned media, so is secreted a very short time after 
production. Despite the use of a wide range of protein extraction buffers MMP-8 
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could not be observed in the cell lysate.   The molecular weight of the protein 
detected was approximately 75kDa, which is in line with published data [32]. 
Two bands are seen with the MMP8 antibody, the larger, and more prevalent, 
likely corresponding to the pro-form, and a lower band likely corresponding to 
the active form. However, active MMP-8 is published to be approximately 
50kDa, and the band observed here is slightly larger so caution must be taken 
when attributing identity. This lower band was not seen with the V5 tag 
antibody, as the tag may have been cleaved off. Despite the presence of a large 
pro-form band a collagenase assay consisting showed high collagenase activity 
and increased ability to contract a Type I Collagen gel with cells stably 
transfected with wild-type MMP8 but not in cells stably transfected with EA 
mutant MMP8 (figure 3.6). Confirmation that the anti-MMP-8 antibody is 
detecting MMP-8 comes from the use of the anti-V5 antibody which detects a 
protein of the same molecular weight as the anti-MMP-8 antibody. Additional 
validation of the antibody came from siRNA knockdown of MMP8 (chapter 5 
section 5.1) where siRNA to MMP8 reduced this band.  Although stable 
transfectants have successfully been generated there were problems associated 
with long-term expression of wild-type MMP-8 which will be addressed later in 
Section 5.1.  
 
Loss of wild-type MMP-8 expression in the stable transfectants was observed in 
as little as two weeks of the cells being in culture. Protein expression of E198A 
mutant MMP-8 was not lost however, and was expressed at slightly higher 
levels than wild-type MMP-8 in the cells. This would suggest that the catalytic 
activity of MMP-8 is detrimental to the breast cancer cells, which can be 
presumed to be due to over-expressing an anti-tumourigenic protein in cancer 
cells. This loss of wild-type MMP-8 expression will be documented in Chapter 5. 
Despite this additional problem when generating the stably transfected cells, a 
subset of MMP-8 over-expressing clonal isolates (figure 3.5B) generated from 
the pooled cells shown in figure 3.5A maintained MMP-8 expression long-term.  
 
Following the generation of these “long-term” MMP-8 over-expressing MDA-
MD-231 clones it was determined whether MMP-8 expression had any 
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phenotypic effects on the cells. Functional cell behaviour, alterations in protein 
expression, changes in EMT and effects on the protease web were examined.  
 
 
 
  
Figure 3.4: Transient transfection of wild-type and E198A 
mutant MMP-8 in breast cancer cell lines. Western blot analysis of 
MMP8 transient transfection of SK-BR-3, MCF-7 and MDA-MB-231 
cell lines. An anti-MMP-8 antibody was used to detect MMP-8 in both 
the cell lysate (CL) and serum free conditioned media (CM) 48 hours 
post transfection.  
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Figure 3.5: Stable expression of MMP-8 in MDA-MB-231 cells. 
Left panels: western blot analysis of MMP-8 in serum free 
conditioned media of cells over-expressing both wild-type and 
catalytically inactive (E198A) MMP8 using both anti-MMP-8 and 
anti-V5 tag antibodies. Right panels: RNA quantification by real-time 
TaqMan RT-PCR of MMP8 normalised to 18S rRNA.  Clonal isolates 
(B) were generated from pools of stably transfected cells (A). Both 
‘empty vector’ and EA Mutant MMP8 over-expressing clonal isolates 
were generated from their respective pool 1s.  
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3.2. Effects of MMP-8 on cell behaviour 
 
Literature has shown that MMP-8 is a tumour suppressor, and has been shown 
to reduce invasion through Matrigel and to increase adhesion to type I collagen 
and laminin-1 when stably over expressed in B16F10 melanoma cells [52]. 
Therefore, the effects of MMP8 on invasion and adhesion on breast cancer cells 
were studied. This was also expanded to examine the effects of MMP8 on cell 
growth, cell cycle and 2D migration on breast cancer cells. One clone of control 
cells, wild-type MMP-8 over-expressing and E198A mutant MMP-8 over-
expressing cells were studied in this section.  
  
Figure 3.6: Collagenase activity as measured by hydroxyproline 
release in MMP-8 over-expressing MDA-MB-231 clonal isolates 
(set 1). Cells were seeded into type I collagen gels in serum free 
conditions. Gels were released from the edges of the plates and were 
digested for 24 hours. As an indirect measure of collagen breakdown 
hydroxyproline levels were measured in the serum free conditioned 
media. n=3, mean ± SEM,  * = p <0.05, ** = p<0.01 *** = p<0.001 
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3.2.1. MMP-8 does not affect the growth or cell cycle profile of “long-
term” MDA-MB-231 stably transfected cells 
 
Cell growth was determined by cell counts every 24 hours for 72 hours.  No 
significant differences in growth were observed between cells over-expressing 
wild-type and mutant MMP-8 and empty vector control cells (figure 3.7) This 
was further investigated by analysing the cell cycle profiles of the cells using 
propidium iodide staining of DNA followed by cell sorting by flow cytometry. All 
cell lines had the same proportion of cells in each phase of the cell cycle, and 
only very few cells (about 2%) were in the sub-G1 phase, which is used to give 
an indication of cells undergoing apoptosis (figure 3.8). Therefore it can be 
concluded that “long-term” MMP-8 over-expression (for a couple of months 
before the experiment) has no effect on either growth or apoptosis (when 
looking at sub G1 cells) of MDA-MB-231 cells.  
Figure 3.7:  Growth of MDA-MB-231 stably expressing MMP8 
“long-term”. Triplicate wells of MDA-MB-231 clonal isolates stably 
over-expressing pcDNA4 ‘empty vector, wild-type MMP8 and E198A 
mutant MMP8 were counted every 24 hours by haemocytometer and 
expressed as percentage proliferation from the number of cells 
initially seeded. n=5, mean ± SEM.  
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Figure 3.8: Flow cytometric analysis of cell cycle parameters of 
wild-type MMP8, E198A mutant MMP8 and empty vector 
control stably transfected MDA-MB-231 cells (clone 1). A) 
Percentage of cells in G1, S and G2 phase and B) percentage of cells 
in sub-G1 phase. n=3, mean ± SEM.   
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3.2.3 Effects of “long-term” MMP-8 expression on 2D migration of 
MDA-MB-231 cells 
 
The “long-term” MDA-MB-231 stable clones  over-expressing either wild-type or 
EA mutant MMP-8 or an control ‘empty vector’ were seeded at a low density 
onto tissue culture plastic. Under serum-free conditions cells movement was 
captured by time-lapse video microscopy over 16 hours. Individual cell 
movements were tracked using Image J (‘manual tracking’ and ‘chemotaxis 
plugins’) and the total distance migrated and velocity of the cells was 
determined. Stable wild-type MMP-8 expression reduced both the overall 
distance migrated and the velocity of the MDA-MB-231 cell lines (figure 3.9A). 
MMP-8 did not only reduce cell migration compared to the control but also 
compared to the cells expressing the E198A mutant, indicating that this 
reduction in 2D, random cell migration, depends on the catalytic activity of 
MMP-8.  
 
Scratch wound assays are similar to the 2D migration assay in that they are 
carried out in 2D on cell culture plastic, where the cells would have laid their 
own matrix on plating in the presence of serum. However, cells are seeded at a 
very high density and cell movement to fill a ‘scratch wound’ is monitored. 
Whereas the 2D migration assay looks at random cell migration this assay looks 
at collective migration. Almost total scratch wound closure (82% closure) was 
observed by 24 hours post scratch in the empty vector control MDA-MB-231 
clonal isolates, compared to only 48% with cells over-expressing wild-type 
MMP-8 and 53% with cells expressing E198A mutant MMP8 (figures 3.9B-C).  
These data provide additional evidence for the anti-migratory actions of MMP-8; 
however reduction in migration occurred independently of the catalytic activity 
of MMP-8. These discrepancies may be due intrinsic features of the assay which 
will be discussed in section 3.4. Despite these differences it can be hypothesised 
that long-term expression of MMP-8 is capable of reducing migration of MDA-
MB-231 cells.  
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To gain more insight into the disparities between the findings of these two 
migration assays we looked at 3D invasion and adhesion. Firstly this was 
because it is much more physiologically relevant to study cellular migration in a 
3D matrix, and secondly, if the cells have different integrin-binding 
requirements it can be hypothesised that the cells may have different adherent 
properties to different cellular matrices.  
 
 
 
  
Figure 3.9: Effects of MMP-8 on MDA-MB-231 cell migration. A) 
Time-lapse light microscopy to determine random 2D migration of 
MDA-MB-231 clonal isolates (clone set 1) stably expressing empty 
vector control, wild-type MMP8 and E198A mutant MMP8. B and C) 
Scratch wound closure of the same cells over 24 hours.  D) Western 
blot analysis of MMP-8 on serum free conditioned media showing 
expression of MMP8 throughout all experiments. n=3, >100 cells, 
mean ± SEM, * = p <0.05, ** = p<0.01 *** = p<0.001 
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Figure 3.9: Effects of MMP-8 on MDA-MB-231 cell migration. A) 
Time-lapse light microscopy to determine random 2D migration of 
MDA-MB-231 clonal isolates (clone set 1) stably expressing empty 
vector control, wild-type MMP8 and E198A mutant MMP8. B and C) 
Scratch wound closure of the same cells over 24 hours.  D) Western 
blot analysis of MMP-8 on serum free conditioned media showing 
expression of MMP8 throughout all experiments. n=3, mean ± SEM, * 
= p <0.05, ** = p<0.01 *** = p<0.001 
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3.2.4 Effect of MMP8 on invasion and adhesion 
 
Since MMP8 has an effect on 2D cell migration it was subsequently determined 
whether it has the same effect on 3D invasion. However, unlike the 2D migration 
assay which was carried out on plastic the 3D invasion was examined through a 
type I collagen matrix. This was because type I collagen is the main ECM 
substrate of MMP-8. To ensure that all cells were on a level plane at the start of 
the experiment, the inverted invasion assay, pioneered by Hennigan et al., 
(1994) was used [163]. This requires cells to move upwards through a matrix, 
collagen in this case.. MDA-MB-231 clonal isolates (set 1) were seeded onto the 
underside of an 8.0µm transwell that had firstly had a collagen gel set within it. 
Media containing 10% FCS and 50ng/ml epidermal growth factor (EGF) was 
applied onto the top of the collagen gel as a chemoattractant and the cells 
invaded up through the collagen gel for 48 hours. Live cells were stained with 
CalceinAM and images were taken using a confocal microscope from the 
membrane through the gel at 15µm intervals. Prior to this any cells that had not 
invaded into the transwell and were just adhered to the underside were wiped 
off, although an image of the underside including adherent non-invading cells 
was taken first.   
 
Invasion through type I collagen did not appear to be reproducible.  Overall 
however there was a slight decrease in invasion of wild-type MMP-8 over-
expressing cells, which is statistically significant with relation to the E198A 
mutant MMP8 over-expressing cells, but not the vector control cells (Figure 3.10 
A, B). As we saw some differences in invasion, albeit with a lot of variability, 
total protein levels of MT1-MMP (MMP-14) were analysed by western blot 
(Figure 3.10E). MT1-MMP has long been thought of as the main collagenase 
responsible for cell invasion through cross-linked collagen [164, 165] so it was 
appropriate to determine whether MMP-8 over-expression in the MDA-MB-231 
cells altered the level of MT1-MMP protein within the cells. No difference in pro- 
or active- MT1-MMP expression was seen between MDA-MB-231 clonal isolates 
expressing the control ‘empty vector’, and cells over-expressing wild-type MMP-
8 or E198A mutant MMP-8.  
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Interestingly, despite inconsistencies between biological replicates with regards 
to cell invasion there were clearly less wild-type MMP-8 expressing cells at the 
bottom of the gel plug compared to empty vector cells and MDA-MB-231 cells 
expressing E198A mutant MMP8. Image J analysis of images taken at the very 
start of the experiment before non-invading cells are wiped off from the bottom 
of the transwell membrane shows that there are significantly more (3.5x) wild-
type MMP-8 over-expressing cells adhering to the bottom of the transwell than 
with the other two cell lines (Figure 3.11).  This is further supported by the 
slight decrease seen in total cells within the collagen gel (Figure 3.10C). Beta1 
integrin is a  major  cell adhesion receptor (especially for fibronectin) [166] and 
a recent publication has suggested that MMP-8 can regulate β1 integrin levels 
and also co-immunoprecipitate with it [167]. Therefore, to determine if β1 
integrin was involved in the increase in adhesion western blot analysis was 
carried out on  both sets of clonal isolates of MMP-8 over-expressing cells and 
compared to control ‘empty vector’ and E198A mutant MMP-8 over-expressing 
clonal isolates. No differences were observed in β1 protein expression with 
wild-type MMP-8 versus the other cell lines when quantifying levels relative to 
the GAPDH loading control (figure 3.11C). However, this does not discount any 
MMP-8-related changes in integrin activation.  
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Figure 3.10: Effects of MMP8 on inverted invasion through type I 
collagen A) Montage generated by confocal microscopy of 
CalceinAM stained MDA-MB-231 clonal isolates (set 1) expressing 
pcDNA4 empty vector control, wild-type and E198A mutant MMP8 
cells at 15µm sections. B) Percentage of cells that have invaded 
beyond 30µm sections relative to the total number of invading cells 
C) Total cells in the type I collagen plug (all quantified using Image J). 
D) Western blot to confirm MMP-8 expression throughout the 
experiments and (E) western blot analysis of MMP-14 (MT1-MMP) 
on total cell lysate of both sets of MDA-MB-231 stable clonal isolates. 
n=4, mean ± SEM, * = p <0.05, ** = p<0.01 *** = p<0.001 
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To further study the effect of wild-type MMP-8 on adhesion, a traditional 
adhesion assay [168] was carried out on clonal isolate sets 1 and 2. This assay 
showed that there were no consistent differences in adhesion to either type I 
collagen or fibronectin across all cell lines. However, the wild-type MMP8 
expressing cells from clone set 2 showed a 2 fold increase of adhesion to type I 
collagen compared to the other cell lines (Figure 3.12A). This may be attributed 
to slight differences between the clones, as the cells were expressing MMP-8 
equally (figure 3.12B). Cells also adhered more to collagen than to fibronectin. 
As the cells in the invasion assay were plated onto the underside of the 
transwells in serum, adhesion in absence of pre-laid matrices was also tested in 
Figure 3.11: Cell adhesion to the under-side of the transwell 
used in the inverted invasion assay. A) Fluorescent confocal 
images of CalceinAM stained MDA-MB-231 cells adhered to the 
underside of the transwell. The cells in focus are on the underside, 
the out of focus cells are cells that have invaded into the gel. B) 
Quantification of total cell area of cells adhered to the transwell. n=4, 
mean ± SEM, * = p <0.05, ** = p<0.01 *** = p<0.001 C) Western blot 
analysis of β1 integrin in cell lysates of stably transfection MDA-MB-
231 cells.  
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serum-containing conditions. No differences were found between cell lines 
under these conditions (data not shown). 
 
Combined, these results suggest that MMP-8 may not have an effect on initial 
adhesion but adhesion contacts may be stronger, with cells adhering to the 
transwell membrane in preference to invading. Once cells have invaded 
however they invade to a similar extent. To fully confirm this however invasion 
assays would have to be carried out on the second set of clonal isolates as well 
as the first.  
 
 
 
 
 
 
 
 
 
 
  
Figure 3.12: Effect of MMP-8 on adhesion of MDA-MB-231 cells. 
A) Adhesion of MDA-MB-231 clonal isolates stably transfected with 
pcDNA4 empty vector, wild-type and E198A mutant MMP8 to type I 
collagen and fibronectin (FN). n=5, mean ± SEM. B) Western blot of 
MMP-8 in the serum free conditioned media of cells used in the 
adhesion assay.  
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3.2.5 “Long-term” MMP-8 expression has no effect on the epithelial 
to mesenchymal transition 
 
The epithelial to mesenchymal transition (EMT) is a process through which 
cancer cells switch from an epithelial, differentiated state to a mesenchymal, de-
differentiated state. It is in this state that cancer cells are more motile, and much 
more likely to metastasise. Some MMPs have been shown to have an effect on 
EMT through the activation of latent EMT-inducing growth factors (e.g. 
Epidermal Growth Factor) by proteolytic cleavage, coupled with evidence 
showing that cells that have undergone EMT produce more MMPs [169]. For 
example, MMP8 has been shown to be expressed during neural crest EMT in 
mouse embryogenesis [170].   
 
MDA-MB-231 cells have already undergone EMT but we postulated that MMP-8 
may have a role in reversing it; mesenchymal-to-epithelial- transition (MET), 
since MMP8 has been shown predominantly to have anti metastatic effects [52, 
65, 77]. However, looking at E-Cadherin and Cytokeratin 18 (CK18) as markers 
of an epithelial state (figure 3.13A-B) and Vimentin and β-Catenin (figures 
3.13C-D) as markers of a mesenchymal state no differences were seen with 
MMP8 over-expression. There is a slight increase in vimentin with both wild-
type and E198A mutant MMP-8 expression compared to cells transfected with 
the empty vector control however, indicating that MMP8 may have some 
influence on EMT, and may actually be pushing it further forward. Therefore it 
can be concluded that over-expression of MMP8 in this cell line was not 
sufficient to induce MET,  at least in relation to the markers examined here.  
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Figure 3.13: Characterisation of EMT markers in MMP-8 
expressing MDA-MB-231 cells. A) Western blot analysis of 
epithelial markers (E-Cadherin and CK18) in the cell lysate of MDA-
MB-231 clonal isolates (both sets) stably expressing wild-type and 
E198A mutant MMP8 and pcDNA4 empty vector control. B) Western 
blot analysis of mesenchymal markers (Vimentin and β-Catenin) in 
the same lysates. Parental MDA-MB-231 cells, MCF-7 cells and G361 
melanoma cells were used as controls. Samples referenced against 
the GAPDH loading controls.  
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3.3 Degradome profiling of MMP-8 over-expressing cells 
 
It has been widely accepted that MMPs are members of a complex “protease 
web”, with over-expression or deletion of an MMP resulting in the change in 
expression of other proteases. In addition, MMPs can have compensatory 
functions whereby a lack of phenotypic defect is observed when one MMP is 
deleted. To determine if this occurred in MDA-MB-231 breast cancer cells over-
expressing MMP8, quantitative real-time PCR was carried out on all the MMPs 
and TIMPs. In addition, three other breast cancer cell lines were also profiled, 
SK-BR-3, T47D and MCF-7s, as well as parental MDA-MB-231 cells, to act as 
positive controls for some of the genes that are not expressed in the MDA-MD-
231 cells, and to control for any influence of transfection alone. Figure 3.14A 
shows a heat map whereby expression levels are depicted broadly by cycle 
threshold (CT) values at which the genes are amplified above background in the 
PCR reaction. Few differences were found between clonal isolates independent 
of MMP8 expression which may be due to an indirect effect of transfection. Such 
differences may only show up on the heat map if differences cross the allocated 
CT boundaries but are indicated by an asterisk.  MMP-8 dependent changes are 
marked by a hash and are shown in detail in figure 3.14B.  
 
MMP-8 is classified as a collagenase along with MMP-1 and MMP-13. MMP-8 
expression does not appear to have any effect on RNA expression of MMP-1 but 
wild-type MMP-8 causes a slight up-regulation of MMP-13 (Figure 3.14D). This 
is more marked in clone 1 of the wild-type MMP-8 over-expressing cells, which 
express MMP-8 to the greater extent (Figure 3.14B). MMP-8 also up-regulates 
MMP-10, a member of the stromelysin family (Figure 3.14C), with greater up-
regulation in clone 1, which expresses higher levels of MMP-8. TIMP-3 is also 
up-regulated with wild-type MMP-8 over-expression (Figure 3.14E). Unlike 
MMP-10 and -13 however, TIMP-3 mRNA levels are higher in clone 2, which 
expressed less MMP-8.  
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Figure 3.14: Taqman degradomic profiling of MMP-8 over-
expressing MDA-MB-231 cells. A) Heat map showing the gene 
expression analysis of MMPs and TIMPs by Taqman PCR categorised 
according to their CT values. CT value is normalised to 18S rRNA and a 
mean generated from the two clonal isolates studied. B-E) Gene 
expression levels of B) MMP8, C) MMP10, D) MMP13 and E) TIMP3 in 
detail between the two sets of clonal isolates. n=2 except n=3 for MMP8. 
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To conclude this chapter, an in vitro expression model has been generated to 
examine the effects of wild-type and E198A mutant MMP8 in the pcDNA4 
expression vector. “Long-term” stable transfection of MMP8 into MDA-MB-231 
cells modulates cell behaviour through reducing 2D cell migration, increasing 
adhesion and slightly altering the protease web.  
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3.4 Conclusions and Discussion 
 
The aim of this project was to determine the mechanisms of action of MMP8 in 
mammary carcinoma. To achieve this an in vitro model system has been 
generated. Whilst it is most physiologically relevant to examine the role of 
proteins within an in vivo system, when carrying out newly emerging research 
in vitro studies should be utilised until the research has reached a firm 
grounding. The most appropriate cells to use are non-commercially available 
breast myoepithelial cells, as in the normal, healthy breast these are the cells 
expressing MMP8. However these cells turned out to be unreliable, exhibiting 
significant phenotypic drifts in both their morphology and in expression of 
myoepithelial markers. As a result the commercially available aggressive breast 
cancer cell line MDA-MB-231 was used. This cell line was chosen over other 
widely used breast cancer cell lines such as MCF-7 as they have many 
characteristics, such as high motility and expression of mesenchymal markers 
that could potentially be reversed with over-expression of MMP8, a 
tumour/metastasis supressing protease.   
 
MDA-MB-231 cells were engineered to over-express MMP8 by stable 
transfection of a plasmid construct. Prior to transfection the plasmid constructs 
were validated by sequencing and also by a series of  restriction digests to 
ensure restriction sites were as expected, and that MMP8 could be excised using 
the restriction sites used in the original cloning.  As a control for the transfection 
a set of cells were transfected with a control ‘empty vector’, and to control for 
mechanisms of MMP8 action attributed to its catalytic activity cells were also 
transfected with a plasmid containing a catalytically inactive mutant MMP8, 
whereby a glutamic acid within the zinc binding site had been mutated to 
alanine (E198A). Firstly a polyclonal pool of stably transfected cells were 
generated which contained a heterogeneous mix of cells with various degrees of 
MMP-8 expression. This would result in variability between experiments so sets 
of clonal isolates were generated from these polyclonal pools resulting in a 
homogeneous cell system with reduced variability. Two pools of cells were 
generated to control for clonal differences, as the transfection strategy 
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employed in this project relies on random integration of the plasmid within the 
genome of the cells. This means that some observed effects could arise due to 
disruption of other genes by integration of the plasmid DNA. In the future a Flp-
InTM system (such as supplied by Invitrogen) could be exploited, where stably 
transfected cells have to be made firstly to generate a Flp Recombination Target 
(FRT) site (sequencing or microarray analysis could firstly be used to ensure 
that this plasmid is not disrupting any genes), and then the DNA of interest has 
to be transfected. This removes the problem of random integration as the DNA 
of interest is only inserted into the genome by recombination at the FRT, 
resulting in isogenic clones.   In most of the functional analysis experiments 
within this chapter only clone set 1 was utilised due to time constraints, 
although both sets were utilised when looking at markers of EMT and 
degradomic profiling of the protease web.  
 
There is little known about the functional effects of MMP8 in vitro but there has 
been one study that looks at the effects of MMP8 on cell growth, adhesion and 
invasion, and another that examines the effects of MMP8 on cell growth.  
Gutiérrez-Fernandez et al., (2008) generated MMP8 (murine MMP8) over-
expressing B16F10 murine melanoma cells and found that MMP8 had no effect 
on cell growth (as measured by an MTS assay), but increased cell adhesion to 
type I collagen and laminin-1 and reduced invasion through Matrigel. 
Concurrent with this research project, Gutiérrez-Fernandez et al., (2008) found 
that MMP8 did not have any effect on cell growth of MDA-MB-231 cells and 
neither did Palavalli et al., (2009) who over-expressed MMP8 in Mel-STR 
melanoma cells [77]. Coupled to this, no difference in apoptosis was observed in 
this project. The effects of MMP8 on apoptosis have not been examined in vitro 
but it has been shown that neutrophils from MMP8 deficient mice accumulate at 
a wound site due to  reduced apoptosis [14], attributed to reduced caspase 11 
and caspase 3 cleavage [42]. In contrast to the research by Gutiérrez-Fernandez 
et al., (2008) no effects were seen in this work on adhesion to type I collagen. 
This may be due to the different cell types used, with Gutiérrez-Fernandez et al., 
(2008) using a mouse melanoma line while a human breast cancer line was used 
in this work. However, differences in adhesion were observed when combined 
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with the inverted invasion assay. Despite great variability in cell invasion 
between experiments wild-type MMP8 over-expressing cells consistently 
adhered to the underside of the transwell significantly more than the other cell 
lines, which corresponded to fewer cells invading into the type I collagen gel. In 
this assay cells were plated onto the bottom of the porous membrane of the 
transwell (polyethylene terephthalate (PET)) in serum-containing conditions 
onto a matrix provided by the serum proteins. This however could not be 
replicated in a traditional adhesion assay when the cells were plated directly 
onto tissue culture treated plastic in serum. An explanation could be that short-
term adhesion of MDA-MB-231 cells is unaffected by MMP8, but once adhered, 
cells expressing wild-type MMP8 adhere more strongly. With regards to the 
invasion assay wild-type MMP8 expressing cells are adhering to the membrane 
in preference to invading into the collagen. In the future this could be tested by 
looking at the de-adhesion of the cells, as if the MMP8 expressing cells exhibit 
enhanced adhesive properties they would take longer to de-adhere. The actin 
cytoskeleton could also be examined by staining F-actin with phalloidin.   
 
The inverted invasion assay used in this research was more complex than the 
invasion assay utilised by Gutiérrez-Fernandez et al., (2008), which may explain 
the variability observed. Gutiérrez-Fernandez et al., (2008) used a basic 
invasion assay whereby B16F10 cells (either over-expressing mMMP8 or a 
control plasmid) were seeded into transwell inserts with 8.0µm pores that had 
been pre-treated with Matrigel. Using 5% FCS as a chemoattractant they stained 
the cells that had reached the underside of the membrane after 8 hours and 
counted them by eye. Additionally, they coated their transwells in a layer of 
Matrigel, whereas in the inverted invasion assay the cells had to invade through 
a collagen plug which provides a more challenging environment for the cells to 
invade through. Matrigel is a protein mixture secreted from mouse sarcoma 
cells and consists of a mix of laminin, collagens and entactin, so therefore is said 
to mimic the extracellular matrix. However, when studying invasion in vitro it is 
important to ensure that the model used represents the in vivo situation and is 
appropriate to the molecule investigated. As a consequence type I collagen was 
used in preference to Matrigel. This was firstly because MMP-8 is a collagenase 
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that predominantly cleaves type I collagen, so thus is more physiologically 
relevant, and secondly, that it has been shown that invasion through Matrigel is 
not MMP dependent [165, 171]. For example MMP inhibition using the broad 
spectrum MMP inhibitor GM6001 blocked invasion of ovarian carcinoma cells 
through a collagen I coated transwell but only reduced invasion through a 
Matrigel-coated transwell by about 30% [172]. Studies into this effect have been 
carried out in our lab and have shown that tube-forming Human Umbilical Vein 
Endothelial Cells (HUVECs) require different proteases and integrins when in 
Matrigel than in type I collagen.  These four major variables: the use of mouse 
cells, the possible effect of gravity, the use of a different matrix coating and the 
fact that a gel was used as opposed to a thin coating may explain the 
discrepancies observed in this work compared to Gutiérrez-Fernandez et al., 
(2008). Additionally the variability observed with the inverted invasion assay 
may be explained by the multi-step complexity of the assay whereby variables 
thought insignificant may have had an influence on the outcome of the 
experiment.  
 
In this chapter 2D cell migration was also examined, with MMP8 showing 
reduced random 2D migration on tissue culture treated plastic dependent on 
catalytic activity and also reduced scratch wound closure, although this 
occurred independently of the catalytic activity of MMP-8. There are differences 
between these assays in that random 2D migration relates to isolated cells and 
their cell-matrix interactions, whereas the scratch wound assay also relates to 
cell-cell interactions as well as cell-matrix interaction [173], suggesting that 
different adhesion and migration molecules may be required for the two 
different types of migration. Scratch wound assays can be criticised for 
differences in scratch wound closure being attributed to differences in cell 
proliferation rather than migration, however the growth rate between all cells 
was found to be equal. Whilst the effect of MMP-8 on in vitro cell migration in 
cancer cells has not been previously researched, the influence of MMP-8 on stem 
progenitor cell (SPC) migration in vitro has shown that MMP-8 is actually 
required for cell migration, with MMP8 knockout cells exhibiting reduced 
migration through both Matrigel and an endothelial monolayer, translating to 
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an in vivo situation whereby MMP-8 promotes the migration of SPCs into 
atherosclerotic plaques [174]. Interestingly within this model system incubation 
of embryonic Sca-1+ SPCs with MMP-8 reduced their adhesion to Matrigel, 
which is concurrent with their observation of MMP8 increasing migration, but 
the presence/absence of MMP-8 had no effect on cell growth [174], which is in 
line with this work. Drawing parallels to the work by Xiao et al., (2013), Steinl et 
al., (2012) examined the role of MMP-8 on the migration of haematopoetic stem 
progenitor cells (HSPCs) whereby MMP-8 was found to have an inhibitory role 
on their migration. This was hypothesised to occur through MMP-8 
inactivational processing of CXCL12, a HSPC chemoattractant [175]. Therefore, 
the role of MMP-8 on cell migration in vivo is conflicting depending on the cell 
type studied and the model used, and due to a lack of in vitro research on this 
subject there are few data to which our results can be compared. To further 
confirm the data gained in this thesis and to dissect a potential mechanism for 
the reduction of migration observed, the experiments could be repeated on 
different matrices. Cell binding to, and migration on different matrices requires 
different integrins, for example integrins α3β1, αβ1 and α6β4 bind laminin 
[176] whereas α1β1 and α2β1 bind collagen [177]. Any changes in migration on 
these matrices may help elucidate the molecules and pathways involved.  
 
Having looked at phenotypic changes as a result of MMP8 over-expression 
finally in this chapter it was sought to determine whether over-expression of 
MMP-8 altered the expression of the cellular markers of MDA-MB-231 cells and 
also the degradomic profile of the cells. MDA-MB-231 cells can be characterised 
by expression of mesenchymal markers as they have undergone EMT and also 
an array of MMPs. As aforementioned in this chapter MMPs can drive EMT 
indirectly through the liberation of matrix-bound EMT driving molecules, and 
also directly like MMP3 [169]. In addition, cells that have undergone the 
transition express more MMPs. We did not see any changes in total protein 
expression of EMT markers with MMP-8 over-expression, except a slight 
increase in vimentin in cells expressing both wild-type and E198A mutant MMP-
8, an effect that is therefore independent of the catalytic activity of MMP-8.  
MDA-MB-231 cells have already gone through EMT so it was a surprise to see an 
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increase in the mesenchymal marker.  In the literature, MMP8 has been shown 
to cause a small increase in E-Cadherin shedding via ADAM10 in stem 
progenitor cells [174], which occurs during loss of epithelial differentiation, but 
as the MDA-MB-231  cells used in this thesis do not express E-Cadherin we 
cannot confirm this in the breast cancer cells.  We did however see some small 
changes in MMP expression with in the wild-type MMP8 over-expressing cells. 
We see a slight up-regulation of MMPs 10 and 13 with wild-type MMP8 over-
expression. However this is very variable depending on the clone of MMP8 over-
expressing cells examined, although expression levels do relate to the slightly 
differing levels of MMP8 expressed in the cells. To determine whether this is a 
true result or just due to clonal variation more clonal isolates need to be 
examined.  
 
MMP-8 and MMP-13 have been shown to have some compensatory functions, 
for example on examination of the role of MMP-13 in wound healing there were 
no defects in wound healing in the Mmp13 knockout mouse. Evidence suggests 
that MMP-8 performed a compensatory role, as expression of MMP-8 increased 
at the wound site from the first day of wounding [178]. This has also been 
paralleled in the bone of newborn mice, with Mmp13 knockout mice exhibiting 
higher expression of MMP8 in RNA extracted from the distal femurs and 
proximal tibias of the newborn mice [179]. In this study however MMP-8 did 
not functionally compensate for the MMP-13 knockout phenotype. There have 
been reports of MMP-8 and MMP-9 having both compensatory functions and 
also direct interactions. A very recent study by Steinl et al., (2012) reports that 
MMP-8 may be functionally compensating for MMP-9 in the mobilisation of 
hematopoetic stem progenitor cells as Mmp9 knockout mice do not exhibit a 
defect in this, and levels of serum Mmp8 rise as HSPC mobilisation occurs [175]. 
Conversely, Gutiérrez-Fernandez et al., (2007) report that  MMP-9 levels 
increased in the wounds of Mmp8 deficient mice, although whether this is 
attributed to the accumulation of neutrophils at the wound site of Mmp8 
deficient mice or whether levels of Mmp9 are increasing to compensate for the 
lack of Mmp8 is unknown. In this situation however MMP-8 and MMP-9 existed 
in a stable complex with each other [14]. We did not see any consistent 
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difference in MMP9 expression at the RNA level, but clone 1 of the wild-type 
MMP8 over-expressing cells did exhibit slightly elevated MMP9 mRNA. When 
looking at MMP-9 protein by zymography the signal was very weak as MMP-9 is 
expressed at low levels in MDA-MB-231 cells. However, there was possibly 
more pro-MMP-9 in both clones of wild-type MMP8 over-expressing cells. This 
hints that MMP-8 and MMP-9 show some sort of interaction either at the 
expression level, protein interactions or both.  
 
The most convincing change in degradome expression with wild-type MMP8 
over-expression is seen in TIMP3 whereby expression in both sets of clones was 
elevated over levels expressed by the control ‘empty vector’ cells and the cells 
over-expressing E198A mutant MMP8. Despite being able to inhibit most MMPs, 
TIMP-3 is yet to be shown to inhibit MMP-8. However, perhaps TIMP-3 can 
actually inhibit MMP-8 and the increase in TIMP3 RNA in the wild-type MMP-8 
expressing cells is part of a compensatory mechanism, or MMP-8 may have 
effects on other metalloproteinases such as ADAMs and ADAMTSs that were not 
investigated in this work which are regulated by TIMP3. To study this further 
the elevation of TIMP3 would firstly have to be confirmed at the protein level. 
To conclude this chapter, this work has built on the limited knowledge of the 
cellular functions of MMP-8. Functional in vitro assays have previously only 
been carried out on mouse melanoma cells, so the work here has provided 
additional information on the wider functions of MMP-8. Whilst differences 
were drawn between these studies and the results in this chapter it has been 
shown that MMP-8 has no effect on the growth of MDA-MB-231 breast cancer 
cells, or the B16F10 melanoma cells used by Gutiérrez-Fernandez et al., (2008) 
[52],  has little or no effect on invasion through type I collagen but may have 
some longer-term effects on adhesion (dependent on its catalytic activity), 
reduces random 2D migration (dependent on its catalytic activity) and scratch 
wound closure (independent of its catalytic activity). MMP-8 did not have any 
effect on EMT, although this was expected as the MDA-MB-231 cells have 
already undergone this transition. It did however cause an increase in TIMP3 
expression at the RNA level, potentially as a mechanism to reduce any adverse 
effects as a result of high expression of the protease. MMP8 does therefore have 
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some functional phenotypic effects on MDA-MB-231 breast carcinoma cells but 
without altering the fundamental molecular characteristics of the cells, with the 
exception of its role in the modulation of the two immune system mediators.  
This makes the system generated appropriate for further analysis into the 
functions of MMP8 in breast carcinoma cells. The following chapter involves 
further investigation of the molecular effects of MMP-8 with respect to its 
published roles in the innate immune response.  
3.5 Summary 
 
 Wild-type MMP8 and catalytically inactive E198A MMP8 expression 
constructs were generated and found to be functional by both transient 
and stable transfection into mammary carcinoma cells. 
 MMP-8 is predominantly secreted from the cell.  
 Stable transfection of MMP-8 was problematic but a set of MDA-MB-231 
clonal isolates were generated that expressed wild-type MMP-8 “long-
term” 
o Stable cells generated (clonal): 
  MDA-MB-231 pcDNA4 empty vector control x2 
  MDA-MB-231 pcDNA4 wild-type MMP8 x2 
  MDA-MB-231 pcDNA4 E198A mutant MMP8 x2 
 Using the “long-term” MDA-MB-231 stably transfected cells behavioural 
characteristics were examined 
o MMP-8 did not affect cell growth or cell cycle profile 
o MMP-8 reduced random 2D migration dependent on catalytic 
activity 
o MMP-8 reduced scratch wound closure independent of catalytic 
activity 
o MMP-8 did not obviously affect EMT 
o MMP-8 potentially induced TIMP3 RNA levels dependent on 
catalytic activity 
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Chapter 4- Investigation of the 
regulation of Interleukins -6 and -8 
by MMP-8 
 
Having generated an in vitro system to discover the role of MMP-8 in mammary 
carcinoma we aimed to determine the actions of MMP-8 at the molecular level. 
The previous chapter showed that MMP8 had effects on migration and adhesion 
of breast carcinoma cells. This chapter examines a novel role for MMP-8 in the 
modulation the immune response through up-regulation of inflammatory 
mediators. Predominantly focussing on the “long-term” MMP-8 expressing 
MDA-MB-231 clonal isolates this chapter delves into this phenomenon aiming to 
discover the regulatory mechanisms and other factors involved.  Some of this 
content has been published (Appendix 3).  
4.1 MMP-8 has a role in modulation of immune responses 
 
MMP-8 has been heavily implicated in diseases of the immune system [44] and 
Mmp8 knockout mouse models have showed that MMP-8 cleaves both murine 
LIX, the orthologue of human interleukin 8 (IL-8), and IL-8 itself [64, 80]. Other 
studies have reported a decrease in LIX protein in the Mmp8 knockout mouse 
[49], which is hypothesised as the result of a reduction in proteolytic release of 
LIX from stores in the extracellular matrix, which may primarily be carried out 
by MMP-8. Other evidence for the involvement of MMP-8 in immune system 
modulation comes from the study showing that  MMP-8 can cleave the anti-
inflammatory cytokine IL-10 in a mouse model of bleomycin-induced lung 
fibrosis, whereby in the Mmp8 knockout mouse there was a decrease in IL-10 
cleavage accompanied by a reduction in lung fibrosis [86]. In addition,  MMP-8 
expression has been found to be up-regulated by addition of IL-1β to ovarian 
cancer cells in culture, with addition increasing MMP-8 protein levels by 5.6 fold 
compared to controls [38]. Therefore, it was appropriate to examine whether 
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MMP-8 expressed by breast cancer cells had any effect on individual 
inflammatory markers.  
 
4.1.1 Cells transiently transfected with wild-type MMP8 induce IL-6 
and IL-8 expression 
 
Through looking at a panel of inflammatory markers (IL-8, IL-1β, IL-10, TNF, IL-
6, and IL-12p70) by FACS in conditioned media from MCF-7 cells transiently 
transfected with MMP8 for 48 hours it was discovered that, of the panel 
examined, MMP-8 had an effect on the levels of the cytokine IL-6 and the 
chemokine, IL-8. ‘Cytokine’ is a blanket term for these immune system 
modulators within which ‘chemokines’ reside. Chemokines are cytokines that 
have a role in inducing cellular chemotaxis. MMP-8, dependent on its catalytic 
activity, caused an increase in both IL-6 (20%) and IL-8 (65%) total protein 
secretion in MCF-7 cells (figure 4.1A). The other inflammatory molecules were 
not expressed by the cells so were not investigated further. To determine if this 
was due to liberation of the cytokines from cellular storage or an actual up-
regulation of their expression, mRNA was examined by Taqman qRT-PCR. It was 
found that over-expression of wild-type MMP8 caused a 250% and 300% 
increase in mRNA levels of IL-6 and IL-8 respectively (figure 4.1B). Mutant 
MMP8 did not cause this response, and showed the same level of cytokine 
induction as the vector only negative control cells, meaning that the effect of 
MMP8 on cytokine expression is due to its catalytic activity. This effect can also 
be seen in SK-BR-3 cells (figure 4.1C) which are mammary gland 
adenocarcinoma cells isolated from a metastatic site of pleural effusion, but not 
in the non-tumourigenic HMT-3522 S1 cells (figure 4.2), suggesting that this 
phenomena is specific to cancer cells.  None of the other inflammatory 
mediators studied in this assay were secreted from the MCF-7 cells at a 
measurable level,  including IL-10, of which MMP-8 has been shown to cleave 
[86] and IL-1β, which has been shown to control MMP8 expression [38] so were 
not examined further.  
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4.1.2 MMP8 up-regulates IL-6 and IL-8 in “long-term” MDA-MB-231 
stable transfectants 
 
Due to the differences observed by FACs and qRT-PCR in MCF-7 cells it was 
decided to look at IL-6 and 8 at both the protein and mRNA level in the MDA-
MB-231 stable transfectants discussed in Chapter 3. Unlike the MCF-7 cells 
MDA-MB-231 metastatic breast cancer cells produce low levels of both IL-6 and 
8 endogenously due to a lack of suppression by the estrogen receptor [180-
183].  However, on stable transfection of wild-type MMP8 IL-6 protein levels 
were increased by 2-5x and mRNA level by 3-6x, and IL-8 protein levels by 2-
10x and mRNA levels by 4-10x (figure 4.2). Two independent clonal isolates 
were examined, which confirms that the observed effect is due to MMP-8 rather 
than an effect of the transfection, but also explains the variation observed as IL-
6 and 8 levels varied between clones.  This effect is again due to the catalytic 
activity of MMP8, as the cells over-expressing the mutant show protein and 
mRNA levels comparable to the control. This effect was confirmed in the pooled 
stably transfected cells that the clonal isolates were derived from, at both the 
RNA and protein level (figure 4.4).  
 
The observation of an induction of IL-6 and IL-8 with wild-type MMP8 over-
expression is apparent in three different cells lines, after a short-term 
transfection  time of 48 hours in the MCF-7 and SKBR3 cells, and also long-term 
stable transfection in MDA-MB-231 cells. This can be confirmed in two separate 
clonal isolates each for vector control cells, wild-type and EA mutant MMP-8 
expressing cells. This trend is also apparent in the pooled stably transfected 
cells  from which these cells were derived but there is more variation due to the 
heterogeneous nature of the cells.   
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Figure 4.1: Transient transfection of MMP8 into MCF-7 and SK-
BR-3 cells. A) ELISA analysis of IL-6 and IL-8 protein levels in serum 
free conditioned media from MCF-7 cells transiently transfected with 
pcDNA4 empty vector, wild-type and E198A mutant MMP8 for 48 
hours. B) Gene expression levels of IL-6 and IL-8 mRNA determined 
by Taqman in MCF-7 cells transiently transfected with pcDNA4 
empty vector, wild-type and E198A mutant MMP8 for 48 hours. 
Values normalised to 18S and expressed relative to the EV control. C) 
Gene expression levels of IL-6 and IL-8 mRNA determined by 
Taqman in SK-BR-3 cells transiently transfected with pcDNA4 empty 
vector, wild-type and E198A mutant MMP8 for 48 hours. Values 
normalised to 18S and expressed relative to the EV control n=3, 
mean ± SEM, * = p <0.05, ** = p<0.01 *** = p<0.001  
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Figure 4.2: Transient transfection of MMP8 into HMT-3522 S1 
cells. Gene expression levels of IL-6 and IL-8 mRNA determined by 
Taqman in HMT-3522 S1 cells transiently transfected with pcDNA4 
empty vector, wild-type and E198A mutant MMP8 for 48 hours. n=3, 
mean ± SEM 
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Figure 4.3: Effect of stable over-expression of wild-type MMP8 
in MDA-MB-231 clonal isolates on IL-6 and IL-8 protein and RNA 
expression Two independent clones of MDA-MB-231 cells stably 
transfected with pcDNA4 empty vector, Wild-Type MMP-8 and 
E198A mutant MMP-8 were analysed. A) ELISA measurements of IL-
6 and IL-8 protein levels in serum-free conditioned media collected 
24hours after serum starvation. B) RNA quantification by real-time 
TaqMan RT-PCR of IL-6 and IL-8 mRNAs in these same cells. n=3, 
mean ± SEM, Statistics: both wild-type MMP-8 clones 1 and 2 were 
different compared to all other cells by at least p<0.05 or p<0.01 
unless where shown otherwise * = p <0.05, ** = p<0.01 *** = 
p<0.001. 
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Figure 4.4: Effect of stable over-expression of wild-type MMP8 
in MDA-MB-231 polyclonal pools on IL-6 and IL-8 protein and 
RNA expression. Two pools of  wild-type MMP-8 expressing cells 
and one pool each of empty vector control and E198A mutant MMP-8 
expressing cells were analysed. A) ELISA measurements of IL-6 and 
IL-8 protein levels in serum-free conditioned media collected 24 
hours after serum starvation. B) RNA quantification by real-time 
TaqMan RT-PCR of IL-6 and IL-8 mRNAs in these same cells. n=3, 
mean ± SEM, * = p <0.05, ** = p<0.01 *** = p<0.001 
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4.1.3. MMP8, IL-6 and IL-8 exist as part of a self-reinforcing loop 
 
Evidence widely suggests that cytokine levels within cells fluctuate dynamically 
in response to a wide variety of stimuli, and so will therefore exist in a range of 
varying feedback loops.  To determine whether a feedback loop is operating in 
the MMP8 over-expressing MDA-MB-231 cells, cells over-expressing wild-type 
MMP8 were treated with siRNAs to IL-6 and IL-8 and levels of both cytokines 
measured by Taqman qRT-PCR. On siRNA knockdown of IL-6 no effect was 
observed on IL-8 RNA expression compared to the non-targeting control siRNA 
(figure 4.5B) indicating that IL-6 has no direct effect on IL-8 expression levels. 
However, on IL-8 siRNA knockdown IL-6 RNA levels were reduced by 75% 
compared to the non-targeting control (figure 4.5A). Finally, to determine if 
either of the cytokines had an effect on endogenous MMP8 expression human 
recombinant IL-6 and IL-8 were added to parental MDA-MB-231 cells for 24 
hours, and the expression level of MMP8 determined by Taqman RT-PCR. 
Recombinant IL-6 was able to induce endogenous MMP8 expression by 
approximately 20%, but IL-8 had a very minor effect (figure 4.5C). This data 
suggests  that there is an self-reinforcing loop occurring whereby MMP8 can 
induce expression of both IL-6 and -8, but also where IL-8 can reinforce IL-6 
expression, and IL-6 expression can induce MMP8 expression (figure 4.5D), 
therefore resulting in a self-perpetuating loop. The remainder of this chapter 
concerns determination of the mechanisms involved in the MMP-8-driven 
induction of IL-6 and IL-8 expression. 
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Figure 4.5: MMP8, IL-6 and IL-8 constitute a self-reinforcing 
loop. A) Gene expression analysis by Taqman of IL-6 levels after 
siRNA knockdown of both IL-6 and IL-8 for 48 hours. B) Gene 
expression analysis by Taqman of IL-8 mRNA levels after siRNA 
knockdown of both IL-6 and IL-8 for 48 hours. C) Gene expression 
analysis by Taqman of MMP8 mRNA after incubation with 100ng/ml 
rhIL-6 and rhIL-8 for 24 hours. D) The proposed self-reinforcing 
loop. n=3, mean ± SEM,  * = p <0.05, ** = p<0.01 *** = p<0.001 
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4.2 Molecular mechanisms of IL-6 and IL-8 up-regulation with 
wild-type MMP8 over-expression 
 
Section 4.1 showed that wild-type MMP8 over-expression induces the 
expression of IL-6 and IL-8 in breast cancer cell lines, but not in normal breast 
cells. This effect is both dependent on the catalytic activity of MMP8 as the same 
effect is not seen in cells transfected with the E198A catalytically inactive 
mutant, and is dependent on malignant transformation. The aim of the rest of 
this chapter is to elucidate the mechanisms behind this up-regulation; firstly 
through a screen of molecular pathway inhibitors, then through an array that 
detects any changes in level of phosphorylated kinases, finishing with some 
mass spectrometry analysis of MMP8-binding partners to give further insight 
into the mechanisms involved. These experiments were carried out on clone set 
1 of the MDA-MB-231 stable cell lines.  
 
4.2.1 Effect of molecular pathway inhibitors on MMP-8 over-
expressing cells  
 
To determine the molecular mechanisms involved in the up-regulation of IL-6 
and IL-8, various pathway inhibitors were used on the cells and IL-6 and IL-8 
protein levels secreted into the cell culture media were measured by ELISA. 
These inhibitors were chosen on the basis of published literature into pathways 
known to affect cytokine production and key cell signalling constituents. The 
inhibitors used and their target pathways were; PD0325901 and U0126 (MAPK-Erk 
pathway), SB203580 (p38), Wortmannin and PI-103 (PI-3K), 
Bisindolylmaleimide 1(PKC), SP600125 (JNK), BAY 11-7082 (NF-κB) and 
SB431542 (TGFβR1). Concentrations used were in accordance to published 
guidelines [184]  (see Chapter 2 table 2.5 for the concentrations used). 
 
The only inhibitor that showed an effect on IL-6 and IL-8 expression selectively 
in the wild-type MMP-8 over-expressing cells only was BAY 11-7082. This is a 
Nuclear Factor Kappa Beta (NFĸB) inhibitor which acts by preventing 
phosphorylation of IĸBɑ, which in its un-phosphorylated form inhibits NFĸB by 
sequestering it in the cytosol [185, 186]. Inhibition of NFĸB signalling resulted 
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in a 60-80% decrease in both IL-6 and -8 protein production in MDA-MB-231 
cells over-expressing MMP-8 (figure 4.6A). The c-Jun-n-terminal kinase (JNK) 
inhibitor, SP600125, also had an effect in IL-6 and -8 protein levels but it did so 
across all three cell lines examined (data not shown). JNK kinases  are involved 
in the activation of AP-1 [187] which is reported to be the second most 
influential transcription factor after  NFĸB in IL-6 and -8 gene regulation [180]. 
IL-6 and -8 can also be differentially regulated, as seen in figure 4.6B after 
addition of SB431542, a TGFβ inhibitor. This exerts its effects by blocking 
signaling through TGFβ-Receptor 1 [188] and has no effect in IL-6 production 
but IL-8 production actually increases on inhibition across all three cell lines, 
showing that TGFβ inhibits IL-8 production in MDA-MB-231 cells (figure 4.6B). 
This inhibitory effect has been reported in the literature in human bronchial 
epithelial cells [189]. Some inhibitors, such as PD0325901 and U0126 affected 
all cells dramatically and caused alteration in phenotype and induced cell death, 
probably due to the MAPK pathway having such a central role in signalling 
within these cells. Despite examination of components of the NFKB pathway by 
western blot it was not possible to show how MMP8 affected its activity or vice 
versa, as no changes were observed in protein levels of either phosphorylated 
or total p65 NFKB nor regulatory proteins, IKK or IKBα (figure 4.7). The 
phosphor IĸBα antibody did not work convincingly and showed many bands so 
lack of effect of MMP8 on the protein may be attributed to a poor antibody 
function.  Additionally, the pathway is large and complex so it is wholly possible 
that MMP8 has an effect on other members not studied here.  
 
Tumour necrosis factor alpha (TNFα) is a member of the TNF family of pro-
inflammatory cytokines which   has been shown to be an activator of NFKB [190, 
191]. It has also been shown to be solubilised by some MMPs [192, 193] to its 
active form. Furthermore, exogenous addition of TNFα to MDA-MB-231 cells can 
increase IL-6 production [194]. To determine whether the MMP-8 released from 
the cells is causing a release of pro-TNFα from the cell surface TNFα levels were 
determined in the cell media by ELISA. This would detect any TNFα that had 
been solubilised. Levels detected by ELISA were very low, and Taqman analysis 
showed that expression of TNFα is very low in MDA-MB-231 cells (CT values of 
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approximately 38). Therefore, it is not likely that MMP8 is acting on NFKB via an 
increase in endogenous, active, TNFα, as the cells are not expressing it. To 
further support this, total TNF was analysed as part of the cytokine bead array 
(CBA) using FACS on conditioned media from MCF-7 cells transiently 
transfected with MMP8 and control constructs, and was undetected in this 
assay.   
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Molecular pathway inhibition in stably transfected 
MDA-MB-231 cells. A) IL-6 and IL-8 secreted protein levels were 
measured by ELISA after incubation of MDA-MB-231 clonal isolates 
stably expressing wild-type or E198A mutant MMP8 and empty 
vector control cells with (A) BAY 11-7082, an NFĸB inhibitor, of (B) 
SB431542, a TGFβRI inhibitor, for 48 hours. n=3, mean ±SEM, * = p 
<0.05, ** = p<0.01 *** = p<0.001 
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Figure 4.7: Investigation of the effects of MMP-8 on NFᴋB family 
members. Western blot analysis of (A) p65 (B), IKKα and (C) IᴋBα in 
MDA-MB-231 clonal isolates (both sets) stably expressing wild-type 
and E198A mutant MMP8 and an empty vector control.  
.  
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4.2.2 Effects of MMP-8 on kinase phosphorylation 
 
 
To dissect further the potential mechanisms through which MMP-8 is inducing 
IL-6 and -8 in the “long-term” stably transfected MDA-MB-231 cell lines, a 
commercially available array was used to determine kinase phosphorylation 
from cell protein samples. Proteins from MDA-MB-231 cells over-expressing 
both wild-type and E198A catalytically inactive MMP8, and an empty vector 
control (clone set 1) were applied to membranes pre-printed with antibodies to 
an array of phosphorylated kinases. After following the manufacturer’s 
instructions the membranes were imaged using HRP and the result was a 
membrane covered in dots of varying intensities (figure 4.8A). Pixel density was 
quantified using Image J and results can be seen in the heat map shown in figure 
4.8B. The graph in the far right column provides a visual representation 
depicting the trend of the results, with those highlighted in yellow showing a 
potentially interesting trend discussed later (See appendix 2 for raw results).  
 
Most interesting is the approximate 2 fold increase in phospho- p38α MAPK in 
the cells over-expressing wild-type MMP-8 compared to cells expressing the 
vector control (EV) or EA mutant MMP8.  This is accompanied by a reduction in 
phospho- ERK 1/2 (MAPK 42/44), MEK 1/2 and MSK 1/2. However, the 
changes in phospho p38α or ERK 1/2 could not be confirmed by western blot. 
The MAPK pathway is involved in the activation of NFᴋB, and thus IL-6 and IL-8 
[195], via phosphorylation of p65 NFĸB by MSK1/2, a downstream effector of 
p38 [196]. Therefore, the increase in phosphorylation may indicate that p38α is 
involved in the pathway downstream of MMP8 to up-regulate IL-6 and -8 
expression. We actually saw a slight decrease in MSK1/2 signalling in the cells 
over-expressing MMP8 however, but as these signalling processes are very 
dynamic, and the samples used in the assay were only a ‘snapshot’ into the ever 
changing signalling pathways within the cells we cannot conclude that this 
pathway is not overactive in the wild-type MMP8 over-expressing cells. Despite 
this there is evidence for active p38α signalling within the cells as levels of 
phosphorylated heat shock protein 27 (hsp27), a downstream target of p38α via 
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MAP kinase-activated protein kinase 2, were elevated in the cells over-
expressing wild-type MMP8.  
 
Other points to note include a slight increase in phosph-STAT3, the main 
downstream signal effector of IL-6, suggesting that IL-6 is signalling effectively 
within the cell. AMP-activated protein kinase alpha 1 (AMPKα1) 
phosphorylation is slightly decreased with wild-type MMP8 expression. This 
protein senses changes in cellular energy, being activated by rising AMP levels 
and falling ATP levels [197]. It can also be activated by the tumour suppressor 
gene LKB1, by which this particular AMPK isoform is primarily regulated [198], 
thereby suggesting there may be some slight alterations in activity of this 
tumour suppressor in the cells over-expressing MMP8. This would need to be 
confirmed through other techniques however, especially considering the 
difference observed in AMPKα1 in wild-type MMP8 over-expressing cells is only 
slight. Plus, p53 is a downstream target [199-201] and was not found to have 
any consistent changes in phosphorylation in this assay, although 
phosphorylation of p53 ser15, described as the target of AMPK [201] is reduced 
by a very small amount in the cells over-expressing wild-type MMP8. There was 
no effect on the AMPKα2 isoform.  
 
It can be concluded from these studies that up-regulation of IL-6 and IL-8 by 
wild-type MMP8 in MDA-MB-231 cells is dependent on NFĸB activity, which 
may be activated through the p38 MAPK pathway. Despite this, these pathways 
are intracellular and thus distant from MMP-8 which functions extracellularly so 
therefore, mass spectrometry analysis of MMP8 binding partners was carried 
out to uncover any of the missing mediating factors involved.  
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Figure 4.8: Effects of MMP-8 on kinase phosphorylation.  
A) Phosphorylated kinase levels in MDA-MB-231 clonal isolates (set 
1) stably transfected with wild-type and E198A mutant MMP8 and 
an empty vector control. Cell lysates were applied to membranes 
pre-printed with antibodies to an array of phosphorylated kinases. 
After following the manufacturer’s instructions the membranes were 
imaged using HRP and the result was a membrane covered in dots of 
varying intensities. B) (next page) Phosphorylated kinase levels in 
MDA-MB-231 clonal isolates (set 1) stably transfected with wild-type 
and E198A mutant MMP8 and an empty vector control. Colours 
broadly relate to expression levels, expressed as pixel density on a 
sliding colour scale. Dark red colours relate to low values up to 1000, 
yellow relates to values around 2000 and dark green relates to the 
highest values of up to 8000.  Right hand graphs give brief 
representations of the trends of the results, with those highlighted in 
yellow referred to in the text. Key: EV = ‘empty vector’ negative 
control cells, WT MMP8 = wild-type MMP8 over-expressing cells and 
EA MMP8 = E198A mutant MMP8 over-expressing cells. 
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Kinase (phosphorylation site) EV WT MMP8 EA MMP8
p38α (T180/Y182) 1434.663 3529.5415 1717.37
ERK 1/2 (T202/Y204, T185/Y187) 6223.941 4036.981 7972.5265
JNK pan (T183/Y185, T221/Y223) 839.663 580.617 698.006
GSK-3α/β (S21/S9) 580.4455 510.7635 518.0315
MEK 1/2 (S218/S222, S222/S226) 2945.103 2095.845 2990.1375
MSK1/2 (S376/S360) 3887.31 3044.6375 4347.3445
p53 (S392) 6941.32 7001.32 6738.456
p53 (S46) 7286.284 6183.0165 5193.7235
p53 (S15) 3866.088 3228.0775 3460.1025
p27 (T189) 1562.906 1232.4555 940.5665
p27 (T175) 1829.941 1402.749 1924.4915
AMPKα1 (T174) 1702.396 1180.249 1747.37
AMPKα2  (T172) 703.299 781.506 958.6275
TOR (S2448) 429.2025 484.1775 522.9455
CREB (S133) 7544.416 5543.4915 3653.3955
HSP27 (S78/S82) 1284.396 2151.956 1607.749
Akt (S473) 946.8345 768.067 1134.3095
Akt (T308) 1449.199 1073.6025 1221.3095
β- Catenin 313.228 335.1675 446.7635
p70 S6 Kinase (T389) 90.364 100.657 392.849
p70 S6 Kinase (T421/S424) 4605.052 4988.052 5349.2945
p70 S6 Kinase (T229) 2377.81 3608.138 3164.32
Paxillin (Y118) 5614.355 4038.163 2819.92
Src (Y419) 3145.992 1746.663 1513.431
Lyn (Y397) 991.213 776.0315 587.6525
Lck (Y394) 960.749 713.274 641.6525
PLCγ-1 (Y783) 6096.477 4188.9305 4617.784
Fyn (Y420) 2682.345 2661.7595 1767.663
Yes (Y426) 3811.077 4443.3445 3186.284
Fgr (Y412) 973.9205 1209.42 1276.6025
c-Jun (S63) 4838.87 4664.284 5744.5875
Pyk2 (Y402) 2062.31 2966.406 2840.577
Hck (Y411) 1531.456 1435.456 1413.724
Chk-2 (T68) 5303.588 4189.87 3851.906
FAK (Y397) 2190.931 1912.42 2380.4305
RSK 1/2/3 (S380) 4404.588 3190.077 3361.138
RSK 1/2 (S221/S227) 2076.163 2073.8955 2387.37
eNOS (S1177) 861.213 1880.895 1201.456
STAT1 (Y701) 5415.941 5204.113 5257.441
STAT2 (Y689) 4912.26 3171.784 3065.4055
STAT3 (S727/Y705) 1946.603 2193.542 1845.8955
STAT4 (Y693) 4978.795 4570.87 4483.1735
STAT5a (Y699) 4523.406 2602.6375 2896.502
STAT5b (Y699) 4637.76 4305.8095 4567.9305
STAT5a/b (Y699) 2610.527 1765.3595 2561.6375
STAT6 (Y641) 4210.174 3033.8955 4924.2595
1000 2000 8000
Key:
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4.2.3 Analysis of MMP8 binding proteins by mass spectrometry 
 
To determine whether MMP8 binds to any of the mediating proteins involved in 
the up-regulation of IL-6 and IL-8, MMP-8 was immunoprecipitated out of 
serum free cell culture media conditioned by the engineered MDA-MB-231 cells 
expressing the control vector, wild-type and EA mutant MMP8. Serum free 
culture media was used as serum contains MMP-8 which would contaminate the 
results. The immunoprecipitation reaction was separated on a gradient gel, 
proteins stained and sections sent for analysis by mass spectrometry (figure 
4.9B). Sections were chosen where visible bands were present. Figure 4.9A 
shows that both wild-type and E198A mutant MMP-8 were successfully 
immunoprecipitated out of the cell culture media by probing a blot that was 
prepared with a small portion of the immunoprecipitates. The results obtained 
were expressed as a probability of a protein being present. Hundreds of 
proteins gave a positive identification, but many of these were caused by the gel 
being contaminated by keratins for example, and these proteins were present in 
all samples. However, focus was centred on proteins that were either present in 
immunoprecipitates of both wild-type and E198A mutant MMP-8, present in the 
E198A mutant MMP-8 precipitate only or in the wild-type MMP-8 precipitate 
only. Binding to the E198A mutant MMP-8 only indicates these proteins are 
maybe MMP-8 substrates but are bound to the inactive enzyme as they have not 
been cleaved. In contrast, proteins that are bound to wild-type MMP-8 only may 
be cleavage products. There were some discrepancies with regards to the 
expected molecular weights of the proteins and the area of the gel from which 
the sample was extracted. However, the facility managers of the mass 
spectrometry services where the samples were analysed explained that some 
very large proteins do not run through the gel uniformly and could therefore 
appear at an unexpected weight and that the molecular weight marker is not 
100% accurate. Also, some of the proteins may have undergone degradation so 
may be seen at multiple locations throughout the gel.  Figures 4.9 C and D show 
the proteins identified that were found in the samples generated from the cells 
over-expressing both wild-type and EA mutant MMP8 or one of the other and 
thus indicating that MMP8 was involved. Figure 4.9C shows the proteins that 
Chapter 4- Investigation of the regulation of Interleukins -6 and -8 by MMP-8 
 
134 
 
are of interest with regards to the induction of IL-6 and -8 by wild-type MMP8 
over-expressing MDA-MB-231 cells (S100-A8, Annexin A1 and Hornerin) and as 
follows is a brief introduction and description as to why they are potentially 
interesting.  
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Figure 4.9: Mass Spectrpometry analysis of MMP-8 binding 
parters. A) Western blot analysis of MMP8 from the 
immunoprecipitation of MMP-8 from serum free conditioned media 
from MDA-MB-231 clonal isolates (set 1) expressing wild-type 
MMP8, E198A Mutant MMP8 and a control ‘empty vector’ B) Sections 
of the gel run from the immunoprecipitation analysed by mass 
spectrometry. Blue boxes indicate the sections analysed and the Row 
ID relates to the entire row, which was analysed in 3 separate 
sections, separated by genotype of the cells. C) Confirmation of 
protein presence by probability that the protein has been identified 
correctly of MMP-8 binding proteins considered of interest to this 
work. D) Confirmation of protein presence by probability that the 
protein has been identified correctly of other MMP-8 binding 
proteins that bind MMP8.  
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S100A8 
There are two main reasons for investigating S100A8 further; its role in 
inflammation and its role in cancer.  
 
S100A8, also known as S100 calcium binding protein A8, calgranulin A or MRP-
8 is a pro-inflammatory calcium binding protein. It is mainly expressed by 
myeloid cells, but is found at very high levels in neutrophils, comprising 45% of 
the total cytosolic proteins [202] and is released during an inflammatory 
response. This has been demonstrated in both patients  with inflammatory 
conditions such as periodontitis in heterodimeric form with S100A9 [203] and 
as a monomer [204], and in vitro [205, 206]. Both monomeric S100A8 and 
heterodimeric S100A8 (S100A8/S100A9) are chemoattractic to neutrophils in 
vitro [207] although S100A8 is sensitive to oxidation, with its chemoattractive 
abilities diminished under these conditions [208]. Extracellular S100A8 can also 
activate MAP kinase and NFĸB signalling pathways, and thus release of pro-
inflammatory cytokines, such as IL-8 [209] via binding to the receptor for 
advanced glycation end products (RAGE) [210-212]. Interestingly, this RAGE 
dependent activation of NFĸB has been shown to be sustained long-term, 
resulting in a prolonged cellular change which can over-ride endogenous 
feedback controls [213].  Such downstream signalling effects have also been 
demonstrated  through binding of S100A8 to the Toll-like receptor 4 (TLR4) 
[209]. 
 
S100A8 has been shown to be expressed in a variety of cancers such as gastric 
cancers [214], colorectal [215], pancreatic [216], prostate (the S100A8 ligand 
RAGE was also upregulated in this study) [217], bladder cancer [218-220] and 
oesophageal squamous cell carcinoma [221]. It is down-regulated in 
oesophageal squamous cell carcinoma but up-regulated in the others. Most 
importantly, and most relevant to this thesis, S100A8 has been found to be up-
regulated in breast cancer [222-224].  Cancemi et al., 2010 carried out a large-
scale proteomic analysis of the S100 proteins in breast cancer tissues, 
comparing cancer tissue with non-cancerous adjacent tissue. S100A8 was found 
to be expressed only in the cancerous tissue, in 71% of the 100 patient samples 
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studied.  Furthermore, S100A8 was present in the tumours at a significantly 
higher level (1.5x) in patients that had developed metastasis within 3 years 
after the initial study compared to patients that had remained disease free 
[222], suggesting that S100A8 expression is associated with more aggressive 
tumours. Interestingly, despite the wealth of literature suggesting that S100A8 
and –A9 act in conjunction with each other, S100A9 was not identified in the 
breast tumour samples studied. In addition to this evidence, Mukhtar et al., 
(2012) found positive associations between high levels of S100A8/S100A9 
immunohistological staining in breast tumour samples and hormone receptor 
status (more S100A8/S100A9 in hormone receptor negative patients), higher 
grade tumours, with the majority of samples stained to a high level being grade 
3 tumours, and age. The patients with higher levels of staining were younger 
than those with low level staining [223].  
 
In vitro studies have given further evidence for pro-tumourigenic actions of 
S100A8. Moon et al., (2008) carried out a genome microarray on H-Ras 
transformed MCF10A breast cells and found that compared to control cells; H-
Ras transformed cells expressed S100A8 and A9. These cells were more 
invasive than control cells, but this effect was reduced dramatically on siRNA 
knockdown of both S100 proteins independently. Incidentally, S100A8 (and A9) 
can increase invasiveness irrespective of the presence of a Ras mutation, as 
over-expression of both S100 proteins (individually or in conjunction)in the 
MCF10A cells increased invasion significantly [225]. This effect was shown to be 
calcium dependent, as its presence is required for protein stability, and also on 
p38 MAPK and ERK signalling pathways [225]. S100A8 appears to act within a 
feedback loop with MAPK pathway members in that inhibition of p38 MAPK and 
ERK reduced S100A8 protein expression, and S100A8 siRNA reduced levels of 
phospho-p38 and phospho-ERK. Similar results have also been shown in LNCaP 
prostate cancer cells whereby cells treated with S100A8 and S100A9 proteins 
showed a dose-dependent increase in p38 MAPK and ERK phosphorylation. This 
was coupled to increased activation of NFĸB, a well-known target of the MAPK 
pathway, and in increase in scratch wound closure [210]. Exogenous addition of 
S100A8 purified from neutrophils has also been shown to increase growth of 
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MCF-7 and MDA-MB-231 breast cancer cells at low concentrations, through 
binding to RAGE on the cell surface [212]. This effect was likely propagated 
through an increase in phosphopylated p38 MAPK and ERK, as was evidenced 
within 30 minutes of S100A8 addition, and NFĸB activation. Finally S100A7, 
S100A8 and S100A9 have been found to be repressed by the breast cancer 
tumour suppressor gene BRCA1, adding another piece of evidence for S100A8 
acting as a tumour promoter [226]. Incidentally, a study by Rhee et al., (2008), 
using an MCF10A breast cell model of tumourigenesis saw that S100A9 mRNA 
and protein expression decreased at the stages of the model representing 
benign proliferation and ductal carcinoma in situ (DCIS), but then increased in 
cells representing  the invasive stages. Also at these early stages over-
expression of S100A8 in cells representing the early stages of breast 
tumourigenesis actually inhibited cell growth [224]. This suggests that S100A8 
is only involved in advanced cancers, but that forcing expression at early stages 
of tumourigenesis, at which stages it is not normally expressed may possibly be 
beneficial. This however is concluded from an in vitro model and, as human 
breast cancer studies show that tumour expression of S100A8 correlates with 
negative effects and poor prognosis care needs to be taken when interpreting 
such findings.  
 
Here, S100A8 is pulled down with both wild-type and EA mutant MMP8 in band 
3 which relates to a section from about 8-15kDa, so as S100A8 is about 10kDa it 
is detected at the correct molecular weight. Most importantly there has been a 
paper that proposed an anti-inflammaory role for MMP-8 showing that S100A8 
(and S100A9) were increased in the lungs of mmp8 deficient mice after LPS 
stimulation in an endotoxemia mouse model [91]. Another paper using a rat 
model to look at ischemia-reperfusion induced acute lung injury found that both 
Mmp8 and S100a8 were the 2 most up-regulated genes in a microarray screen 
(Mmp9 and S100a9 were also highly up-regulated). Tissue protein IL-6 levels 
were also highly up-regulated 60 mins after ischemia, although RNA levels were 
unchanged [227]. 
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Consequently, due to the role of S100A8 in inflammation, breast cancer and its 
production from the same location as MMP8 it was deemed worthy or further 
investigation.  Unfortunately the antibody available to validate this interaction 
by western blot did not work.  
 
Annexin A1 
Annexin A1 (also known as lipocortin 1) is a membrane binding protein that is 
regulated by calcium and has roles in trafficking of proteins in and out of the cell 
[228]. Some annexins however can be secreted, although through unknown 
mechanisms, with the majority of research highlighting a potential extracellular 
role for Annexin A1. For example, Christmas et al., (1991) reported that despite 
Annexin A1 not having a ‘traditional’ signal sequence, it is secreted from 
epithelial cells within the prostate duct into the seminal fluid, whereas Annexin 
A4 which is expressed in the same cells is not secreted [229]. Annexin A1 is 
found at high levels in the cytoplasm of neutrophils [230-232], and one group 
have shown that it is stored in gelatinase granules in the cytoplasm of the 
resting neutrophil. On binding of the neutrophil to an endothelial barrier 
Annexin A1 is mobilised to the cell surface, whereby some is released. 
Therefore, the group postulate that annexin A1 is exocytosed following 
degranulation of the gelatinase granules [232]. Whether a similar mechanism 
occurs in prostate cells is unknown. Release of Annexin A1 from neutrophils in 
vitro has also been reported [233]. MMP-8 is stored within the specific granules 
of neutrophils [30-32] associated with lactoferrin [33] , the majority of which 
also contain gelatinase [234]so it is plausible that MMP-8 and Annexin A1 are 
secreted together from the same granules on neutrophil activation.  However 
there is a conundrum that the majority of the evidence points towards a pro-
inflammatory role for MMP8, and Annexin A1 (and its active N-terminal Ac2-16 
peptide), exerts anti-inflammatory roles through the prevention of neutrophil 
extravasation into the blood stream [235] [236, 237] [238] [239].  In contrast, 
there has been a report of a novel role for an Annexin A1 C-terminal cleavage 
product on activating ERK in endothelial cells and as a consequence enhancing 
neutrophil extravasation [240] but the majority of evidence points towards an 
anti- inflammatory function as in addition to inhibition of neutrophil 
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extravasation, Annexin A1 has been implicated in the promotion of neutrophil 
apoptosis [241] and phagocytosis of these neutrophils [242-244] and more 
recently has been implicated in the clearance of senescent neutrophils in the 
bone marrow by bone marrow-resident macrophages , thus preventing chronic 
inflammation.  
 
Annexin A1 has been studied in many cancers such as lung whereby expression 
is seen at a much higher level in cancer tissue than normal lung tissue, with 
expression correlating with higher tumour grade, metastasis and reduced 
survival [245]. Similar correlations have also been found in gastrointestinal 
cancer [246, 247]. Conversely, loss of Annexin A1 expression has been reported 
in head and neck and prostate cancers [248, 249], whereby down-regulation of 
Annexin A1 was associated with poor patient outcome. 
 
 With regards to breast cancer conflicting reports have been published. Within 
the normal breast Annexin A1 has been found to be expressed in the 
myoepithelial cells [250-252] and also in the luminal epithelial cells [251, 252]. 
Some studies show an involvement of Annexin A1 in the early stages of breast 
cancer development [250] whereas it has also been also been found to be down-
regulated in breast tumour samples compared to healthy tissue [251] [252]. 
In addition, a significant positive correlation has been shown between basal-like 
breast cancers and Annexin A1 expression, and a trend was observed between 
Annexin A1 protein expression and recurrence [252]. This can be further 
supported by the expression of Annexin A1 in breast cancer cell lines, with it 
being highly expressed in basal-like cell lines such as MDA-MB-231 and 
expressed at very low levels in luminal-line cell lines such as MCF7 and T47D 
[252, 253]. Khau et al., (2011) even showed that Annexin A1 could be used to 
distinguish between basal and luminal breast cancer cell lines [254]. In contrast 
to MMP8, evidence points to Annexin A1 having a pro-metastatic role in breast 
cancer progression through its ability to constitutively activate NFᴋB. 
Constitutive NFĸB expression is observed in solid tumours and also aggressive 
breast cancer cells lines and in vitro it has been shown that Annexin A1 is able to 
constitutively activate NFĸB in MCF-7 and MDA-MB-231 breast cancer cells 
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through binding to the IKK complex, resulting in phosphorylation of IĸBα and 
activation of NFĸB [253] and driving the metastatic spread of the cancer cells 
[255]. The overall conclusion from studies into Annexin A1 in breast cancer 
suggests that that its expression promotes metastasis.  
 
Despite this contradictory evidence it is conclusive that Annexin A1 is expressed 
in myoepithelial cells in normal breast tissue, which is where MMP8 is 
expressed. This, plus Annexin A1 and MMP8 being expressed in the granules of 
neutrophil adds to the evidence of there being a link between the two proteins.   
In the mass spectrometry analysis Annexin A1 was found bound to wild-type 
MMP8, albeit in a segment of the gel of a higher molecular weight than expected 
for the protein.  Despite validating a working antibody to confirm these data by 
western blot Annexin A1 could not be detected in an immunoprecipitation 
reaction, even when a large reaction volume was used. The mass spectrometry 
technique used was very sensitive and could detect very small amounts of 
protein so perhaps there was not enough protein bound to MMP8 to be detected 
by western blot.  
 
Hornerin 
Hornerin is another S100 protein, also known as S100A16 and S100A18 due to 
its calcium binding properties and homology to other S100 proteins, but studied 
to a lesser extent than other S100 proteins.  Originally in 2001 it was identified 
in the mouse epidermis, and was found to be cleaved during epidermal 
differentiation [256], and most subsequent studies have focussed in the role of 
hornerin in the skin [257-260], under both normal and disease conditions. It is 
only in the last couple of years that hornerin has been examined in any other 
cells types or conditions, and the only condition studied has been breast cancer 
[261, 262]. Fleming et al., (2010) carried out mass spectrometry on the 
extracellular matrix of whole breast tissue of African-American and Caucasian-
American women in order  to determine if the reason behind  African-American 
women getting a higher rate of aggressive breast cancers was due to protein 
differences in the breast microenvironment between the two groups of women.   
A significant difference in hornerin expression between the two populations 
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was discovered, with expression being much higher in the ECM of breast tissue 
from Caucasian-American women [261] potentially indicating a tumour-
suppressive role. This potential role can be heightened by evidence from their 
recent paper  whereby hornerin was shown to be expressed more highly in less 
aggressive, early stage (TMN grade 1), lymph node negative tumours [262]. 
However, using the same MCF10A in vitro model of tumour progression 
employed by Rhee et al., (2008) when examining the role of S100A8 [224], 
hornerin mRNA and protein expression  increased with increasing invasiveness 
of the cells, potentially indicating a pro-tumourigenic role. Hornerin is 
expressed by  primary breast fibroblasts and primary breast epithelial cells and 
also in breast cancer cell lines such as MCF10As, MDA-MB-231s, T47Ds and 
MCF7s, where it is seen to be heavily cleaved into many fragments ranging from 
260-50kDa [262]. When Fleming et al., 2012 examined hornerin expression 
using the MCF10A tumourigenesis model total hornerin mRNA increased, as did 
protein levels of the intact 260kDa protein. However, in these cells a 100kDa 
fragment is observed, but only in the non-invasive and DCIS-like cells. Perhaps 
this could indicate that this smaller fragment is exerting the anti-tumourigenic 
effects of hornerin, or alternatively this cleavage renders the 260kDa protein 
inactive, so the more cleavage that occurs, the less intact protein there is to 
exert pro-tumourigenic effects.  However, as this is an in vitro model on one cell 
type so one cannot draw firm conclusions.   
 
Interestingly in the mass spectrometry data generated from MDA-MB-231 cells 
hornerin was only detected immunoprecipitated to wild-type MMP8 and at 
approximate molecular weights of 50kDa and 15kDa. Products of up to 250kDa 
were not examined by the mass spec so intact protein would not have been 
detected. Fleming et al., (2012) detect many hornerin cleavage products 
between 260kDa and 50kDa which we do not see. However, they examined cell 
lysates whereas our experiments were looking at secreted hornerin, which may 
account for the smaller products we observed. Hornerin is likely secreted from 
breast cancer cells in exosomes [262]. 
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As hornerin has only been recently associated with breast cancer it would have 
been exciting to follow this up. Hornerin was only found bound to wild-type 
MMP8 and at two molecular weights possibly suggesting that it had been 
cleaved by MMP8. Unfortunately there was no available antibody to validate this 
result as the antibody used by Fleming et al., (2012) [262] had been 
discontinued.  
4.3 Conclusions and Discussion 
 
Through looking at a panel of inflammatory mediators (IL-8, IL-1β, IL-10, TNF, 
IL-6, and IL-12p70) secreted by MCF-7 cells transiently transfected with MMP8 
and control constructs, secreted IL-6 and IL-8 levels were increased in cells 
transfected with wild-type MMP8. This effect did not occur in cells transfected 
with E198A mutant MMP8 so is dependent on catalytic activity. This effect was 
more evident in MDA-MB-231 cells engineered to stably over-express MMP8 
and could be observed in both clonal isolates and the pooled stably transfected 
cells  from which the clones were generated. Two groups have shown that 
MMP8 can proteolytically cleave, and thus activate LIX, the mouse orthologue of 
human IL-8, given it greater potency as a neutrophil chemoattractant [64, 80], 
which is a crucial event in the inflammatory cascade post infection [80] .  
Additionally, another group has shown that LIX protein levels are higher in the 
Mmp8 wild-type compared to the Mmp8 knockout mouse, which was postulated 
to be due to liberation of LIX from ECM stores by MMP8 [49]. In vitro MMP-8 has 
been shown to cleave human IL-8, resulting in the potent chemoattractive 
fragment [80]. This research has formed a solid functional link between MMP-8 
and IL-8 in vivo, not only within the realms of resolving an inflammatory 
response, but also within cancer cells themselves. 
 
Although it is unknown whether MMP-8 cleaves IL-8 in this work, the data show 
that MMP-8 can actually induce IL-8 expression. The increase in IL-8 in the 
culture media as a result of wild-type MMP-8 over-expression was not due to 
liberation of IL-8 that was already present,  but due to an increase in expression 
level. This was evidenced from an increase in IL-8 mRNA within the cells over-
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expressing wild-type MMP8. Interestingly MCF-7 cells do not produce any 
endogenous IL-8 as expression is supressed by the estrogen receptor expressed 
in these cells [180, 181], so MMP-8 can actually induce cells to express IL-8, thus 
over-riding this suppression. This is plausible as studies have shown the IL-8 
promoter is still functional [180, 181], but the NFĸB binding site is 
hypoacetylated [182]. Therefore, the data obtained in this thesis is credible due 
to the already established action of MMP-8 on IL-8, but it adds greater depth to 
the literature as MMP-8 can actually induce IL-8 expression too. The induction 
of IL-6 in cells expressing wild-type  MMP-8 is new and was unexpected. So far 
there has been no literature to suggest that MMP8 has any effect on IL-6. Some 
data has been published to suggest that IL-6 has an effect on MMP expression 
(MMP1 [263], MMP8 [39] and 13 [39, 264], MMP2 and 9 [265], MMPs 2,3,9 and 
13 [266], and MMP10 [267] but not vice versa. However, in the last year MMP-2 
has been shown to regulate IL-6/STAT3 survival signalling in glioma indirectly, 
through formation of a complex with α5β1 integrin [268].  
 
To conclude so far, a new phenomenon has been discovered involving the ability 
of MMP8, through its catalytic activity, to induce the expression of IL-6 and IL-8 
in breast carcinoma cells, but not in normal breast cells (at least in the one cell 
line examined). This phenomenon occurs as part of a self-reinforcing loop, with 
IL-8 having a role in promotion of IL-6 expression levels, and IL-6 being able to 
induce MMP8 expression. This is the second report of IL-6 having an effect on 
MMP8 expression, as previously Wahlgren et al., (2001) showed that addition of 
recombinant IL-6 to RPMI 8226 myeloma cells increased MMP8 (and MMP13) 
protein and RNA levels by up to nine-fold [39]. Only a 20% increase in MMP8 
RNA levels were observed on addition of the same concentration of rhIL-6 used 
by Wahlgren et al., (2013) to naïve MDA-MB-231 cells, but this could be 
attributed to differences in cell line. The cytokine network is complex and 
dynamic [269], and a similar loop has been described by Lederle et al., (2011) 
where IL-6 is involved in a cytokine network which include the up-regulation of 
MMP1 [130].  Unfortunately we do not know whether this signalling pathway is 
functionally active, as we do not know if IL-8 is proteolytically processed to its 
super-active form by MMP8 due to unavailability of appropriate techniques. 
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Also, despite the effect of IL-8 on IL-6 expression,  IL-8 must not be signalling 
through its cognate receptors CXCR1 and CXCR2 as they are not expressed in 
these cells (as determined by Taqman qRT-PCR). There is evidence that IL-8 can 
activate these receptors [270] in endothelial cells, but this is not observed, 
probably due to lack of expression in the first place. We do know from the slight 
increase in phosphorylated STAT3 in cells over-expressing wild-type MMP8 that 
IL-6 is probably signalling (at least via STAT3) though.  
 
A big disadvantage of using the in vitro model of stably transfected breast 
cancer cells in isolation is that there is only one cell type so it is not 
physiologically relevant when looking events on the tumour microenvironment. 
IL-8 is not signalling through its receptors as the cells do not express them. 
However, if these engineered cells were cultured in a multi-cellular 
environment, such as the organotypic breast cancer model pioneered by 
Holliday et al., (2009) where luminal epithelial cells, myoepithelial cells and 
fibroblasts were grown together in a 3D collagen gel [271], much more could be 
discovered about the functionality of the up-regulated signalling pathways. This 
would be enhanced further by the addition of immune cells to the mix, although 
this would add massive complications to the assay due to the short life of the 
immune cells. Another option would be to generate MMP-8 expressing murine 
breast cells and inject them into mice. This would give the benefit of a mutli-
cellular environment, plus the influence of an immune system and would 
therefore give further insight into whether the same loop occurs in mice, both in 
the inflammatory system and within a cancer environment.  
 
One of the published key regulators of IL-6 and -8 is NFĸB [180, 269], and this has 
been confirmed in this work. Inhibition of NFĸB with addition of an inhibitor 
reduced IL-6 and -8 protein levels in cells over-expressing wild-type MMP8 to near 
base-line levels, although not totally, suggesting that other factors are involved that 
would need inhibiting in conjunction with NFĸB to see a total reduction. We have no 
evidence f how/if MMP8 is affecting NFĸB, as no changes have been found in either 
phosphorylated or total levels of either p65 NFĸB or two regulatory molecules, IKKα 
or IĸBα. There are other aspects of the pathway to be looked at such as p50 NFĸB 
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and IKKβ and γ, along with changes in promoter binding of NFĸB which could be 
determined by carrying out an Electrophoretic Mobility Shift Assay (EMSA).  As 
NFĸB is intraceullar and MMP-8 is extracellular further invesigtaion to determine 
mediators between them is required. Literature investigation of  intracellular 
pathways up-stream of NFĸB showed that IL-8 can be induced via the Ras pathway 
resulting in increase in NFĸB transcriptional activity [153]. However, conclusions 
could not be made as inhibition of some members of this pathway, specifically 
MAPK inhibitors, were toxic to the cells so cell death masked any potential effects.   
Therefore,  the array to look at levels of phosphorylated kinases within the cells was 
aimed to define the pathway responsible for IL-6 and IL-8 induction further. 
Interestingly phospho-p38 MAPK emerged as being up-regulated 3 fold in cells 
over-expressing wild-type MMP8 compared to cells expressing the control vector 
and also E198A mutant MMP8. Two inhibitors against p38 were used in the inhibitor 
screen but they adversely affected the cells so it was impossible to determine if there 
were any real effects on IL-6 and -8, so it is still possible that the p38 MAPK 
pathway is somehow activated by MMP8 which in turn activates NFĸB and IL-6 and 
IL-8 expression.  
 
The mass spectrometry analysis of MMP8 binding partners aimed to identify further 
members that could be involved. Two proteins that have been shown to be involved 
in both breast cancer and inflammation and that draw some parallels to MMP8 were 
identified: S100A8 and Annexin A1. A third protein, Hornerin, was also identified 
and considered of interest due to its recently found role in breast cancer. S100A8 was 
definitely worthy of consideration as it has been shown that levels of S100A8 are 
increased in MMP8 deficient mice [91]. Perhaps S100A8 is bound to, and 
sequestered by MMP8, so higher levels are seen in the knockout mouse as a result of 
this not occurring. Additionally, both S100A8 and Annexin A1, like MMP8, are 
predominantly produced in the neutrophils [30, 31, 202, 230-232], and in the normal 
breast both Annexin A1 and MMP8 are expressed in the myoepithelial cells [250-
252] and have published roles in inflammation. The S100A8/A9 heterodimer has 
been shown to induce expression of pro-inflammatory cytokines through activation 
of p38 MAPK and NFĸB [210, 272]. In contrast, Annexin A1 has been found to 
negatively regulate p38 [273] and NFĸB [274, 275], although reports exist to the 
contrary [253, 255]. This experiment could not be confirmed by western blot as a 
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working antibody to S100A8 could not be found and the antibody to Hornerin was 
no longer available. A working Annexin A1 antibody was found when tested on total 
cell lysate, but Annexin A1 was not detected by western blot after MMP8 
immunoprecipitation. This could mean that it was secreted at such low levels into the 
media that could only be detected by the sensitive mass spectrometer but not by an 
antibody for western blot.  
 
Therefore, although some potential mediators of MMP8 involved in the up-
regulation of IL-6 and -8 were identified they could not be validated so cannot be 
confirmed to be involved, although they are still worthy of follow-up. In addition, it 
would be wise to expand the search for MMP8 effectors especially as the up-
regulation of IL-6 and IL-8 with MMP8 over-expression is dependent on its catalytic 
activity. Due to this it would be worthwhile in the future to carry out a more 
comprehensive mass spectrometry analysis of the total cell culture media from cells 
over-expressing both wild-type and the catalytically inactive E198A mutant MMP8 
to determine protein cleavage products generated by wild-type MMP8. Intact 
proteins detected in the culture media of cells over-expressing E198A MMP8, the 
catalytically inactive form whereby the proteins should not be cleaved, should be 
used as a comparison. Techniques such as Stable Isotope Labelling by Amino Acids 
in Cell Culture (SILAC) [276] and Isobaric Tag for Relative and Absolute 
Quantification (iTRAQ) [277] could be used to quantify changes in both protein 
levels and protein cleavage. These techniques utilise Liquid Chromatography- 
MS/MS, (LC-MS/MS) a tandem MS system whereby proteins separated by LC 
are passed through the MS system twice: quantified in terms of a ratio between 
the abundance of a particular protein between the conditions in the first run 
(MS1) and being further fragmented on the second run (MS2) and identified. 
With SILAC cells are labelled by growing them in the presence of either a heavy 
or a light isotope of an amino acid in the culture media, which is incorporated 
into its proteins as they are expressed. The protein source is then identified by 
the isotope [276]. With iTRAQ the proteins are chemically labelled directly with 
an “iTRAQ tag” consisting of an N-hydroxysuccinimide (NHS) group linked to an 
isobaric tag. These are distinguished by molecular weight. Eight tags are 
available with different molecular weights which allows for multi-plexing as 
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many as eight different conditions that can be compared in one reaction [277]. 
These methods could also be used to determine whether MMP8 is cleaving IL-8, as 
unless MMP8 binds to IL-8 it would not have been detected in the mass spectrometry 
screen carried out in this thesis. 
 
To conclude this chapter it has been shown that the catalytic activity of MMP8 
induces and up-regulates the expression of two inflammatory mediators, IL-6, a 
predominantly pro-inflammatory cytokine, and IL-8, a pro-inflammatory chemokine, 
in breast cancer cells, both on acute exposure (transient transfection) and on “long-
term” exposure (stable transfection) This is most likely occurring through the p38 
MAPK- NFĸB pathway although further validation is required to determine exactly 
how. In addition, three proteins have been identified that bind to MMP8 in the cell 
culture media and that have a role in inflammation. These may provide the missing 
link between MMP8 and the MAPK and NFĸB pathways but further analysis is 
required for validation. The next chapter of this thesis seeks to address the reasons 
underpinning the up-regulation of the inflammatory mediators.  
4.4 Summary 
 
 MMP-8 induced expression of IL-6 and IL-8 in malignantly transformed 
mammary carcinoma cells on acute exposure (transient transfection), 
dependent on its catalytic activity. 
 MMP-8 also induced/up-regulated expression of IL-6 and IL-8 on stable 
transfection, in “long-term” expressing MDA-MB-231 cells, again 
dependent on catalytic activity. 
 In the “long-term” wild-type MMP-8 expressing MDA-MB-231 clonal 
isolates MMP-8 initiated a self-reinforcing loop with IL-6 and IL-8 
 IL-6 and IL-8 up-regulation by wild-type MMP-8 was dependent on NFĸB 
activity and possibly on p38 MAPK. 
 In this system IL-8 was inhibited by TGFβ signalling. 
 MMP-8-binding proteins (S100A8, Annexin A1 and Hornerin) were 
discovered by mass spectrometry that may be involved in IL-6 and IL-8 
up-regulation, but they require further investigation. 
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Chapter 5- Further insights into the 
cellular effects of MMP-8  
 
In the previous chapter it was shown that MMP-8 induced expression of IL-6 
and IL-8 at both the RNA and protein level. This occurred on an acute basis as 
shown by transient transfection of MMP-8 into multiple cell lines, and also in 
long-term MMP-8-expressing stably transfected MDA-MB-231 cells. This effect 
was dependent on the catalytic activity of MMP-8, as no such induction was seen 
in cells over-expressing EA mutant MMP8. In these “long-term” stably 
transfected cells MMP-8, IL-6 and IL-8 were found to be part of a self-
reinforcing loop whereby IL-8 was found to be partly responsible for IL-6 
induction, and IL-6 was found to be capable of inducing endogenous MMP8. 
However, as introduced in chapter 3, MMP-8-expressing stably transfected cell 
lines were difficult to generate, with wild-type MMP-8 expression being 
routinely switched off. These “long-term” MMP-8 stably expressing MDA-MB-
231 cells used in this thesis and characterised in chapters 3 and 4 are therefore 
rare clones that emerged that could maintain MMP-8 expression for months. 
This chapter aims to determine why MMP-8 stable clones were so difficult to 
generate and why wild-type MMP-8 is switched off by the cells in the majority of 
stable transfectants. The behaviour of these “long-term” MMP-8 expressing cells 
in vivo will also be examined. Some of this content has been published 
(Appendix 3).  
5.1 Loss of wild-type MMP-8 expression 
 
As aforementioned in chapter 3, generation of wild-type MMP8 over-expressing 
MDA-MB-231 stably transfected cells was difficult. The majority of stable cell 
lines lost wild-type MMP8 expression within a few weeks of culture. The stable 
cell lines used in this thesis were those that maintained wild-type MMP8 
expression for months enabling their use in multiple experiments without fear 
of MMP-8 expression loss mid-experiment. Figure 5.1A documents the loss of 
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Figure 5.1: Unstable expression of wild-type MMP-8 under serial 
passage and sustained selection in culture. MDA-MB-231 cells were 
transfected with pcDNA4 wild-type MMP8, pcDNA4 E198A MMP8 and 
pcDNA4 vector control and maintained under zeocin selection for 6 
weeks. At this point MMP-8 expressing pools of cells were divided and 
half maintained and passaged either under zeocin selection (+) and the 
other half without (-). MMP-8 expression was determined every other 
week by western blot. Three pools of cells expressing wild-type MMP-8 
(divided into 2 at 6 weeks with half under selection and half without) and 
1 pool each of cells expressing E198A Mutant MMP-8 and the ‘empty 
vector’ control (half of the pool under selection and half maintained 
without) were monitored. A) Western blot analysis of MMP-8 in 20x 
concentrated serum free conditioned media from pools of stably 
transfected cells at 7 weeks post transfection (top panel), and 11 weeks 
post transfection (bottom panel). B) Analysis of MMP-8 DNA by Taqman 
PCR on DNA isolated from the cells 11 weeks post transfection. * = p 
<0.05, ** = p<0.01 *** = p<0.001 
 
wild-type MMP8 from pools of stably transfected MDA-MB-231 cells from 7 to 
11 weeks post-transfection. Three different pools of wild-type MMP8 over-
expressing pools were monitored alongside an empty vector control and a pool 
of cells over-expressing E198A mutant MMP8.  
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Pools of cells expressing MMP-8 at 6 weeks post transfection were divided into 
two, with half being passaged and maintained under continuous zeocin 
selection and the other half maintained and passaged with no selection reagent. 
Loss of wild-type MMP-8 effect occurred independently of whether the cells 
were maintained under Zeocin selection or not, as pools expressing MMP-8 at 7 
weeks post transfection lost wild-type MMP-8 expression at the same rate as 
their sister cells from the same original pool, irrespective of selection reagent. 
E198A mutant MMP-8 expression was consistently high across the 4-week 
monitoring period, and was expressed to a higher level than wild-type MMP-8 
initially. DNA analysis showed that the exogenous MMP8 inserted into the 
genome was still present after 11 weeks (figure 5.1B), suggesting that the cells 
still contain the plasmid DNA. Based on the equivalent retention of plasmid DNA 
in cells that were expressing wild-type MMP-8 and cells still expressing E198A 
mutant MMP-8 it is likely that the cells may have epigenetically silenced MMP8. 
However, it is also possible that an expression control element of the plasmid 
may have been deleted. In the cells that had lost wild-type MMP-8 expression 
IL-6 and -8 were only expressed at baseline levels comparable to levels 
expressed by the empty vector control cells, with cells expressing slightly more 
MMP8 expressing slightly more IL-6 and IL-8 (data not shown). This proves a 
causal link between MMP8 expression and IL-6 and -8, as the cells that lose 
MMP8 expression also lose IL-6 and -8 expressions. Therefore, the rare clones 
used throughout this work that are able to express wild-type MMP-8 “long-
term” have most likely undergone permanent phenotypic changes in order to 
maintain wild-type MMP-8 expression.  
 
5.2 Detrimental effects of MMP-8 on MDA-MB-231 cells 
 
Based on the progressive loss of wild-type MMP-8 expression over prolonged 
culture (figure 5.1), it is possible that the active MMP-8 enzyme may exert 
deleterious effects on some aspects of cell growth or survival that result in a 
negative selection pressure on wild-type MMP-8 expressing cells. As shown in 
chapter 3 wild-type MMP-8 had no effect on cell growth or cell cycle profile of 
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MDA-MB-231 cells expressing MMP-8 “long-term”. Therefore it was 
hypothesised that MMP-8 may affect cell behaviour either acutely (within days) 
or in a short (within a couple of weeks) time-frame.  
 
5.2.1 MMP8 has no acute effects on apoptosis 
 
Although it was shown in figure 3.8 (section 3.2.1), through looking at the Sub-
G1 peak by flow cytometry, that MMP-8 has no effect on apoptosis in the stably 
transfected cells, it was deemed appropriate to determine whether MMP-8 
affected apoptosis after only short exposure to the protease. Caspases 3, 7, 9 and 
poly (ADP-ribose) polymerase (PARP) were examined (7, 9 and PARP in MCF-7 
cells) as a measure of apoptosis by western blot in MDA-MB-231 and MCF-7 
cells transiently transfected with wild-type MMP8, EA Mutant MMP8 and an 
‘empty vector’ control. IL-6 and -8 up-regulation was observed by 72 hours post 
transfection as seen in chapter 4 (figure 5.2A-B). A staurosporine time-course 
was conducted in MDA-MB-231 and MCF-7 cells to determine their sensitivity to 
apoptosis-inducing agents (figure 5.2C). These samples were consecutively used 
as positive controls for other western blots.  
 
Some caspase cleavage was observed across all samples which was probably 
due to stress from the transfection and not MMP8 specifically (figure 5.4D for 
MDA-MB-231 cells and E for MCF-7 cells). In MDA-MB-231 cells caspase 3 and 
PARP cleavage products only observed in the positive control and not in 
transfected cells. The 116 and 89kDa bands appear rectangular but this is an 
artefact of the imaging device. Caspases 7 and 9 however were cleaved in all 
transfected cells in response to transfection. In addition, in MCF-7 cells two 
products of caspase 7 cleavage were observed. The 25kDa fragment was 
observed in the positive control and in all transfected samples and a lower band 
of approximately 17kDa was detected in all samples transfected for 48 and 72 
hours. In addition, an 89kDa PARP cleavage product was observed in all 
transfected samples, peaking at 48 hours post transfection. There was always a 
strong PARP band across all samples in both cell lines (including positive and 
negative controls) at approximately 37kDa. This could not be identified in the 
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literature and was not explained in the anti-body specification. It could 
therefore just be an artefact or a phosphorylated form. It was difficult to 
observe a caspase 9 cleavage product, even in the positive control. This showed 
that acutely, MMP8 is not having any observable adverse effects on these cells. 
Added confirmation comes from examination of p21, p53 and PDCD4, of which 
none were affected by MMP-8 expression (data not shown).  
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Figure 5.2A-B: Examination of the acute effects of MMP-8 on 
apoptosis- transient transfection of MMP8 into MDA-MB-231 
and MCF-7 cells. MDA-MB-231 and MCF-7 cells were transiently 
transfected with pcDNA 4 constructs (wild-type and E198A mutant 
MMP8 and empty vector control) for 24, 48 and 72 hours. A) 
Western blot analysis of MMP-8 on 20x serum free conditioned 
media. B) Gene expression analysis of IL-6 and IL-8 by Taqman RT-
PCR in samples collected 72 hours post transfection.   
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Figure 5.2C: Examination of the acute effects of MMP-8 on 
apoptosis- Staurosporine timecourse in naïve MDA-MB-231 and 
MCF-7 cells.  MDA-MB-231 and MCF-7 cells were treated with 10µM 
Staurosporine for 6-24 hours to induce apoptosis. C) Western blot 
analysis of Caspase 3 (MDA-MB-231 cells only as not expressed by 
MCF-7 cells) Caspase 7, Caspase 9 and PARP.  
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Figure 5.2D: Examination of the acute effects of MMP-8 on 
apoptosis- MDA-MB-231 cells. D) Western blot analysis of 
Caspases -3, 7 ,9 and PARP in MDA-MB-231 cells transiently 
transfected with wild-type, E198A mutant MMP8 and empty vector 
control. Positive control was MDA-MB-231 cells treated with 
sstaurosporine for 16 hours.  
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Figure 5.2E: Examination of the acute effects of MMP-8 on 
apoptosis- MCF-7 cells. D) Western blot analysis of Caspases- 7 ,9 
and PARP in MCF-7 cells transiently transfected with wild-type, 
E198A mutant MMP8 and empty vector control. Positive control was 
MCF-7 cells treated with sstaurosporine for 6 hours. 
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5.2.2 “Mid-term” exposure to wild-type MMP8 reduces colony 
formation 
 
On an acute basis MMP-8 did not appear to affect apoptosis. Colony formation 
assays on the other hand examine effects over 2-3 weeks. There were 3 times 
fewer colonies in the plate transfected with wild-type MMP8 than those 
transfected with either the empty vector control or E198A mutant MMP8 (figure 
5.3). There were no differences in size of the colonies. This showed that wild-
type MMP8 has detrimental effects between 2 and 3 weeks post-transfection.  
The colonies that are able to grow may either be cells that had switched off 
wild-type MMP-8 or cells that had undergone alterations in order to cope with 
its presence.  
 
To conclude, wild-type MMP8 is detrimental to cells after medium term 
exposure as exhibited by reduced colony formation, but not on an acute term as 
determined by apoptosis on western blot and neither in the “long-term” MMP-8 
expressing stably transfected cells as shown in Chapter 3. However, as some 
caspase activity (as determined by small cleavage products) was observed due 
to transfection alone, any effects of MMP8 may have been masked. Transient 
transfection of MMP8 can induce IL-6 and -8 acutely due to the high levels of 
MMP8 being expressed, but it is only a limited number of cells that are able to 
overcome the detrimental effects of MMP8 and maintain wild-type MMP8 
expression long term. Thus, the MDA-MB-231 clonal isolates used in this thesis 
seem to be rare cells that underwent  phenotypic changes to cope with the 
presence of wild-type MMP8. This change may be permanent and may include 
the observed elevation of IL-6 and -8 expression levels. Such changes will be 
examined next.  
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Figure 5.3: Effect of wild-type MMP-8 on colony formation of 
MDA-MB-231 cells. MDA-MB-231 cells stably transfected with wild-
type and E198A mutant MMP8 and empty vector control were 
maintained under Zeocin selection for 20 days before staining of 
colonies with methylene blue. A) Western blot analysis of MMP-8 in 
20x concentrated serum free conditioned media at the start of the 
experiment B) Methylene blue stained colonies and C) Colony 
counts. n=6 (except EV where n=5), mean ± SEM, * = p <0.05, ** = 
p<0.01 *** = p<0.001 
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5.3 “Long-term” MMP-8 expressing cells have undergone 
permanent phenotypic changes  
 
It was hypothesised that to enable expression of MMP-8 “long-term”, MDA-MB-
231 clonal isolates had undergone permanent phenotypic changes to over-come 
the growth inhibitory effects of MMP-8 on colony formation (figure 5.3). Such 
changes may include up-regulation of IL-6 and IL-8. Having showed a causal link 
between wild-type MMP-8 expression and IL-6 and IL-8 regulation in section 
5.1, this section will focus on the hypothesised changes that  have occurred in 
these “long-term” MMP-8 expressing cells, including examination of whether 
elevated IL-6 and IL-8 levels may be a permanent feature of these cells, and 
whether MMP-8 is actually still required for their up-regulation. MDA-MB-231 
cells are metastatic breast cancer cells, and MMP-8 has been shown to be an 
anti-metastatic protease [52, 65], so it is plausible that the cells will react to the 
presence of MMP-8. IL-6 and IL-8 have been widely shown to be pro-
tumourigenic inflammatory modulators so up-regulation of these may 
compensate for the negative effects of MMP-8. 
 
5.3.1 MMP-8 is dispensable in the up-regulation of IL-6 and IL-8 after 
long-term culture 
 
It was sought to determine whether MMP-8 presence was still required in the 
self-reinforcing loop to maintain the enhanced IL-6 and -8 expression observed 
in MDA-MB-231 cells stably over-expressing wild-type MMP8 long-term (shown 
in figure 4.5), or whether this phenomenon was a permanent phenotypic change 
as a result of “long-term” wild-type MMP-8 expression. MMP inhibitors and 
siRNA were used to investigate this. The pan-MMP inhibitor CT1746 reduced IL-
6 and IL-8 levels slightly whereas GM6001 had no effect (figure 5.4A-B), 
suggesting that metalloproteinases (MMPs, ADAMs or ADAMTss) may have 
some role to play depending on the inhibitor used. These two inhibitors are not 
specific and can inhibit most MMPs as well as some ADAMs and ADAMTSs. They 
do show a stronger specificity towards MMP2 and 9 above others however. Next 
a specific MMP8 inhibitor DL111 was added and this also had no effect on IL-6 
and -8 levels (figure 5.4C). These data suggest that MMP-8 is no longer required 
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for maintained elevated IL-6 and IL-8 levels in “long-term” wild-type MMP-8 
over-expressing MDA-MB-231 clones, although other metalloproteinases may 
be involved.  As further confirmation of this lack of MMP-8 requirement, siRNA 
knockdown of MMP8 had no effect on IL-6 RNA levels whereas IL-8 expression 
increased 3 fold (figure 5.5).  
 
  
Figure 5.4. Effect of MMP inhibition on IL-6 and IL-8 levels. IL-6 
and IL-8 protein secretion as measured by ELISA  from “long-term” 
MMP-8 expressing stable MDA-MB-231 clonal isolates and cells 
expressing E198A mutant MMP-8 and empty vector control cells 
after incubation with broad spectrum MMP inhibitors CT1746 (A), 
GM6001 (B) and an MMP-8 specific inhibitor (C). n=3 (DL111 n=1), 
mean ± SEM, ND= not detected, * = p <0.05, ** = p<0.01 *** = p<0.001 
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Figure 5.5: MMP8 siRNA in wild-type MMP-8 over-expressing 
MDA-MB-231 cells. A) Western blot analysis of MMP-8 in 20x 
concentrated serum free conditioned media using an anti-MMP-8 
antibody after siRNA knockdown The Ponceau S stain shows the 
presence of protein on both lanes of the western blot. B) Gene 
expression analysis of IL-6 and IL-8 by Taqman RT-PCR after siRNA 
knockdown of MMP8 fold. n=4, mean ± SEM, * = p <0.05, ** = p<0.01 
*** = p<0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially, IL-8 expression increased with MMP8 knockdown in order to 
maintain the self-reinforcing loop described in figure 4.5. MMP8 was not easy to 
silence with siRNA, it required two consecutive siRNA transfections before 
MMP8 was seen knocked down at the protein level so as to be undetectable in 
the cell culture media (figure 5.5A). In addition, cells were washed frequently 
with serum free media during the knockdown to ensure that any residual MMP-
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8 secreted post-transfection was removed. Therefore it was concluded that 
despite extra efforts to knock MMP-8 down totally at the protein level and 
ensure that there was no MMP-8 still present in the culture media, IL-6 was not 
reduced and IL-8 increased. There is possibility though that molecules 
downstream of MMP-8 would have to be silenced in combination with MMP-8 to 
observe a decrease in expression of the cytokines. 
This suggests that MMP-8 is no longer required in to induce IL-6 and IL-8 and 
that the cells have undergone a permanent phenotypic change whereby MMP-8 
is no longer required. Another interesting discovery was that MMP8 expression 
is required for these adaptations to occur, as exogenous addition of 4-
aminophenylmercuric acetate (APMA) activated human recombinant MMP8 to 
naïve MDA-MB-231 cells had no effect on IL-6 and IL-8 levels (figure 5.6).  
 
It can therefore be concluded that cells expressing MMP-8 “long-term” have 
undergone permanent changes to over-come the detrimental effects of wild-
type MMP-8. These effects are evident by 20 days post transfection and  result 
in epigenetic silencing of wild-type MMP-8 in the majority of clones. Changes in 
the “long-term” wild-type MMP-8 expressing cells include the permanent 
elevation of IL-6 and IL-8 independent of the presence of MMP-8. A proposed 
model of IL-6 and IL-8 up-regulation in these cells follows.  
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5.3.2 Additional regulatory mechanisms required for IL-6 and IL-8 
up-regulation 
 
Based on preliminary data and evidence from the literature, a model of IL-6 and 
IL-8 up-regulation involving Protease Activated Receptor 2 (PAR2), otherwise 
known as F2RL1, was proposed. The PAR family is a family of 4 (PARs 1-4) G-
Protein Coupled Receptors (GPCRs) which can be activated, or inactivated 
depending on the site of cleavage, by proteases. This cleavage, historically 
carried out by serine proteases, results in a tethered ligand which can then bind 
back to the receptor irreversibly [278, 279] . PAR2 is the only PAR other than 
Figure 5.6: Addition of recombinant human MMP8 to naïve 
MDA-MB-231 cells A) Gene expression analysis by IL-6 and IL-8 by 
Taqman PCR after rhMMP8 addition, either inactive or activated 
with APMA, to naïve MDA-MB-231 cells. B) Western blot analysis of 
rhMMP8 either activated by APMA or incubated with the control 
buffer at 37°C for 2 hours. MMP8 pro-form = 75kDa, active forms = 
50 and 37kDa. n=4, mean ± SEM 
Chapter 5- Further insights into the cellular effects of MMP-8 
 
166 
 
PAR1 to be expressed in epithelial cells [279], although PAR1 was not found to 
be expressed in the MMP-8 expressing stably transfected MDA-MB-231 cells 
used in this thesis (J. Decock, unpublished data),  and has been heavily linked to 
inflammation [280]. It is expressed in neutrophils [281] and plays a role in 
neutrophil migration [282] and IL-6 and IL-8 up-regulation and/or  secretion 
from a range of cell types, including neutrophils [282], epithelial cells [283, 284] 
and endometreotic stem cells (IL-6 only) [285]. It can signal through p38 MAPK 
and NFĸB [280, 285].  Lastly it has been shown that PARs can be cleaved and 
activated by MMPs. For example, MMP1 has been shown to activate PAR1 in 
melanoma [286], in the breast microenvironment [287] and during endothelial 
cell activation [288]. MMP-3, -8 and -9 could cleave a synthetic peptide 
containing conventional PAR1 cleavage sites [289]. Therefore, it is plausible that 
MMP8 may be influencing PAR2, either by changing expression levels or 
activating/inactivating it through cleavage.  
 
Firstly total PAR2 levels were examined in the MDA-MB-231 clonal isolates 
(sets 1 and 2) at both mRNA and protein levels. Although only partially 
significant,  an up-regulation of PAR2 mRNA was observed in both sets of wild-
type MMP8 over-expressing clones (figure 5.7A). There was no difference in 
protein level, but this could be due to it being recycled rapidly, which would 
explain the increase in mRNA expression. There were many bands 
corresponding to PAR2 on the western blot, which reflect its phosphorylatyed 
forms [290]. MMP-8 probably does not act directly on PAR2 as siRNA 
knockdown of MMP8 had no effect on PAR2 levels (figure 5.7B), but was 
effecting its expression levels somehow.  
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To test whether PAR2 acts on IL-6 and IL-8 in this system PAR2 siRNA was 
applied, both alone and in conjunction with MMP8 siRNA. PAR2 knockdown 
alone reduced IL-6 protein by 90% and mRNA expression levels by 60% (figure 
5.8B). IL-8 levels actually increased compared to the non-targetting siRNA 
control (figure 5.8C); by 80% at mRNA level and 60% at the protein level. MMP8 
knockdown in conjunction with PAR2 knockdown did not have any exaggerated 
effects on the cells on IL-6, but IL-8 mRNA levels were slightly reduced with 
combined PAR2 and MMP8 knockdown. However, IL-8 levels were still slightly 
higher than that of the non-targetting control and this effect was not mirrored at 
Figure 5.7: Effects of MMP-8 on PAR2. Gene expression levels of 
PAR2 by Taqman RT-PCR and western blot analysis of PAR2 in (A) 
“long-term” MMP-8 expressing MDA-MB-231 clonal isolates and (B) 
after MMP8 siRNA knockdown in clone 1 of wild-type MMP-8 
expressing cells compared to the non-targetting control (gene 
expression only). n=3, mean ± SEM, * = p <0.05, ** = p<0.01 *** = 
p<0.001 
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Figure 5.8A: Effect of PAR2 and MMP8 siRNA on IL-6 and IL-8. A)  
Left panel: Western blot analysis of PAR2 (in cell lysate) and MMP-8  
(in 20x concentrated serum free conditioned media) in “long-term” 
wild-type  MMP-8 expressing MDA-MB-231 clone set 1 after siRNA 
knockdown of PAR2 alone or in conjunction with MMP8 knockdown. 
Right panel:  Gene expression analysis of PAR2 and MMP8 by 
Taqman RT-PCR in the same cells. Mean ± SEM  
the protein level. This gives further suggestion of the redundancy, long-term, of 
MMP-8 in this system but may indicate that MMP-8 and PAR2 may be acting 
through the same pathway.   
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Figure 5.8 B-C Effect of PAR2 and MMP8 siRNA on IL-6 and IL-8. 
B) Left panel: Gene expression analysis of IL-6 measured by taqman 
RT-PCR in “long-term” wild-type MMP-8 expressing MDA-MB-231 
clone set 1 after siRNA knockdown of PAR2 alone or in conjunction 
with MMP8 knockdown alone. Right panel: IL-6 protein secretion 
measured by ELISA in the same cells. C) Left panel: Gene expression 
analysis of IL-8 measured by taqman RT-PCR in “long-term” wild-
type MMP-8 expressing MDA-MB-231 clone set 1 after siRNA 
knockdown of PAR2 alone or in conjunction with MMP8 knockdown 
alone. Right panel: IL-8 protein secretion measured by ELISA in the 
same cells.  
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This has introduced a novel pathway through which MMP8 acts to induce IL-6 
and IL-8 (summarised in figure 5.9) via its catalytic activity in the “long-term” 
MMP-8 expressing cells.  MMP8 induced PAR2 expression, and then MMP8, or 
another unknown protease, activated the receptor, resulting in increased NFᴋB 
activity (possibly via p38) and an up-regulation of IL-6 and IL-8. IL-8 was then 
able to compensate for removal of MMP8 by siRNA knockdown by increasing 
expression levels, thus perpetuating a self-reinforcing loop that once 
established occurred independently of MMP8. These changes may have 
occurred to cope with the negative effects of wild-type MMP-8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Summary of the proposed mechanistic actions of 
MMP8 leading to the up-regulation of IL-6 and IL-8. Wild-type 
MMP8 has been shown to increase PAR2 expression, which it likely 
indirect. Wild-type MMP8 may also cleave and activate PAR2 but this 
is unknown. PAR2 has been shown in the literature to activate NFᴋB 
as part of pro-inflammatory pathways, and in this thesis it has been 
shown that NFᴋB is the key factor responsible for the up-regulation 
of both IL-6 and IL-8 in MDA-MB-231 cells stably transfected with 
wild-type MMP8. It has already been shown in chapter 4 that IL-8 
has a role in up-regulating IL-6, and IL-6 can act back on MMP8 itself 
to maintain this self-reinforcing loop. Solid arrows = pathways 
indicated from this thesis. Dashed arrows = pathways inferred from 
a combination of the literature and preliminary studies in this thesis.  
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To end this chapter, the question arose whether these cells would exhibit the 
tumour-repressive features observed by Gutiérrez-Fernández et al., (2008)[52], 
or whether the elevated IL-6 and -8 levels would cause the “long-term” MMP-8 
expressing MDA-MB-231 cells to be more aggressive in vivo. This experiment 
was not carried out earlier as immunocompromised mice would have to be used 
to avoid reaction to the human cells. However, if MMP-8 was dynamically 
influencing cytokine levels, as was initially thought, using such mice would 
render these experiments meaningless.  This is likely not the situation however 
as subsequent research presented in this chapter has strongly suggested that 
cells expressing wild-type MMP-8 “long-term” have undergone permanent 
phenotypic changes where IL-6 and IL-8 levels are maintained independent of 
MMP-8 expression.   Therefore, it was subsequently sought to determine how 
these ‘altered’ cells behaved in vivo.  
5.4 Effects of MMP8 in vivo 
 
As shown in chapter 4 “long-term” wild-type MMP-8 over-expressing cells 
exhibited reduced random 2D migration, dependent on its catalytic activity, and 
reduced scratch wound closure, independent of catalytic activity. This indicates 
that MMP-8 is exerting a tumour-suppressive role in vitro. To determine the 
effect of MMP-8 over-expression in these cells in vivo, set 1 of the wild-type 
MMP8, E198A mutant MMP8 and empty vector MDA-MB-231 “long-term” clonal 
isolates (figure 5.10A), were injected subcutaneously into CD1 nu/nu mice. 
These mice do not produce T cells but do have all other immune cells and hence 
will not react to the injection of human cells but should still be reactive to the 
higher levels of IL-6 and -8 produced by the wild-type MMP8 over-expressing 
cells. Presence of tumours was assessed by weekly palpation. Interestingly by 
day 54, 62% of mice injected with MDA-MB-231 cells expressing the empty 
vector control had a tumour (5/8), compared to 16% of mice injected with wild-
type MMP-8 expressing cells (1/6), while none of the mice injected with E198A 
mutant MMP-8 expressing cells had a tumour (0/6) (figure 5.10B). Nothing can 
be concluded about tumour size due to the small sample size, but figure 5.10C 
shows the range of tumour size from mice injected with control ‘empty vector’ 
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transfected cells. This potentially shows that MMP-8, irrespective of catalytic 
activity, is tumour-protective in this model. It also suggests that this occurs 
irrespective of IL-6 and -8, and their pro-survival signals. It must be noted 
however, that the mice are partially immunocompromised which may have an 
effect on the response to the cytokines. Therefore, in line with other research, 
MMP8 is exerting anti-tumourigenic effects in vivo, which is likely independent 
of raised IL-6 and -8 levels. This aspect suggests that IL-6 and IL-8 may be a 
non-functional by-product of “long-term” MMP-8 expression that occur as a 
result of changes in other proteins and pathways that are yet to be determined 
and highlights that further investigation is required into the functional effects of 
MMP-8 in mammary carcinoma. Additionally it shows the complexities of the 
protease and how it can exert different effects in vitro and in vivo. 
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Figure 5.10: Effects of MMP- 8 in vivo on subcutaneous injection 
of “long-term” MMP-8 expressing MDA-MB-231 clonal isolates. 
“Long-term” MMP-8 expressing MDA-MB-231 clonal isolates (clone 
set 1) stably over-expressing wild-type MMP8, E198A mutant MMP8 
and the ‘empty vector’ control were injected subcutaneously (16 cells 
per mouse in PBS into the left upper flank) into CD1 nu/nu mice. A) 
Western blot analysis of MMP-8 in 20x concentrated serum free 
conditioned media from the cells prior to subcutaneous injection.  B) 
Tumour load (B) and tumour size (C) by day 54. n =6-8. 
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5.5 Conclusion and Discussion 
 
This chapter aimed to determine the reason why MMP-8 stably expressing cells 
were so difficult to generate, and whether the observed induction and up-
regulation of IL-6 and IL-8 with wild-type MMP-8 expression had any 
involvement. The most common outcome when generating the MDA-MB-231 
stable transfectants used in chapters 3 and 4 of this work was that wild-type 
MMP-8 was lost from cells. This chapter documented wild-type MMP-8 loss in 
pools of stably transfected MDA-MB-231 cells and showed that expression was 
likely lost through epigenetic silencing. These cells expressed IL-6 and IL-8 at 
baseline levels showing a causal link between MMP-8 and IL-6 and IL-8 up-
regulation. In a rare set of “long-term” wild-type MMP-8 expressing MDA-MB-
231 clones it has been hypothesised that permanent phenotypic changes occur 
to allow continued expression of wild-type MMP-8, which may include IL-6 and 
IL-8 up-regulation. However, it has been shown that in these rare clones MMP-8, 
IL-6 and IL-8 expression has become decoupled and MMP-8 is no longer 
required for maintained elevated expression, emphasising the likelihood of 
permanent changes within the cells; Levels of IL-6 and IL-8 in the “long-term” 
wild-type MMP-8 expressing clones were only slightly reduced by a broad 
spectrum MMP inhibitor CT1746, but not be GM6001, nor by an MMP-8 specific 
inhibiter, DL-111. IL-6 levels were also unaffected by MMP8 siRNA and IL-8 
levels actually increased. Exogenous addition of rhMMP-8 to cells had no effect 
on IL-6 and IL-8 levels. This firstly suggests that MMP8 expression is required to 
propagate  pathways involved in regulation of the cytokines and secondly that 
the mechanism involving the induction of IL-6 and -8 may  occur as a “private” 
mechanism that can not be affected by exogenous inhibitors or proteins. This is 
plausible as IL-6 has been reported previously to exert autocrine effects on cells 
as part of a “private” intracellular mechanism that could only be diminished by 
siRNA transfection, and not by the addition of exogenous inhibitors [291]. 
 
Further experiments aimed to determine what detrimental effects MMP-8 had 
on cells. Acute exposure to MMP-8 through transient transfection had no effect 
on apoptosis as shown through lack of MMP-8 dependent caspase cleavage on 
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western blot. Lack of acute effects cannot be discounted completely however as 
transfection alone induced apoptosis, which may have masked the effects of 
MMP-8. In the future more quantitative techniques could be used to examine 
apoptosis such as flow cytometry or a Terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) assay.  As shown in chapter 3, 
wild-type MMP-8 in the “long-term” expressing cells had no effect on cell 
growth or cell cycle profile.  However, wild-type MMP8 was found to have 
effects on mid-term exposure. Wild-type MMP8 reduced colony formation of 
MDA-MB-231 cells at 20 days post transfection, confirming that MMP-8 
adversely affects the cells. The colony formation assay examines whether stable 
expression of a protein can cause either cell cycle arrest or cell death, and also 
the ability of individual cells to form colonies Although the effects of MMP-8 on 
colony formation have not been examined in the literature, MMP-8 has been 
shown by Palavalli et al., (2009) to reduce colony growth on soft agar [77]. This 
assay is different from the assay employed in this thesis as it examines the 
ability of anchorage independent growth. Anchorage independent growth is a 
marker of a stem cell phenotype [292], thus this study indicates that MMP-8 
may be reducing the stem cell fraction. More experiments could in future be 
carried out to unravel the effects of medium-term exposure to wild-type MMP-8 
including the soft agar focus formation assay. In addition, caspase cleavage, such 
as that examined on short-term transfection could be examined at 20 days post 
transfection. This therefore confirms that wild-type MMP8 adversely affects 
these cells, and this can first be documented 2 weeks post transfection, with 
total wild-type MMP8 expression shut down occurring approximately after 7 
weeks post transfection. It is only the cells that have phenotypically altered in 
order to maintain wild-type MMP8 expression long-term over a period of 
months that exhibit up-regulation of IL-6 and -8 protein and RNA levels.  
 
Further analysis of the mechanism behind IL-6 and IL-8 up-regulation in these 
rare “long-term” wild-type MMP-8 expressing cells resulted in the proposal of a 
model involving PAR2. PAR2 has been shown in the literature to be involved in 
cytokine up-regulation [280, 282-284], specifically IL-6 and -8, and can act 
through NFĸB [280]. NFĸB was shown in chapter 4 to be a key factor involved in 
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IL-6 and -8 up-regulation in this system. It is also expressed by the neutrophils, 
as is MMP8 in vivo [281]. PAR2 is likely to act downstream of MMP8 as it need to 
be proteolytically processed to become active. PAR2 mRNA was found to be up-
regulated in wild-type MMP-8 expressing MDA-MB-231 clonal isolates. 
However, MMP8 siRNA had no effect on PAR2 mRNA levels, so the effects of 
MMP8 on PAR2 are likely to be indirect, and may even act through multiple 
factors which are yet to be determined.  PAR2 was confirmed to be part of the 
MMP8, IL-6 and IL-8 self-reinforcing loop as siRNA knockdown of PAR2 reduced 
IL-6 mRNA and protein levels almost to baseline. Similarly to MMP8 siRNA 
however, PAR2 siRNA also increased IL-8 protein and mRNA levels. This 
indicates that this self-reinforcing loop, partly propagated by IL-8, is very 
difficult to impair, but also gives evidence that PAR2 and MMP-8 are functioning 
from the same side of the loop, and possibly in conjunction. There is also the 
possibility that IL-8 may be increasing to maintain the circuit but this could not 
be proven unless numerous other factors were examined. There are likely many 
unknown molecules involved in this circuit which may be uncovered using 
broad screens such as a microarray, or a broader cytokine array.  Only a handful 
of inflammatory mediators were examined in the initial cytokine screen and 
many other cytokines and chemokines may also be altered as a result of wild-
type MMP8 over-expression. Despite this unknown complexity, it is interesting 
to note that the TGFβ small molecule inhibitor described in chapter 4 had the 
same effect on IL-8 expression as both the MMP8 and PAR2 siRNA, in that IL-8 
levels increased when TGFβ was inhibited.  This suggests that TGFβ may 
comprise part of this ever-expanding self-reinforcing loop involving proteases, 
receptors and cytokines which may in part serve to compensate for the 
deleterious effects of MMP-8 on breast cancer cells.  
 
Initially it was considered fallacious to examine the behaviour of these “long-
term” MMP-8 stable transfectants in vivo. This was because 
immunocompromised mice would have to be used to avoid a reaction to the 
human cells, and this would be meaningless when looking at the effect of raised 
levels of immune system modulators. However, after the discovery that the cells 
were not exhibiting dynamic changes in IL-6 and IL-8 levels and that elevated 
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levels appeared to be a permanent feature of the “long-term” expressing cells it 
was deemed acceptable to carry out an in vivo assay.  
 
It was unknown whether these cells would exhibit the tumour-repressive 
features observed by Gutiérrez-Fernández et al., (2008), whereby Mmp8 over-
expressing B16F10 cells reduced experimental lung metastasis [52], or by 
Palavalli et al., (2009), whereby wild-type MMP8 expressing Mel-STR melanoma 
cells resulted in fewer metastatic lesions, or whether the elevated IL-6 and -8 
levels would constitute a more aggressive cellular phenotype. IL-6 and -8 have 
been heavily implicated in the literature to promote tumourigenesis [123, 124, 
130, 132, 138, 142, 143, 146, 147, 155, 293]. Immunodeficient CD1 nu/nu mice 
were used so that the presence of human tumour cells would be tolerated. They 
are only deficient in T cells so should respond to the higher levels of IL-6 and IL-
8 produced by the wild-type MMP8 over-expressing cells; mice express the IL-6 
receptor  and the IL-8 receptors CXCR1 and CXCR2, which are functional against 
human IL-8 [294]. Additionally, human CXCR2 can even functionally replace the 
mouse version. Although mice do not express IL-8 and use LIX instead, human 
IL-8 will still activate their CXCR receptors [295], rendering this a valid model.  
 
No tumour growth was observed in nu/nu mice injected with cells over-
expressing either wild-type, or EA mutant MMP-8 compared to 63% of nu/nu 
mice injected with empty vector control cells. This shows that in this model 
system MMP-8 is anti-tumourigenic, independent of its catalytic activity, but 
also indicates that IL-6 and -8 are not pro-tumourigenic in this in vivo system.  
Both Gutiérrez-Fernández et al., (2008) and Palavalli et al., (2009) used the 
same model system of subcutaneous injection of MMP8 over-expressing cells 
[52, 77]. Palavalli et al., (2009) used human melanoma cells over-expressing 
human MMP8 and injected them into NOD/SCID immunocomprimsed mice [77]. 
However, in contrast,  Gutiérrez-Fernández et al., (2008) used murine 
melanoma cells as opposed to human breast cancer cells and their cells were 
engineered to over-express murine Mmp8 so they could be injected into mice 
with an intact immune system [52].  Gutiérrez-Fernández et al., (2008) found no 
difference in primary tumour growth, whereas a stark difference was observed 
Chapter 5- Further insights into the cellular effects of MMP-8 
 
178 
 
in this thesis. Their main observation was a reduction in experimental lung 
metastasis which was dependent on the catalytic activity of MMP-8. However, 
this was determined from tail vein injection of transfected B16F10 cells, and not 
spontaneous lung metastasis resulting from subcutaneous injection. Palavalli et 
al., (2009) saw a reduction in ulcerating lesions, which is a characteristic of 
melanoma metastatic potential, in mice injected with wild-type MMP8 over-
expressing cells. This protective effect was dependent on the catalytic activity of 
MMP8 [77]. They did not use a transitional EA mutant but instead a panel of 
mutants observed in patient samples which they had demonstrated were 
catalytically inactive. They only found lung metastasis in mice injected with the 
cells expressing the range of catalytically inactive MMP8 mutants and so 
concluded that mutant MMP8 may have a dominant negative function. In this 
work no lung metastasis were found, even in the mice that had primary 
tumours. To summarise, MMP8, independently of its catalytic activity, reduces 
tumour formation on subcutaneous injection of MMP8 over-expressing MDA-
MB-231 cells. This may also be independent of the raised IL-6 and -8 secretions 
by the wild-type MMP8 over-expressing cells. These conflicting reports are 
likely due to differences in the mouse model used, the type of cancer cells 
studied and the species of MMP8 examined. Further in vivo experiments could 
be carried out to further dissect the role of MMP-8 in mammary carcinoma. An 
Mmp8 knockout mouse model has already been established in the laboratory 
which examines the rate of mammary tumour growth using the PyMT mouse 
model of mammary carcinogenesis (Dr. Julie Decock), with preliminary data 
suggesting that MMP8 reduces the rate of tumour growth and lung metastasis. 
Another option would be to generate MMP-8 over-expressing mouse mammary 
carcinoma cells (EMT6 mammary epithelial carcinoma cells isolated from the 
BALB/cCrgl mouse) which could then be injected sub-cutaneously into a mouse 
with an intact immune system. However, within the scope of this thesis the 
model used was most appropriate for the human tools we had available.  
 
To summarise and conclude this chapter, expression of wild-type MMP-8 is 
detrimental to MDA-MB-231 cells on mid-term culture, dependent on its 
catalytic activity. In addition, wild-type MMP-8 expression is shut off in the 
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majority of stably transfected cell lines, whereas cells transfected with the 
E198A mutant MMP-8 maintain their expression long-term. In these cells IL-6 
and IL-8 levels are at baseline.  Rare clones of stably transfected MDA-MB-231 
cells have been established that express wild-type MMP-8 “long-term” for 
months and within these cells permanent phenotypic changes have occurred 
allowing for the continued elevated IL-6 and IL-8 levels even in the absence of 
MMP-8. Within these rare cells MMP-8 initiated a self-reinforcing loop whereby 
IL-8 is partly responsible for the increase in IL-6 levels and IL-6 can induce 
MMP8 expression by a small amount. This loop is dependent on NFĸB signalling 
and also in this chapter has been partly been found to be dependent on PAR2. 
PAR2 mRNA levels are increased in clones over-expressing wild-type MMP8, but 
levels in clones expressing the vector control and E198A mutant MMP8 are 
equivalent. PAR2 is likely acting downstream of MMP-8, although indirectly, or 
in combination with another protein, as MMP8 siRNA did not have any effect on 
PAR2 mRNA levels over 48 hours of siRNA knockdown. However, PAR2 siRNA 
reduced IL-6 levels indicating its involvement in this self-reinforcing loop. IL-8 
levels actually increased on PAR2 knockdown, as was the case in MMP8 siRNA 
knockdown and also TGFβ inhibition, although TGFβ inhibition had no impact 
on the expression of IL-6. This shows that IL-6 and -8 regulation can be 
uncoupled from each other and interdependently regulated as well as co-
ordinately. Despite this knowledge there are many other factors yet to be 
discovered in this system, and the data gained from the behaviour of the stably 
transfected MDA-MB-231 cells  in vivo add a further level of complexity  as 
MMP-8, independent of its catalytic activity,  and also independent of elevated 
IL-6 and IL-8 levels, reduce/prevented primary tumour growth.  
 
This chapter has shown that wild-type MMP-8 is routinely switched off by MDA-
MB-231 mammary carcinoma cells and prevents colony growth.  Phenotypic 
changes may have occurred in cells that do express MMP-8 long-term as a 
coping mechanism. Changes, in addition to up-regulation of IL-6 and IL-8, have 
likely occurred in such cells, and these require consideration in the clinic.   
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5.6 Summary 
 
 Wild-type MMP-8 is detrimental to mammary carcinoma cells and 
expression is epigenetically silenced, through presently unknown 
mechanisms.   
 Rare wild-type MMP-8 expressing stable clones emerge that can express 
wild-type MMP-8 continuously for months 
 Permanent phenotypic changes occurred within these “long-term” wild-
type MMP-8 expressing cells to cope to allow continued MMP-8 
expression, and this may include the permanent up-regulation of IL-6 
and IL-8 
 “Long-term” wild-type MMP-8 expressing cells are no longer exhibiting 
dynamic fluctuations in IL-6 and IL-8 and have altered permanently 
 MMP-8, independent of its catalytic activity supresses primary tumour 
growth after subcutaneous injection into CD1 nu/nu mice  
o IL-6 and IL-8 may not be functional in vivo as both wild-type and 
catalytically inactive E198A mutant MMP-8 expressing cells 
prevent primary tumour growth. This however cannot be 
confirmed as it is not known for certain whether the mice can 
react to the human IL-6 and -8, neither whether IL-6 and IL-8 
were still being expressed in the injected cells.  
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Chapter 6- General Discussion and 
Future Directions 
 
MMP-8 has a tumour protective role in human breast cancer and other cancers.  
However, apart from the knowledge that MMP8 is required for cognate immune 
responses, little is known mechanistically about how it exerts these effects. Its 
influence on the immune system during acute immune responses suggests that 
MMP8 may be tumour-protective via its immuno-modulatory functions. The 
aims of this work were to dissect the functions of MMP8 in mammary carcinoma 
cells through the generation of an MMP8 in vitro expression model.  
 
To summarise this work in its entirety, wild-type and catalytically inactive 
E198A MMP8 expression constructs were generated. These were functional in 
both transient and stable transfection into mammary carcinoma cells, with 
MMP-8 predominantly secreted from cells into the culture media and wild-type 
having activity against type I collagen. To determine the long-term effects of 
MMP-8, MDA-MB-231 cells were transfected to stably express wild-type MMP8, 
catalytically inactive MMP8 to control for effects dependent on the catalytic 
activity of MMP-8, and an empty vector control to control for effects of 
transfection. Stable transfection of MMP-8 proved problematic but a set of MDA-
MB-231 clonal isolates were generated that expressed wild-type MMP-8 “long-
term”. Using these “long-term” MDA-MB-231 stable transfectants behavioural 
characteristics were examined and it was found that MMP-8 did not affect cell 
growth or cell cycle profile, but it reduced random 2D migration dependent on 
catalytic activity and MMP-8 reduced scratch wound closure independent of 
catalytic activity. MMP-8 also increased cellular adhesion in some expreiments. 
Additionally, MMP-8 prevented primary tumour growth after subcutaneous 
injection of MDA-MB-231 stable cell lines into CD1 nu/nu immuno-
compromised mice. MMP-8 did not affect EMT (at least in the markers 
examined) and expression had minimal effects on the protease web, with only 
an increase in TIMP3 mRNA levels in cells expressing wild-type MMP-8.  
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Interestingly, MMP-8 induced expression of IL-6 and IL-8 in malignantly 
transformed mammary carcinoma cells on acute exposure (transient 
transfection) dependent on its catalytic activity. This same up-regulation also 
occurred in the “long-term” expressing MDA-MB-231 stable cells, again 
dependent on catalytic activity. Within these “long-term” wild-type MMP-8 
expressing MDA-MB-231 clonal isolates MMP-8 initiated a self-reinforcing loop 
with IL-6 and IL-8, with IL-8 having a role in IL-6 promotion and IL-6 having a 
role in the promotion of MMP8 expression. Mechanistically this effect was 
dependent on NFĸB activity and also possibly on p38 MAPK signalling. 
However, IL-6 and IL-8 could be differentially regulated, as IL-8 was inhibited 
by TGFβ signalling and also by PAR2, whereas IL-6 levels were unaffected by 
TGFβ signalling and attenuated on PAR2 siRNA knockdown.  Wild-type MMP-8 
resulted in a modest increase in PAR2 mRNA expression levels although this is 
likely indirect as MMP-8 siRNA did not affect PAR2 levels. Potential additional 
players in this system were identified by mass spectrometry but require further 
investigation. 
 
Along with some tumour suppressive phenotypic characteristics and MMP-8 
driven IL-6 and IL-8 up-regulation, the fundamental take-home message of this 
work is that wild-type MMP-8 is detrimental to mammary carcinoma cell 
growth on medium term exposure (approximately 20 days exposure) and 
apparently as a direct consequence cells switch off the expression of wild-type 
MMP-8 transfected gene, likely through epigenetic silencing. In these cells that 
have lost wild-type MMP-8 expression, IL-6 and IL-8 levels returned to baseline, 
supporting a causal link between MMP-8 and IL-6 and -8.  However, the 
majority of this work was carried out on a rare set of wild-type MMP-8 
expressing stable clones that can express wild-type MMP-8 continuously for 
months. It was inferred that permanent phenotypic changes had occurred 
within these “long-term” wild-type MMP-8 expressing cells to allow continued 
MMP-8 expression, and this may include the permanent up-regulation of IL-6 
and IL-8, independently of MMP-8, rather than a dynamic interaction between 
MMP-8 and the inflammatory molecules. It is also unclear whether IL-6 and IL-8 
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from these cells are functional in vivo as both wild-type and catalytically inactive 
E198A mutant MMP-8 expressing cells prevent primary tumour growth after 
subcutaneous injection into CD1 nu/nu mice. This could not be certified 
however as although the mice should be able to react to higher IL-6 and IL-8 
levels they were immunocompromised so the model was not entirely valid. 
Despite this, the tumour-protective roles of MMP8 were reinforced by this 
experiment and throw up some interesting ideas to develop this project further. 
As a whole this work has contributed to the limited knowledge of the role of 
MMP-8 in breast cancer cells and has also highlighted an additional role for 
MMP-8 in the immune system with respect to IL-6 and IL-8 up-regulation which 
has so far been unreported. 
 
Due to the published pro-tumourigenic roles of both IL-6 and IL-8 [123-125, 
130, 142-144] it at first appeared paradoxical that anti-tumourigenic MMP-8 
would up-regulate these proteins. However, MMP-8 may exert different effects 
acutely and chronically, which may influence its effects on immune system 
meditating molecules, and thus tumourigenesis. It is already widely 
acknowledged that MMP-8 can cleave IL-8 in vitro, and that MMP-8 presence is 
required for cognate immune responses [80]. Absence of MMP-8 results in 
chronic inflammation [14, 64, 80, 83] which can promote tumour development 
[21, 296]. It has also been hypothesised that MMP-8 may influence IL-8 levels, 
as it was shown that Mmp8 knockout mice in an experimental model of 
periodontitis had reduced IL-8 levels, although this was hypothesised to be a 
reduction in release of IL-8 from extracellular matrix stores in the absence of 
Mmp8 [49]. This work has shown that MMP-8 may operate to induce IL-8 at the 
expression level, although it is also plausible that MMP-8 may also liberate IL-8 
from ECM stores. There have been no previous reports suggesting that MMP-8 
can influence IL-6 levels, so this aspect of this work is novel.  
 
MMP-8 produced by neutrophils is thought to be vital for normal innate 
immune responses. However, it is plausible that MMP-8 from tumour cells 
themselves could initiate an immune response against the expressing cell in 
order to destroy themselves and reduce cancer growth and spread. Acute 
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expression of MMP-8 by tumour cells may drive the expression and release of 
IL-8, attracting neutrophils to the cancer cell and eventually resulting in 
destruction of the cancer cell.  This hypothesis can also be applied to the 
mechanism behind which MMP-8 reduces metastasis, as any MMP-8 expressing 
micrometastatis will be party to their own destruction.  This work has shown 
that induction of IL-8 expression in acute response to MMP-8 only occurs in 
malignantly transformed cells, making this a valid hypothesis. In addition, the 
IL-6 secreted by the cells, which in these “long-term” MMP-8 expressing cells is 
partly driven by IL-8 can be translated to an in vivo situation where IL-6 induced 
by MMP-8 and IL-8 may act to promote the immune response. Whether IL-8 can 
induce IL-6 in an immune situation is not studied in the literature. However, this 
may be plausible as there are many pathological and inflammatory conditions 
where they are up-regulated together [297-301]. Further support for MMP-8 
initiating destruction of the host cell comes from a recent study showing that IL-
6 and IL-8 are secreted by apoptosing cells and may function to recruit 
phagocytes to destroy and remove the cell [302].  
 
As cancer progresses cells accrue mutations that enable immune system evasion 
[303]. If this occurs then IL-6 and IL-8 secreted from MMP-8 expressing cells 
will switch from having a role in cancer destruction, to a role in cancer 
promotion. IL-6 and IL-8 can induce Cancer-Stem Cell (CSC) -like changes in 
mammary carcinoma cells, such as self-renewal [304-306]. For example The IL-
8 signalling pathway is up-regulated and active in breast CSC [307]. Inhibition of 
IL-8 signalling by CXCR1/2 small molecule has been shown to be effective at 
selectively targeting CSC in xenograft models [304] and at reducing 
mammosphere formation of primary breast cancer cells [307]. In addition, it has 
been shown that IL-8  levels in breast cancer patient metastatic fluid correlated 
with increased mammosphere formation of tumour cells from the same patient, 
which was propagated through CXCR1/2  [306]. IL-6 can transform breast cells 
to mammosphere forming CSCs in an epigenetic switch involving NFĸB, that 
resulted in long-term, stable,  transformed cells that maintained a CSC state 
even when the initial inducing signal was removed [305, 308].  
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The “long-term” MMP-8 expressing MDA-MB-231 cells used throughout this 
work exhibit elevated IL-6 and IL-8 levels independent of MMP-8 presence, 
suggesting that the cells have undergone permanent genetic or epigenetic 
changes. These changes may be driving the cells towards a Cancer Stem Cell 
(CSC) phenotype. The definition of a CSC is “...a cell within a tumour that 
possesses the capacity to self-renew and to cause the heterogeneous lineages of 
cancer cells that comprise the tumour” [309]. A small proportion of cells in 
commercially available mammary carcinoma cell lines, including MDA-MB-231, 
exhibit the molecular signature of CSCs such as positive staining for ALDH [310], 
a commonly used marker to separate stem from non-stem breast cancer cells, 
and ability to grow in mammosphere culture [311]. The mammosphere assay, 
developed by Dontu [292], is a non-adherent in vitro culture where 
differentiated cells that require adherence for growth die, and only cells that 
have the capacity for self-renewal can survive and proliferate. These cells form 
spherical floating cultures called mammospheres [292]. This assay, plus the 
ability for cells to colonise in vivo, are the two ‘gold standard’ methods for 
detecting CSC activity.  
 
MMP-8 appears to induce permanent alterations in the “long-term” expressing 
MDA-MB-231 stable transfectants. Due to the published of IL-6 and IL-8 in 
driving the self-renewal of  breast CSCs, especially the evidence that IL-6 can 
drive permanent transformation, it would therefore be appropriate to 
determine whether MMP-8, via IL-6 and IL-8 up-regulation, is driving 
differentiated cells to be CSC. Alternatively, MMP-8 may be supporting the stem 
cell niche. Future work could include the mammosphere assay and looking at 
the ALDH levels in the cells, as if MMP-8 was diving cells to a CSC phenotype we 
would expect to see increased mammosphere formation and self-renewal of the 
MMP-8 expressing cells, and also a higher proportion of these cells would be 
ALDH positive.  
 
Within these “long-term” MMP-8 expression cells it is still not known whether 
cells up-regulate IL-6 and IL-8 as a coping strategy to over-come the detrimental 
effects of wild-type MMP-8 on mid-term culture, or whether they are up-
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regulated as a by-product. Acute exposure to MMP-8 by transient transfection 
did not appear to have any detrimental effects on the mammary carcinoma cells, 
but they still induced IL-6 and IL-8 expression. Perhaps on this time-frame 
MMP-8 is still dynamically affecting the cells, and this reflects the system 
observed in vivo in acute inflammation to a cancer cell. However, the “long-
term” MMP-8 expressing cells have overcome the detrimental effects on cell 
growth and viability evidenced by reduced colony formation 20 days post 
transfection. Possibly IL-6 and IL-8 levels are initially maintained in response to 
MMP-8, but perhaps continued exposure may have caused both MMP-8 
dependent and independent changes within the cell whereby their expression 
profiles have permanently altered. If IL-6 and IL-8 were up-regulated as a 
coping mechanism it would be expected that if IL-6 and IL-8 were removed from 
the cells the MMP-8 dependent negative effects would dominate resulting in 
reduced cell growth and even maybe cell death. Knock-down of IL-6 and IL-8 by 
siRNA had no effect on the cell cycle profile of the “long-term” MMP-8 
expressing cells, neither was there an increase in cell population in the subG1 
phase, which indicates apoptosing cells. This suggests that IL-6 and IL-8 are not 
sufficient to compensate for the deleterious effects of MMP-8, and that there 
may be additional growth factor/cytokine loops altered within these cells that 
have not yet been discovered, and that are acting in conjunction with IL-6 and 
IL-8 to maintain cell viability. Another suggestion is that if cells have been 
driven to a CSC-like phenotype anchorage dependent growth may not be 
affected, but the cells may exhibit reduced anchorage independent growth on 
siRNA knockdown of IL-6 and IL-8. Additionally, it may take longer for the 
negative effects of MMP-8 to prevail, and a short-term siRNA transfection may 
not be enough. In contrast, the suggestion by Cullen et al., (2013) that IL-6 and 
IL-8 are secreted by cells undergoing apoptosis as a “Find Me” signal, fits with 
observations within this work that MMP-8 may be inducing apoptosis on 
medium-term exposure to the protease, and thus resulting in IL-6 and IL-8 
secretion [302]. The majority of MMP-8 stable transfectants generated switched 
off MMP-8 expression gradually over-time, with a corresponding reduction in 
IL-6 and IL- 8 levels, suggesting that it may take time for such effects to be 
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reversed. These are all strong possibilities and in the future require further 
investigation and clarification.  
 
The hypothesis that long-term MMP-8 may be driving cells to a CSC-like 
phenotype would constitute a more aggressive cell. However, this work has also 
shown that the “long-term MMP-8 expressing cells have some tumour 
suppressive functions. On the other side of the table this work has shown that 
MMP-8 has anti-tumourigenic effects in the functional studies looking at 
migration, invasion and adhesion. Some of these effects were independent of 
proteolytic activity. In addition, MMP-8, independent of its catalytic activity, 
prevented primary tumour growth in immuno-compromised mice. The ‘gold-
standard’ for assessing the stem cell capabilities of cells is the ability for cells to 
develop primary tumours after injection into immuno-compromised mice [312], 
and this work has therefore given some indication that MMP-8 may actually 
reduce the stem cell fraction. All of these assays suffer from the same flaw 
however as effects of MMP-8 are examined in isolated cell lines. Obviously the in 
vivo assay is much more physiologically relevant but the mice do not have a fully 
functioning immune system. They should react to human IL-6 and IL-8 but the 
complexities of the immune system may mean that the absence of T-Cells in 
these mice may have some unknown profound effects on their reactions to the 
cytokines. This experiment may also suggest that MMP-8 employs different 
molecular mechanisms in vivo than in vitro, with different molecules and 
pathways affected by MMP-8 expression. To confirm this further analysis of 
MMP-8 in vivo is required.    
 
Although it has been observed consistently that wild-type MMP-8 induces IL-6 
and IL-8 expression in malignantly transformed cells the precise mechanisms 
involved remain elusive. As summarised in figure 5.9, this induction is 
dependent on NFĸB signalling, and IL-6 is also dependent on PAR2. IL-6 and IL-
8 are also differentially regulated as TGFβ and PAR2 signalling inhibit IL-8. 
However, it is unlikely that the changes in IL-6 and IL-8 expression are caused 
by direct interactions between MMP-8, NFĸB and PAR2. S100A8, Annexin A1 
and Hornerin were identified in chapter 4 as MMP-8 binding partners, so may fit 
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into the IL-6 and IL-8 regulatory mechanism proposed in this work. Like MMP-8 
and PAR-2, S100A8 and Annexin A1 are produced by the neutrophils [202, 230-
232]. There have been no published reports linking Annexin A1 to PAR2 but 
recently two studies have shown that S100A8 exerts  anti-oxidant [313], anti-
inflammatory [314] effects on neutrophils via PAR-2. This left the initial 
inflammatory response unaffected but dampened it down later [313], 
suggesting its requirement for cognate innate immune responses.  This 
mechanism was uni-directional as PAR-2 was required for S100A8 functionality 
but S100A8 had no effect on PAR-2 activation [313]. This work hypothesised 
that MMP-8, which can bind S100A8, was acting up-stream of PAR-2. Lack of 
effect of MMP-8 siRNA knockdown on PAR2 mRNA levels suggested that MMP-8 
was not acting on PAR-2 directly, but by other undetermined proteases. 
However, perhaps PAR-2 may be up-stream of MMP-8 in the signalling cascade 
and the up-regulation of PAR-2 in MMP-8 expressing cells may be the 
consequence of unknown factors, or even IL-6 and IL-8 as part of the self-
reinforcing loop discussed in chapter 4. No evidence could be found in the 
literature to suggest that IL-6 and IL-8 can induce PAR2 though. In addition, no 
evidence could be found linking Hornerin to PAR2. Both PAR-2 and TGFβ 
inhibited IL-8 expression in this work, and one study has shown that addition of 
hrTGFβ to endometreotic stem cells increased PAR2 gene expression levels, 
resulting in an increase in IL-6 [285]. It is widely acknowledged in the literature 
that TGFβ can induce IL-6 [315-317]  but in this work a TGFβ inhibitor had no 
effect on IL-6 protein levels. However, if TGFβ is acting through PAR-2, residual 
PAR-2 protein present may be enough to sustain IL-6 protein levels. PAR-2 
appears to have a slow turnover as in this work siRNA knockdown of PAR-2 
reduced mRNA levels by 90% but protein levels were not reduced by nearly as 
much. To add further complexity,  TGFβ had been shown to down-regulate 
MMP-8 RNA and protein expression [88], although this was in dental pulp cells 
rather than carcinoma cells or neutrophils. Therefore, no further light has been 
shed on the mechanisms underpinning the up-regulation of IL-6 and IL-8 with 
wild-type MMP-8 expression, except that TGFβ and S100A8 may also be 
involved. To gain further clarity into the signalling cascades initiated by MMP-8 
it would be useful in the future to study the growth and other phenotypic 
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characteristics of these “long-term” MMP-8 expressing MDA-MB-231 cells in co-
culture with other cell types such as stromal fibroblasts in an organoid model 
such as those used by Holliday et al., (2009) and Nyström et al., (2005) [271, 
318]. 
 
To conclude, this work has contributed to the understanding of the molecular 
mechanisms of MMP-8 under-pinning its anti-tumourigenic roles. Despite many 
unanswered questions, unconfirmed conjecture and hypothesising, it is clear 
that MMP-8 is detrimental to carcinoma cells and has a more commanding role 
in the immune system than previously thought, to which its anti-tumourigenic 
functions may be attributed. Continuation of this work will include 
determination of the underlying function of MMP-8, such as whether MMP-8 
drives cells towards a CSC phenotype, or whether MMP-8 actually reduces the 
stem cell population, and whether IL-6 and IL-8 up-regulation is a consequence 
of prolonged MMP-8 expression, is a cellular coping mechanism for MMP-8, or 
whether they serve any functionality at all. Additionally further in vivo work is 
required to define how MMP-8, irrespective of catalytic activity, reduces 
primary tumour growth. This work has answered some questions, but also set 
up a host more and revealed further stepping stones, to increase understanding 
of the elusive anti-tumourigenic protease, MMP-8.  
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6.1 Summary of all experiments  
 
This table (table 6.1) shows a summary of all the functional cell experiments 
within this thesis. 
 
Experiment Section Cells Result 
Dependent on 
MMP-8 Catalytic 
Activity 
Collagen Digestion 3.1.3 
MDA-MB-231 
stably transfected 
cells 
Wild-type MMP-
8 over-expressing 
cells degrade 
collagen 3x more 
than control cells 
Yes 
Cell growth 3.2.1 
MDA-MB-231 
stably transfected 
cells 
No difference N/A 
Cell cycle 3.2.1 
MDA-MB-231 
stably transfected 
cells 
No difference NA 
2D Migration 3.2.3 
MDA-MB-231 
stably transfected 
cells 
Wild-type MMP-
8 reduced 
migration 
Yes 
Scratch wound 
assay 
3.2.3 
MDA-MB-231 
stably transfected 
cells 
Wild-type and 
E198A mutant 
MMP-8 reduced 
scratch wound 
closure 
No 
3D inverted 
invasion through 
type I collagen 
3.2.4 
MDA-MB-231 
stably transfected 
cells 
Wild-type MMP-
8 slightly reduces 
invasion 
Yes 
Adhesion 3.2.4 
MDA-MB-231 
stably transfected 
cells 
Wild-type MMP-
8 increased 
adhesion 
depending on the 
assay 
Yes 
EMT 3.2.5 
MDA-MB-231 
stably transfected 
cells 
No NA 
Changes in 
degradome profile 
3.3 
MDA-MB-231 
stably transfected 
cells 
TIMP3 RNA 
levels may be 
increased with 
wild-type MMP-
8 expression 
Yes 
 
 
 
 
 
 
Table 6.1: A summary of the main experiments within this thesis 
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Experiment Section Cells Result 
Dependent on 
MMP-8 Catalytic 
Activity 
IL-6 and IL-8 up-
regulation 
4.1 
Transient 
transfection of 
MMP8 into MCF-7, 
MDA-MB-231 and 
SK-BR-3 cells and 
MDA-MB-231 
stably transfected 
cells 
Wild-type MMP-
8 increased IL-6 
and IL-8 protein 
and RNA levels 
Yes 
PAR2 up-regulation 5.3.2 
MDA-MB-231 
stably transfected 
cells 
Wild-type MMP-
8 increased 
PAR2 mRNA 
Yes 
Mass Spectrometry 
analysis of MMP-8 
binding partners 
4.2.3 
MDA-MB-231 
stably transfected 
cells 
Wild-type and 
E198A mutant 
MMP-8 bound 
S100A8 and 
Annexin A1, 
wild-type MMP-
8 bound to 
Hornerin 
NA 
Loss of MMP-8 
expression in stably 
transfected cells 
5.1 
Pools of stably 
transfected MDA-
MB-231 cells 
Wild-type MMP-
8 expression was 
lost from cells 
Yes 
Acute effects of 
MMP8 on apoptosis 
5.2.1 
Transiently 
transfected MDA-
MB-231 and MCF-7 
cells 
No difference NA 
Colony formation 5.2.2 MDA-MB-231 cells 
Transfection of 
wild-type MMP8 
reduced colony 
formation 
Yes 
Subcutaneous 
injection of cells 
into CD1 nu/nu 
immuno-
compromised mice 
5.4 
MDA-MB-231 
stably transfected 
cells 
Both wild-type 
and E198A 
mutant MMP-8 
prevented 
primary tumour 
growth 
No 
 
 
 
 
 
 
 
 
Table 6.1: A summary of the main experiments within this thesis 
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Appendix 1- MMP8 sequence 
 
Key: Bold underlined = start codon, blue = wild-type base, red = mutant 
base 
         
Wild-type MMP8 sequence using T7 primer: 
 
DNA sequence: 
 
CCAGGCTGACCTGCCGTTTAACTTAAGCTTGGTACCGAGCTCGGATCCAC
TAGTCCAGTGTGGTGGAATTCATGTTCTCCCTGAAGACGCTTCCATTTCT
GCTCTTACTCCATGTGCAGATTTCCAAGGCCTTTCCTGTATCTTCTAAAGA
GAAAAATACAAAAATTGTTCAGGACTACCTGGAAAAGTTCTACCAATTA
CCAAGCAACCAGTATCAGTCTACAAGGAAGAATGGCACTAATGTGATCG
TTGAAAAGCTTAAAGAAATGCAGCGATTTTTTGGGTTGAATGTGACGGGG
AAGCCAAATGAGGAAACTCTGGACATGATGAAAAAGCCTCGCTGTGGAG
TGCCTGACAGTGGTGGTTTTATGTTAACCCCAGGAAACCCCAAGTGGGAA
CGCACTAACTTGACCTACAGGATTCGAAACTATACCCCACAGCTGTCAGA
GGCTGAGGTAGAAAGAGCTATCAAGGATGCCTTTGAACTCTGGAGTGTT
GCATCACCTCTCATCTTCACCAGGATCTCACAGGGAGAGGCAGATATCAA
CATTGCTTTTTACCAAAGAGATCACGGTGACAATTCTCCATTTGATGGAC
CCAATGGAATCCTTGCTCATGCCTTTCAGCCAGGCCAAGGTATTGGAGGA
GATGCACATTTTGATGCCGAAGAAACATGGACCAACACCTCCGCAAATT
ACAACTTGTTTCTTGTTGCTGCTCATGAATTTGGCCATTCTTTGGGGCTCG
CTCACTCCTCTGACCCTGGTGCCTTGATGTATCCCAACTATGCTTTCAGGG
AAACCAGCAACTACTCACTCCCTCAAGATGACATCGATGGCATTCAGCCA
TCTATGGACTTTCAAGCAACCCTATCCAACCTACTGGACCAAGCACACCC
AAACCCTGTGACCCCAGTTTGACATTTGATGCTATCACCACACTCCGTGG
AGAAATACTTTTCTTTAAAGACAGGTACTTCTGGAGAGGCATCCTCAGCT
ACAAGAGTCGAAATGAATTTTATTTCTCTATTCTGGCCATCCCTTCCAACT
GGTAAACAGGCTGCTTATGGAGATTTTGACGAGACCTCATTTCTATTAAG
GCACATACTGGGCTCTGAGTGCTATGATATTCTGCAAGTTATCCCAGATA
TTTTCAAACTATGCCTCCCCAAGCAGCGTCAAGCATTGAACGCGACTGGT
TTCTACGAAGTAAACTTACTCTGAATGACATTCTGGAATTGGATACAGAC
ATTTCCATGAAGCAGGATTATTCACAA 
 
Translated protein sequence 5’-3’: 
 
ccaggctgacctgccgtttaacttaagcttggtaccgagctcggatccactagtccagtgtg 
   R  L  T  C  R  L  T  -  A  W  Y  R  A  R  I  H  -  S  S  V  
gtggaattcatgttctccctgaagacgcttccatttctgctcttactccatgtgcagatt 
 V  E  F  M  F  S  L  K  T  L  P  F  L  L  L  L  H  V  Q  I  
tccaaggcctttcctgtatcttctaaagagaaaaatacaaaaattgttcaggactacctg 
 S  K  A  F  P  V  S  S  K  E  K  N  T  K  I  V  Q  D  Y  L  
gaaaagttctaccaattaccaagcaaccagtatcagtctacaaggaagaatggcactaat 
 E  K  F  Y  Q  L  P  S  N  Q  Y  Q  S  T  R  K  N  G  T  N  
gtgatcgttgaaaagcttaaagaaatgcagcgattttttgggttgaatgtgacggggaag 
 V  I  V  E  K  L  K  E  M  Q  R  F  F  G  L  N  V  T  G  K  
ccaaatgaggaaactctggacatgatgaaaaagcctcgctgtggagtgcctgacagtggt 
Appendix 1- MMP8 sequence 
 
215 
 
 P  N  E  E  T  L  D  M  M  K  K  P  R  C  G  V  P  D  S  G  
ggttttatgttaaccccaggaaaccccaagtgggaacgcactaacttgacctacaggatt 
 G  F  M  L  T  P  G  N  P  K  W  E  R  T  N  L  T  Y  R  I  
cgaaactataccccacagctgtcagaggctgaggtagaaagagctatcaaggatgccttt 
 R  N  Y  T  P  Q  L  S  E  A  E  V  E  R  A  I  K  D  A  F  
gaactctggagtgttgcatcacctctcatcttcaccaggatctcacagggagaggcagat 
 E  L  W  S  V  A  S  P  L  I  F  T  R  I  S  Q  G  E  A  D  
atcaacattgctttttaccaaagagatcacggtgacaattctccatttgatggacccaat 
 I  N  I  A  F  Y  Q  R  D  H  G  D  N  S  P  F  D  G  P  N  
ggaatccttgctcatgcctttcagccaggccaaggtattggaggagatgcacattttgat 
 G  I  L  A  H  A  F  Q  P  G  Q  G  I  G  G  D  A  H  F  D  
gccgaagaaacatggaccaacacctccgcaaattacaacttgtttcttgttgctgctcat 
 A  E  E  T  W  T  N  T  S  A  N  Y  N  L  F  L  V  A  A  H  
gaatttggccattctttggggctcgctcactcctctgaccctggtgccttgatgtatccc 
 E  F  G  H  S  L  G  L  A  H  S  S  D  P  G  A  L  M  Y  P  
aactatgctttcagggaaaccagcaactactcactccctcaagatgacatcgatggcatt 
 N  Y  A  F  R  E  T  S  N  Y  S  L  P  Q  D  D  I  D  G  I  
cagccatctatggactttcaagcaaccctatccaacctactggaccaagcacacccaaac 
 Q  P  S  M  D  F  Q  A  T  L  S  N  L  L  D  Q  A  H  P  N  
cctgtgaccccagtttgacatttgatgctatcaccacactccgtggagaaatacttttct 
 P  V  T  P  V  -  H  L  M  L  S  P  H  S  V  E  K  Y  F  S  
ttaaagacaggtacttctggagaggcatcctcagctacaagagtcgaaatgaattttatt 
 L  K  T  G  T  S  G  E  A  S  S  A  T  R  V  E  M  N  F  I  
tctctattctggccatcccttccaactggtaaacaggctgcttatggagattttgacgag 
 S  L  F  W  P  S  L  P  T  G  K  Q  A  A  Y  G  D  F  D  E  
acctcatttctattaaggcacatactgggctctgagtgctatgatattctgcaagttatc 
 T  S  F  L  L  R  H  I  L  G  S  E  C  Y  D  I  L  Q  V  I  
ccagatattttcaaactatgcctccccaagcagcgtcaagcattgaacgcgactggtttc 
 P  D  I  F  K  L  C  L  P  K  Q  R  Q  A  L  N  A  T  G  F  
tacgaagtaaacttactctgaatgacattctggaattggatacagacatttccatgaagc 
 Y  E  V  N  L  L  -  M  T  F  W  N  W  I  Q  T  F  P  -  S  
aggattattcacaa 
 R  I  I  H     
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E198A mutant MMP8 sequence using T7 primer: 
 
DNA sequence: 
 
TCGGCCTTAGCCTGCCGTTTACTTAAGCTTGGTACCGAGCTCGGATCCAC
TAGTCCAGTGTGGTGGAATTCATGTTCTCCCTGAAGACGCTTCCATTTCT
GCTCTTACTCCATGTGCAGATTTCCAAGGCCTTTCCTGTATCTTCTAAAGA
GAAAAATACAAAAATTGTTCAGGACTACCTGGAAAAGTTCTACCAATTA
CCAAGCAACCAGTATCAGTCTACAAGGAAGAATGGCACTAATGTGATCG
TTGAAAAGCTTAAAGAAATGCAGCGATTTTTTGGGTTGAATGTGACGGGG
AAGCCAAATGAGGAAACTCTGGACATGATGAAAAAGCCTCGCTGTGGAG
TGCCTGACAGTGGTGGTTTTATGTTAACCCCAGGAAACCCCAAGTGGGAA
CGCACTAACTTGACCTACAGGATTCGAAACTATACCCCACAGCTGTCAGA
GGCTGAGGTAGAAAGAGCTATCAAGGATGCCTTTGAACTCTGGAGTGTT
GCATCACCTCTCATCTTCACCAGGATCTCACAGGGAGAGGCAGATATAAA
CATTGCTTTTTACCAAAGAGATCACGGTGACAATTCTCCATTTGATGGAC
CCAATGGAATCCTTGCTCATGCCTTTCAGCCAGGCCAAGGTATTGGAGGA
GATGCACATTTTGATGCCGAAGAAACATGGACCAACACCTCCGCAAATT
ACAACTTGTTTCTTGTTGCTGCTCATGCATTTGGCCATTCTTTGGGGCTCG
CTCACTCCTCTGACCCTGGTGCCTTGATGTATCCCAACTATGCTTTCAGGG
AAACCAGCAACTACTCACTCCCTCAAGATGACATCGATGGCATTCAGGCC
ATCTATGGACTTTCAAGCAACCCTATCCAACCTACTGGACCAAGCACACC
CAAACCCTGTGACCCCAGTTTGACATTTGATGCTATCACCACACTCCGTG
GAGAAATACTTTTCTTTAAAGACAGGTACTTCTGGAGAAGCATCCTCAGC
TACAAAGAGTCGAAATGAATTTTATTTCTCTATTCTGGCCATCCCTTCCAA
CTGGTATACAGCTGCTATGAGATTTGACAGAGACCTCATTTCCTATTTAA
GCAACCAATACTGGGCTCTGAGTGCTATGAATATCTGCAAGTTATTCCCA
GAAATATCAACTATGCCTTCCCAGCACGGTTCAGCATTGACGCAGCTGTT
TTCTACGAGTAAACACTTCTTGTAATGACATTCGAATGAACAGACATCAT
GACAGTATCTCCAAGCATTATCAGGTTCCCATAGC 
 
Translated protein sequence 5’-3’: 
 
tcggccttagcctgccgtttacttaagcttggtaccgagctcggatccactagtccagtgtg 
   G  L  S  L  P  F  T  -  A  W  Y  R  A  R  I  H  -  S  S  V  
gtggaattcatgttctccctgaagacgcttccatttctgctcttactccatgtgcagatt 
 V  E  F  M  F  S  L  K  T  L  P  F  L  L  L  L  H  V  Q  I  
tccaaggcctttcctgtatcttctaaagagaaaaatacaaaaattgttcaggactacctg 
 S  K  A  F  P  V  S  S  K  E  K  N  T  K  I  V  Q  D  Y  L  
gaaaagttctaccaattaccaagcaaccagtatcagtctacaaggaagaatggcactaat 
 E  K  F  Y  Q  L  P  S  N  Q  Y  Q  S  T  R  K  N  G  T  N  
gtgatcgttgaaaagcttaaagaaatgcagcgattttttgggttgaatgtgacggggaag 
 V  I  V  E  K  L  K  E  M  Q  R  F  F  G  L  N  V  T  G  K  
ccaaatgaggaaactctggacatgatgaaaaagcctcgctgtggagtgcctgacagtggt 
 P  N  E  E  T  L  D  M  M  K  K  P  R  C  G  V  P  D  S  G  
ggttttatgttaaccccaggaaaccccaagtgggaacgcactaacttgacctacaggatt 
 G  F  M  L  T  P  G  N  P  K  W  E  R  T  N  L  T  Y  R  I  
cgaaactataccccacagctgtcagaggctgaggtagaaagagctatcaaggatgccttt 
 R  N  Y  T  P  Q  L  S  E  A  E  V  E  R  A  I  K  D  A  F  
 
gaactctggagtgttgcatcacctctcatcttcaccaggatctcacagggagaggcagat 
 E  L  W  S  V  A  S  P  L  I  F  T  R  I  S  Q  G  E  A  D  
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ataaacattgctttttaccaaagagatcacggtgacaattctccatttgatggacccaat 
 I  N  I  A  F  Y  Q  R  D  H  G  D  N  S  P  F  D  G  P  N  
ggaatccttgctcatgcctttcagccaggccaaggtattggaggagatgcacattttgat 
 G  I  L  A  H  A  F  Q  P  G  Q  G  I  G  G  D  A  H  F  D  
gccgaagaaacatggaccaacacctccgcaaattacaacttgtttcttgttgctgctcat 
 A  E  E  T  W  T  N  T  S  A  N  Y  N  L  F  L  V  A  A  H  
gcatttggccattctttggggctcgctcactcctctgaccctggtgccttgatgtatccc 
 A  F  G  H  S  L  G  L  A  H  S  S  D  P  G  A  L  M  Y  P  
aactatgctttcagggaaaccagcaactactcactccctcaagatgacatcgatggcatt 
 N  Y  A  F  R  E  T  S  N  Y  S  L  P  Q  D  D  I  D  G  I  
caggccatctatggactttcaagcaaccctatccaacctactggaccaagcacacccaaa 
 Q  A  I  Y  G  L  S  S  N  P  I  Q  P  T  G  P  S  T  P  K  
ccctgtgaccccagtttgacatttgatgctatcaccacactccgtggagaaatacttttc 
 P  C  D  P  S  L  T  F  D  A  I  T  T  L  R  G  E  I  L  F  
tttaaagacaggtacttctggagaagcatcctcagctacaaagagtcgaaatgaatttta 
 F  K  D  R  Y  F  W  R  S  I  L  S  Y  K  E  S  K  -  I  L  
tttctctattctggccatcccttccaactggtatacagctgctatgagatttgacagaga 
 F  L  Y  S  G  H  P  F  Q  L  V  Y  S  C  Y  E  I  -  Q  R  
cctcatttcctatttaagcaaccaatactgggctctgagtgctatgaatatctgcaagtt 
 P  H  F  L  F  K  Q  P  I  L  G  S  E  C  Y  E  Y  L  Q  V  
attcccagaaatatcaactatgccttcccagcacggttcagcattgacgcagctgttttc 
 I  P  R  N  I  N  Y  A  F  P  A  R  F  S  I  D  A  A  V  F  
tacgagtaaacacttcttgtaatgacattcgaatgaacagacatcatgacagtatctcca 
 Y  E  -  T  L  L  V  M  T  F  E  -  T  D  I  M  T  V  S  P  
agcattatcaggttcccatagc 
 S  I  I  R  F  P  -     
 
 
 
 
 
  
 
Appendix 2- Phosphokinase array raw 
results 
 
Raw data for the phosphokinase array described in chapter 4 section 4.2.2. 
Figure A2.1 shows the membranes annotated with co-ordinates  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2.1: Effects of MMP-8 on kinase phosphorylation. 
Phosphorylated kinase levels in MDA-MB-231 clonal isolates (set 1) 
stably transfected with wild-type and E198A mutant MMP8 and an 
empty vector control. Cell lysates were applied to membranes pre-
printed with antibodies to an array of phosphorylated kinases. After 
following the manufacturer’s instructions the membranes were 
imaged using HRP and the result was a membrane covered in dots of 
varying intensities. 
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A A1 Positive control
A A2 Positive control
A A3 p38α (T180/Y182) 1491.749 3798.456 1559.042
A A4 p38α (T180/Y182) 1377.577 3260.627 1875.698
A A5 ERK 1/2 (T202/Y204, T185/Y187) 6387.941 3215.92 8158.355
A A6 ERK 1/2 (T202/Y204, T185/Y187) 6059.941 4858.042 7786.698
A A7 JNK pan (T183/Y185, T221/Y223) 806.456 652.678 630.385
A A8 JNK pan (T183/Y185, T221/Y223) 872.87 508.556 765.627
A A9 GSK-3α/β (S21/S9) 643.92 478.435 479.678
A A10 GSK-3α/β (S21/S9) 516.971 543.092 556.385
A B3 MEK 1/2 (S218/S222, S222/S226) 2977.749 1965.749 2576.991
A B4 MEK 1/2 (S218/S222, S222/S226) 2912.456 2225.941 3403.284
A B5 MSK1/2 (S376/S360) 4149.163 3067.698 4659.698
A B6 MSK1/2 (S376/S360) 3625.456 3021.577 4034.991
A B7 AMPKα1 (T174) 1875.042 1071.456 1734.991
A B8 AMPKα1 (T174) 1529.749 1289.042 1759.749
A B9 Akt (S473) 927.627 791.335 1085.456
A B10 Akt (S473) 966.042 744.799 1183.163
A C1 TOR (S2448) 434.556 427.263 557.506
A C2 TOR (S2448) 423.849 541.092 488.385
A C3 CREB (S133) 8310.77 5511.406 2993.749
A C4 CREB (S133) 6778.062 5575.577 4313.042
A C5 HSP27 (S78/S82) 1250.042 2319.163 1714.335
A C6 HSP27 (S78/S82) 1318.749 1984.749 1501.163
A C7 AMPKα2 (T172) 723.506 844.92 932.335
A C8 AMPKα2 (T172) 683.092 718.092 984.92
A C9 β- Catenin 317.728 326.021 489.971
A C10 β- Catenin 308.728 344.314 403.556
A D1 Src (Y419) 3482.82 1539.335 1736.113
A D2 Src (Y419) 2809.163 1953.991 1290.749
A D3 Lyn (Y397) 920.213 836.092 535.092
A D4 Lyn (Y397) 1062.213 715.971 640.213
A D5 Lck (Y394) 971.749 685.506 699.627
A D6 Lck (Y394) 949.749 741.042 583.678
Pixel Density
Table A2.1 show the pixel densities of the dots on the membranes in figure A2.1.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
Table A2.1. Effects ofMMP-8 on levels of kinase phosphorylation. Raw 
pixel density of the dots on the membranes in figure A2.1 
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A D7 STAT2 (Y689) 4344.406 3099.698 3107.82
A D8 STAT2 (Y689) 5480.113 3243.87 3022.991
A D9 STAT5a (Y699) 4851.82 2823.284 2250.87
A D10 STAT5a (Y699) 4194.991 2381.991 3542.134
A E1 Fyn (Y420) 2547.577 2529.406 1578.749
A E2 Fyn (Y420) 2817.113 2794.113 1956.577
A E3 Yes (Y426) 3785.87 4300.991 3269.577
A E4 Yes (Y426) 3836.284 4585.698 3102.991
A E5 Fgr (Y412) 1066.042 1433.92 1356.163
A E6 Fgr (Y412) 881.799 984.92 1197.042
A E7 STAT3 (S727/Y705) 1975.749 2072.749 1615.749
A E8 STAT3 (S727/Y705) 1917.456 2314.335 2076.042
A E9 STAT5b (Y699) 4401.406 3999.335 4555.577
A E10 STAT5b (Y699) 4874.113 4612.284 4580.284
A F1 Hck (Y411) 1821.163 1453.042 1469.406
A F2 Hck (Y411) 1241.749 1417.87 1358.042
A F3 Chk-2 (T68) 4725.113 4451.284 3952.406
A F4 Chk-2 (T68) 5882.062 3928.456 3751.406
A F5 FAK (Y397) 2293.698 1876.627 2226.284
A F6 FAK (Y397) 2088.163 1948.213 2534.577
A F7 STAT6 (Y641) 4032.82 3184.456 4992.406
A F8 STAT6 (Y641) 4387.527 2883.335 4856.113
A F9 STAT5a/b (Y699) 2704.527 1840.213 2364.577
A F10 STAT5a/b (Y699) 2516.527 1690.506 2758.698
B A13 p53 (S392) 6750.941 6424.234 6738.456
B A14 p53 (S392) 7131.698 7578.406 4514.627
B B11 Akt (T308) 1269.577 1081.163 1122.749
B B12 Akt (T308) 1628.82 1066.042 1319.87
B B13 p53 (S46) 7286.284 7113.406 5311.87
B B14 p53 (S46) 2882.042 5252.627 5075.577
B C11 p70 S6 Kinase (T389) 77.364 141.364 301.435
B C12 p70 S6 Kinase (T389) 103.364 59.95 484.263
Pixel Density  
Table A2.1. Effects ofMMP-8 on levels of kinase phosphorylation. Raw 
pixel density of the dots on the membranes in figure A2.1 
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B C13 p53 (S15) 3496.527 3165.406 3596.456
B C14 p53 (S15) 4235.648 3290.749 3323.749
B C15 p27 (T189) 1286.991 1393.991 994.92
B C16 p27 (T189) 1838.82 1070.92 886.213
B C17 Paxillin (Y118) 5655.062 4586.991 2845.92
B C18 Paxillin (Y118) 5573.648 3489.335 2793.92
B D11 p70 S6 Kinase (T421/S424) 4459.406 5002.82 5678.355
B D12 p70 S6 Kinase (T421/S424) 4750.698 4973.284 5020.234
B D13 RSK 1/2/3 (S380) 4666.355 3111.284 3230.87
B D14 RSK 1/2/3 (S380) 4142.82 3268.87 3491.406
B D15 p27 (T175) 1690.648 1287.335 2014.406
B D16 p27 (T175) 1969.234 1518.163 1834.577
B D17 PLCγ-1 (Y783) 6084.477 4200.698 4332.577
B D18 PLCγ-1 (Y783) 6108.477 4177.163 4902.991
B E11 p70 S6 Kinase (T229) 2408.87 5002.82 3333.82
B E12 p70 S6 Kinase (T229) 2346.749 2213.456 2994.82
B E13 RSK 1/2 (S221/S227) 2200.87 2302.042 2399.577
B E14 RSK 1/2 (S221/S227) 1951.456 1845.749 2375.163
B E15 c-Jun (S63) 4681.284 1990.749 5889.941
B E16 c-Jun (S63) 4996.456 4664.284 5599.234
B E17 Pyk2 (Y402) 2013.456 4944.991 2754.456
B E18 Pyk2 (Y402) 2111.163 2966.406 2926.698
B F11 STAT1 (Y701) 5299.355 2447.577 5179.234
B F12 STAT1 (Y701) 5532.527 5204.113 5335.648
B F13 STAT4 (Y693) 5091.648 4543.87 4547.941
B F14 STAT4 (Y693) 4865.941 4597.87 4418.406
B F15 eNOS (S1177) 941.506 1863.87 1126.456
B F16 eNOS (S1177) 780.92 1897.92 1276.456
B F17 Negative 0 0 0
B F18 Negative 0 0 0
Pixel Density 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A2.1. Effects ofMMP-8 on levels of kinase phosphorylation. Raw 
pixel density of the dots on the membranes in figure A2.1 
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Matrix Metalloproteinase 8 (Collagenase 2) Induces the
Expression of Interleukins 6 and 8 in Breast Cancer Cells*
Received for publication, February 26, 2013, and in revised form, April 30, 2013 Published, JBC Papers in Press, April 30, 2013, DOI 10.1074/jbc.M113.464230
Sally Thirkettle‡, Julie Decock‡, Hugh Arnold‡1, Caroline J. Pennington‡, Diane M. Jaworski§,
and Dylan R. Edwards‡2
From the ‡School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, United Kingdom and
the §Department of Neurological Sciences, University of Vermont College of Medicine, Burlington, Vermont 05405
Background:Matrixmetalloproteinase 8 is ametastasis-suppressingmetalloprotease that regulates neutrophil chemotaxis
in inflammation.
Results:MMP-8 expression by breast cancer cells is deleterious to long-term growth, but it induces IL-6 and IL-8, factors that
conventionally promote malignancy.
Conclusion:MMP-8 influences signaling that regulates expression of proinflammatory factors.
Significance: These effects may contribute to how MMP-8 controls the onset and resolution of inflammation.
Matrix metalloproteinase 8 (MMP-8) is a tumor-suppressive
protease that cleaves numerous substrates, including matrix
proteins and chemokines. In particular, MMP-8 proteolytically
activates IL-8 and, thereby, regulates neutrophil chemotaxis in
vivo. We explored the effects of expression of either a WT or
catalytically inactive (E198A) mutant version of MMP-8 in
human breast cancer cell lines. Analysis of serum-free condi-
tioned media from three breast cancer cell lines (MCF-7, SK-
BR-3, andMDA-MB-231) expressingWTMMP-8 revealed ele-
vated levels of IL-6 and IL-8. This increase was mirrored at the
mRNA level and was dependent on MMP-8 catalytic activity.
However, sustained expression of WTMMP-8 by breast cancer
cells was non-permissive for long-term growth, as shown by
reduced colony formation comparedwith cells expressing either
control vector orE198AmutantMMP-8. In long-termculture of
transfected MDA-MB-231 cells, expression of WT but not
E198A mutant MMP-8 was lost, with IL-6 and IL-8 levels
returning tobase line. Rare clonal isolates ofMDA-MB-231 cells
expressingWTMMP-8 were generated, and these showed con-
stitutively high levels of IL-6 and IL-8, although production of
the interleukinswas no longer dependent uponMMP-8 activity.
These studies support a causal connection between MMP-8
activity and the IL-6/IL-8 network, with an acute response to
MMP-8 involving induction of the proinflammatory mediators,
which may in part serve to compensate for the deleterious
effects ofMMP-8 on breast cancer cell growth. This axis may be
relevant to the recognized ability of MMP-8 to orchestrate the
innate immune system in inflammation in vivo.
The matrix metalloproteinases (MMPs)3 are a family of 24
secreted proteases in humans that have fundamental roles in
the catabolic turnover of extracellular matrix structures. Their
activities are important in both normal and pathological tissue
remodeling processes. However, the past decade has witnessed
a growing appreciation of the fact that although these enzymes
were originally identified by virtue of their ability to break down
extracellular matrix components, they also control cell behav-
ior via precise regulatory proteolytic cleavage of growth factors,
receptors, adhesion molecules, and chemokines (1). Moreover,
MMPs were originally considered to play an exclusively facili-
tatory role in tumor cell invasion and metastasis, but following
the failure of syntheticmetalloproteinase inhibitors in the clinic
(2, 3), it has become recognized that MMPs and proteases of
other classes can have powerful actions as suppressors ofmalig-
nancy (4, 5). This is particularly the case forMMP-8, which has
been reported to suppress tumor formation or metastasis,
depending on the model system (6–10).
Originally identified as neutrophil collagenase, MMP-8 was
the second member of the MMP family shown to cleave triple-
helical collagen fibrils (11). It is found in specific granules in
neutrophils but is also expressed by diverse cell types, including
epithelial cells, fibroblasts, macrophages, and endothelial cells
(12). Several studies have demonstrated tumor- or metastasis-
suppressive activities of MMP-8. Firstly, maleMmp8-null ani-
mals show a dramatic increase in the incidence of carcinogen-
induced skin papillomas (6). Secondly, in clonal cell lines
derived from MDA-MB-435 cancer cells that display high
(M-4A4) or low (NM-2C5)metastatic ability, overexpression of
MMP-8 reduced the metastatic ability of M-4A4 cells, whereas
ribozyme-mediated gene knockdown of MMP-8 enhanced
metastasis of the NM-2C5 line (7, 13). A C/T single nucleotide
polymorphism in the MMP8 promoter that affects MMP-8
expression has been linked to survival of breast cancer patients
with early-stage disease, with the high expression T allele
equating to better survival (8). Higher MMP8 RNA levels in
* This work was supported by a Big C PhD studentship (to S. T.); by the Breast
Cancer Campaign, Cancer Research-UK; and by European Union FP6 (Can-
cerdegradome) and FP7 (SaveMe) projects.
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primary breast cancers are associatedwith reduced lymph node
metastasis and with improved relapse-free and overall survival
in node-negative patients (9). The metastasis-suppressive
properties of MMP-8 were confirmed in this study and shown
to be dependent on its MMP activity (9). Expression ofMMP-8
has also been found to be protective in human squamous cell
carcinoma of the tongue and in a carcinogen-induced mouse
model (10).
In addition to its suppressive roles in cancer progression,
MMP-8 is protective in bleomycin-induced lung fibrosis (14),
ventilator-induced lung injury (15), periodontitis (16), and
allergen-induced airway inflammation (17). In contrast,
Mmp8-deficient mice show reduced development of experi-
mental autoimmune encephalomyelitis, suggesting that
MMP-8 promotes pathology in this model of multiple sclerosis
(18). It is likely that underlying all of these pathologies is the
influence ofMMP-8 on innate immune responses via its actions
on chemokines and other immunomodulators. Cleavage of
murine LPS-induced CXC chemokine (LIX) at Ser4-Val5 and
Lys79-Arg80 by MMP-8 activates the chemokine, leading to
enhanced neutrophil chemotaxis (19). Although other MMPs
can process LIX in vitro, MMP-8 appears to be essential in vivo
for LPS-stimulated neutrophil chemokinesis. MMP-8 also exe-
cutes comparable processing of interleukin 8 (CXCL8/IL-8)
and CXCL5/ENA-88, the human orthologues of LIX (19).
Thus, MMP-8 released from neutrophils and potentially other
cellular sources at sites of inflammation activates LIX/IL-8, cre-
ating a “feed-forward” response that drives further neutrophil
recruitment and potentially orchestrating subsequent events in
the inflammatory process, including its resolution. In the
absence of MMP-8, inflammation is persistent and non-resolv-
ing, which is the situation found in the delayed skin wound
healing seen inMmp8-null mice (20).
On the basis of the known tumor- or metastasis-suppressive
effects of MMP-8 in several cancers and its links to inflamma-
tory responses, we sought to explore in more detail its actions
on cytokine and chemokine networks elaborated by breast can-
cer cells. We show here that expression of catalytically active
MMP-8 leads to increased production of the proinflammatory
mediators IL-6 and IL-8 in multiple breast cancer cell lines but
not in normal mammary epithelial cells. In turn, IL-6 enhances
endogenousMMP8 expression in breast cancer cells, and IL-8
is responsible in part for the increased expression of IL-6. Our
data support the idea that MMP-8 can create a self-reinforcing
protease-immunomodulatory circuit that may underpin its
function in diverse physiological repair and defense mecha-
nisms. However, we also show that expression of catalytically
active MMP-8 is not sustainable in breast cancer cells in long-
term culture without additional stochastic events that allow the
emergence of high-expressing clones. These resultsmay, there-
fore, help to integrate the roles of MMP-8 in inflammation and
as a negative regulator of tumor progression.
EXPERIMENTAL PROCEDURES
Cell Lines and Plasmids—MDA-MB-231 and MCF-7 breast
cancer cell lines (ATCC) were maintained in DMEM  Glu-
taMAXTM (Invitrogen) supplemented with 10% fetal bovine
serum. The SK-BR-3 breast cancer and G361 melanoma cell
lines (ATCC) were maintained in McCoy’s 5A medium (Invit-
rogen) supplemented with 10% fetal bovine serum.
The full-length coding sequence of human MMP-8 was
cloned into the eukaryotic expression vector pcDNA4TM
V5-His A plasmid (Invitrogen) using the BamH I and EcoR I
restriction sites. A catalytically inactive mutant (E198A) was gen-
erated using a mutagenesis PCR kit (Stratagene, La Jolla, CA) and
the following primers: 5-CTTGTTGCTGCTCATGCATTTG-
GCCATTCTTTGGand5-CCAAAGAATGGCCAAATGCA-
TGAGCAGCAACAAG. Empty vector pcDNA4TM V5-His A
was used as a control.
Transient and Stable Transfection—To obtain transient
overexpression ofMMP-8, cells were plated 24 h prior to trans-
fection at a density of 3.1 104/cm2 and transfected at 80–90%
confluencywith 1g of plasmidDNAusing LipoD293 (SignaGen
Laboratories, Rockville, MD). Conditioned medium and RNA
were collected 48 h post-transfection.
Stable overexpression of MMP-8 in MDA-MB-231 cells was
achieved using calcium phosphate transfection, and selection
in DMEM  GlutaMAXTM supplemented with 10% fetal
bovine serum and 40g/ml zeocin (Invitrogen). Isolated clones
were generated by serial dilution of a polyclonal pool of stably
transfected cells, and expression of MMP-8 was assessed by
Western blot analysis and real-time RT-PCR.
Preparation of Cell Lysates and Conditioned Media—Cell
lysates were prepared in radioimmune precipitation assay lysis
buffer supplemented with protease inhibitors (Roche). Condi-
tioned media was collected from MDA-MB-231 stably trans-
fected cells after 24 h serum starvation or 48 h after siRNA
transfection. For Western blot analysis, the conditioned media
were concentrated 20 and resuspended in reducing Laemmli
sample buffer.
Cytometric Bead Array—Serum-free conditioned media
from cells transiently transfected with pcDNA4 vector control,
WT MMP-8, and E198A mutant MMP-8 plasmid constructs
for 48 hwere used in the commercially available human inflam-
matory cytokine kit (BD Biosciences, catalog no. 551811)
according to the guidelines of the manufacturer, and a
BDFACSAriaTM II flow cytometer was used to determine the
levels of IL-8, IL-1, IL-10, TNF, IL-6, IL-12p70 in the condi-
tioned media from the transiently transfected cells.
Western Blot Analysis—Cell lysates and 20 concentrated
conditioned media samples were reduced and denatured in
Laemmli sample buffer, and equal amounts of total protein
were loaded on a 10% polyacrylamide gel. Protein samples were
transferred onto polyvinylidene fluoride membrane (Millipore,
Billerica, MA), blocked in PBS-0.1% Tween containing 5%
bovine serum albumin, and incubated overnight at 4 °C with
primary antibodies diluted in PBS-0.1% Tween containing 5%
bovine serum albumin (MMP-8, Abcam, catalog no. ab81286 at
1:2000; V5, Invitrogen, catalog no. 460705, at 1:5000). Mem-
branes were washed with PBS-0.1% Tween and incubated for
2 h with infrared-labeled secondary antibodies diluted in PBS-
0.1% Tween with 5% bovine serum albumin (donkey anti-
mouse IRDye 800CW and donkey anti-rabbit IRDye 800CW,
Li-Cor Biosciences, Lincoln, NE). Finally, membranes were
washed in PBS-0.1% Tween and imaged using an infrared scan-
ner (Odyssey, Stamford, CT).
MMP-8 Induces Interleukin 6 and 8 Production
JUNE 7, 2013•VOLUME 288•NUMBER 23 JOURNAL OF BIOLOGICAL CHEMISTRY 16283
ELISA—Conditioned media collected after 24 h serum star-
vation were used to assess the total levels of IL-6, IL-8, and
TNF using specific ELISAs (eBiosciences, San Diego, CA) fol-
lowing the guidelines of the manufacturer.
Quantitative RT-PCR—Cell pellets were harvested in RNA-
Bee RNA isolation reagent (Amsbio, Lake Forest, CA) followed
by a combination method of chloroform extraction and RNA
isolation using the SV Total RNA isolation system (Promega,
Madison, WI) and stored at80 °C.
RNA quantity and quality were assessed by A260/A280 and
A230/A280 absorbance ratios using the Nanodrop (Thermo
Fisher Scientific, Waltham, MA). A total of 1 g of RNA was
reverse-transcribed to 50 ng/l cDNA, and real time RT-PCR
was performedon anABI 7700PCRmachine (Invitrogen) using
the following cycles: 2min at 50 °C and 10min at 95 °C followed
by 40 cycles of 15 s at 90 °C and 1 min at 60 °C. IL-6 and
IL-8 cDNA expression was quantified using human-specific
5FAM-3TAMRATaqman gene expression primer/probe sets
(Hs00985639_m1 and Hs00174103_m1, Invitrogen), and PAR-2
cDNA expression was quantified using the following primers:
5CGTCCAGTGGAGCTCTGAGT-3 and 5-GCAGGAGA-
GAGAGGCTGCTA-3 and universal probe #3 (Roche).
Expression levels were normalized to levels of 18 S rRNA
(forward primer 5-GCCGCTAGAGGTGAAATTCTTG-3,
reverse primer 5-CATTCTTGGCAAATGCTTTCG-3, and
probe ACCGGCGCAAGACGGA). For detection of human
MMP8 expression, custom-made primers (Primer Design)
were used.
Cell Stimulation and Inhibition Experiments—Recombinant
human IL-6 (R&D Systems, Minneapolis, MN, catalog no. 206-
IL/CF) and IL-8 (R&D Systems, catalog no. 208-IL/CF) were
added to serum-starved (2 h) MDA-MB-231 cells at 0.3, 0.6,
and 100 ng of IL-6 and 0.5, 1.5, and 100 ng of IL-8 for 24 h.
For inhibitor treatments, cells were plated at 2.6  104/cm2
24 h before addition of inhibitors in serum-free conditions.
Inhibitors used were as follows: p38 inhibitors: 1 M SB203580
and 1 M BIRB (catalog nos. CAY13067 and CAY10460, Cay-
man Chemicals); MKK1 inhibitors: 0.1 M PD0325901 and 10
M U0126 (catalog nos. CAY13034 and CAY70970, Cayman
Chemicals); PI3K inhibitors: 1 M Wortmannin and 0.5 M
PI-103 (catalog no. W1628, Sigma, and catalog no. 10009209,
Cayman Chemicals); PKC inhibitor: 360 nm bisindolylmaleim-
ide (catalog no. 203290, Calbiochem); JNK inhibitor: 20 M
SP600125 (catalog no. S5567, Sigma); NFB inhibitor: 10 M
BAY 11-7082 (catalog no. 196871, Calbiochem); TGF inhibi-
tor: SB431542 (catalog no. CAY13031, Cayman Chemicals);
and MMP-8 inhibitor: 1 M DL111 (a gift from Prof. Vincent
Dive, CEA Saclay, Gif-sur-Yvette, France). Inhibitors were
replenished after 24 h, and conditioned media were collected
after a total incubation of 48 h.
SiRNA Knockdowns—MDA-MB-231 cells stably overex-
pressing wild-type MMP-8 were transfected at 60% confluency
with 25 nM of either IL-6 (siGENOMESMARTpoolM-007993-
02-0005, Dharmacon, Lafayette, CO), IL-8 (siGENOME
SMARTpool M-004756-00-0005, Dharmacon), or control
siRNA (siGENOME non-targeting siRNA pool #1 D-001206-
13-05, Dharmacon) using DharmaFECT 1 transfection reagent
(Dharmacon, catalog no. T-2001-02). RNA was collected 48 h
later for analysis. Cells transfected with MMP-8 siRNA
(siGENOME SMARTpoolM-005969-00-0005, Dharmacon) or
F2RL1 (PAR-2) (siGENOME SMARTpool, M-005098-01-005,
Dharmacon) were transfected a second time 24 h later. Serum-
starved conditionedmedia and cell pellets for RNA and protein
isolation were collected 48 h after the second transfection.
Colony Formation Assay—MDA-MB-231 cells were trans-
fected using the calcium phosphate method for stable overex-
pression and selected using 200 g/ml zeocin. Approxi-
mately 20 days after transfection, individual colonies were
visualized by staining with methylene blue for 30 min at
room temperature.
Statistical Analysis—Unless stated otherwise, data were
tested using two-tailed Student’s t tests and are presented as
mean S.E.
RESULTS
MMP-8 Up-regulates of IL-6 and IL-8 Production by Breast
Cancer Cells—To explore the effects of MMP-8 on inflamma-
tory mediators generated by breast cancer cells, we generated a
full-length wild-type human MMP-8 expression construct in
pcDNA4 and a mutant in which the essential glutamic acid
residue in the catalytic core motif HE198FGH was altered to
alanine (E198A mutant MMP-8). These constructs were tran-
siently transfected into MCF-7 cells, and after 24 h, serum-free
conditioned media were analyzed by a FACS cytokine bead
array for levels of IL-6, IL-8, IL-10, IL-1, TNF, and IL-12p70
released. Like IL-8, IL-10 is known to be a substrate of MMP-8
(14), whereas IL-1 has been shown to up-regulate MMP-8
expression (21). Expression of IL-6 and -8 in MCF-7 cells is
reported to be low because of inhibition by the estrogen recep-
tor (22–25). We detected a 20% increase in IL-6 and a 65%
increase in IL-8 protein levels in the conditioned media in
WT-MMP-8-expressing cells compared with empty vector
(EV) (Fig. 1A, upper panels). This increase was dependent on
the catalytic activity of MMP-8 because cells transfected with
the E198Amutant MMP-8 showed levels similar to the control
cells. None of the other inflammatory mediators were detected
in the MCF-7 cell-conditioned media at measurable levels.
Wild-type and E198A mutant MMP-8 were expressed and
released into the conditioned media at equivalent levels as
determined by Western blotting (Fig. 1B). We anticipated that
the increased detection of the inflammatory mediators might
be attributable to release of matrix- or cell-associated IL-6 and
IL-8 by MMP-8. However, the increases in IL-6 and IL-8 pro-
tein were mirrored at the mRNA level, with WT MMP-8
increasing both IL-6 and IL-8mRNA levels 2- to 3-fold. Similar
results were obtained with another breast cancer cell line (SK-
BR-3) transiently transfected with WT MMP-8 and E198A
MMP-8 (Fig. 1C), but this phenomenon was not seen on tran-
sient transfection into a non-cancerous breast epithelial cell
line, HMT-3522 S1 (D).
The human breast cancer cell lines we examined (MDA-MB-
231,MCF7, and SK-BR-3; Fig. 2A and data not shown) did not
express MMP-8 at a level that was detectable by Western blot
analysis, and only MDA-MB-231 cells expressed a very small
amount of endogenousMMP8 that was detectable by TaqMan
quantitative real-time RT-PCR (data not shown, see also Fig.
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FIGURE1.Transient expressionofWTMMP-8 causesanup-regulationof IL-6 and IL-6proteinandmRNAexpression that is dependenton the catalytic
activity of MMP-8. A, MCF-7 cells were transiently transfected with pcDNA4 empty vector, wild-typeMMP-8, and E198Amutant MMP-8 (EA). Top panel, FACS
cytokine bead array measurements of IL-6 and IL-8 protein levels in serum-free conditioned media collected 24 h after transfection. Lower panel, RNA
quantification by real-time TaqMan RT-PCR of IL-6 and IL-8 mRNAs in cells. *, p 0.05; **, p 0.01; ***, p 0.001. B, Western blot analysis of WT MMP-8
and E198A MMP-8 expression in transfected MCF-7 cells. C, RNA quantification by real-time TaqMan RT-PCR of IL-6 and IL-8 mRNAs in SK-BR-3 cells
transiently transfectedwith pcDNA4 empty vector, WTMMP-8, and E198Amutant MMP-8.D, RNA quantification by real-time TaqMan RT-PCR of IL-6 and
IL-8 mRNAs in HMT-3552 S1 cells transiently transfected with pcDNA4 empty vector, WT MMP-8, and E198A mutant MMP-8. CL, cell lysate; CM,
conditioned media.
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5C). Using the highly metastatic MDA-MB-231 cells (estrogen
receptor-/progesterone receptor-/HER2), we generated stably
transfected clones carrying theWTMMP-8, E198Amutant, or
EV control vector. Fig. 2A shows that comparable levels of the
wild-type and catalytically inactive MMP-8 proteins were
expressed and released into the conditioned media and that
MMP8 transcript levels originating from the transfected genes
were also similar. The levels of MMP-8 protein expression
achieved in these transfected clonal lines were similar to that of
endogenousMMP-8 in conditionedmedia from the G361mel-
anoma cell line, which was included as a control. The major
MMP-8 band was 75 kDa, likely corresponding to pro-MMP-8,
but a faster migrating band was detected by the MMP-8 anti-
body, although this could be a C-terminally processed form
because it was undetectable by the antibody toward the V5 tag.
However, functional collagenolytic activity of the wild-type
MMP-8 was confirmed by demonstration of elevated hydroxy-
proline release compared with the E198A mutant-expressing
cells and the empty vector control (Fig. 2B). Analysis of IL-6 and
8 protein production by ELISA of conditioned media from two
independent clonal isolates of WT MMP-8 stably transfected
MDA-MB-231 cells (Fig. 3,upper panels) showed a 2- to 12-fold
increase in IL-6 and an 2- to 8.5-fold increase in IL-8 protein in
comparison to EV control cells. Again, the E198A inactive
mutant MMP-8-expressing cells showed no increases com-
pared with the EV control cells. Also, as with the transiently
transfected MCF-7 cells, we found that in the MDA-MB-231
stably transfected cells, mRNA levels were increased 4-fold for
IL-6 and 4- to 12-fold for IL-8 in stableWTMMP-8-expressing
MDA-MB-231 clones (Fig. 3, lower panels), mirroring the
increased levels of the soluble proteins.
We conclude that the effect of MMP-8 on the inflammatory
mediators is primarily at the level of gene expression and that its
catalytic activity is required because all cells overexpressing the
E198A mutant show IL-6 and IL-8 protein and mRNA levels
comparable with those of control-transfected cells. Further-
more, the induction of IL-6 and IL-8 was observed for all breast
cancer cell lines examined (MCF-7, SK-BR-3, and MDA-MB-
231) but not for HMT-3522 S1 normal mammary epithelial
cells.
MMP-8 Expression Is Detrimental to Breast Cancer Cell
Growth—WhenMDA-MB-231 cells were transfected with our
suite of expression vectors and placed under antibiotic (zeocin)
selection, after 20 days we observed a 50–60% reduction in
colony formation by cells expressing WT MMP-8 compared
with EV or E198AmutantMMP-8 (Fig. 4A). However, in shorter-
termexperiments following transient transfection of eitherWT
or E198A mutant MMP-8 into MCF-7 or MDA-MB-231 cells
FIGURE 2.Generation of an in vitromodel to examine the effects ofMMP-8 expression inMDA-MB-231 breast carcinoma cells. A, expression of MMP-8
in serum-free conditioned media of MDA-MB-231 cells stably transfected with pcDNA4 empty vector, wild-type MMP-8, and E198Amutant MMP-8 as shown
byWestern blot analysis using both anti-MMP8 antibody (top panel) and anti-V5 antibody (bottom panel). Media from G361melanoma cells were included as
a positive control for endogenous MMP-8 and parental MCF-7 and MDA-MB-231 cell conditioned media as negative controls. All media were concentrated
20.Right panel,RNAquantificationby real-timeTaqManRT-PCRofMMP-8mRNAs in the samecells.B, collagen-degradingactivity ofMDA-MB-231 cells stably
transfected with pcDNA4 empty vector, WT MMP-8, and E198A mutant MMP-8 cultured within collagen gels and measured indirectly by hydroxyproline
release. ***, p 0.001.
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for up to 72 h, we saw no effects on cell growth or apoptosis
(data not shown). We therefore monitored independent pools
of transfected MDA-MB-231 cells carried forward for up to 3
months in culture with or without zeocin selection (Fig. 4B).
Although expression was initially comparable early after trans-
fection (data not shown), by 7weeks, levels ofWTMMP-8were
reduced compared with E198Amutant MMP-8 (Fig. 4B, upper
panel). By 11 weeks in culture, WT MMP-8 expression was
barely detectable in any of the cell pools regardless of zeocin
selection, whereas expression of E198A mutant MMP-8
remained at a consistently high level, again regardless of selec-
tion (Fig. 4B, lower panel). PCR analysis of genomic DNA iso-
lated from the cell populations from this experiment confirmed
that the transfected MMP8 expression vectors were present
and at the same levels in both WT and E198 mutant MMP-8
transfected cells after 11 weeks (data not shown), suggesting
that the WT MMP8 expression cassette was silenced during
continued passage of the cells. Moreover, IL-6 and IL-8 expres-
sion returned to base line in the cell pools that lost MMP-8
expression (data not shown).
These data, therefore, support a causal link betweenMMP-8
and up-regulation of the expression and secretion of IL-6 and
IL-8. Furthermore, they argue that the occasional stably trans-
fected clones that maintainWTMMP-8 expression long-term,
for longer than 3 months, such as those shown in Fig. 3, have
likely undergone phenotypic alteration to compensate for the
detrimental effects of MMP-8. This conclusion was supported
by the observations that neither knockdown of MMP-8 in the
“long-term” WT MMP-8-expressing cells or blockade of its
activity using a selective small molecular weight inhibitor,
KL-111, led to a reduction in IL-6 or IL-8 production (data not
shown). These data emphasize that additional compensatory
mechanisms that are independent ofMMP-8 are operational to
allow breast cancer cells to maintain elevated expression of the
otherwise deleterious MMP.
MMP8, IL-6, and IL-8 Are Components of a Self-reinforcing
Loop—Because IL-6 and IL-8 are powerful proinflammatory
mediators that exert effects on the expression of many genes,
we sought to determine whether their up-regulationmight link
them into a dynamic self-regulating network. To determine
whether a feedback loop is operating in the long-term WT
MMP-8-expressing MDA-MB-231 cells, the cells were treated
with siRNAs to IL-6 and IL-8 and levels of both cytokines mea-
sured by TaqMan qRT-PCR. SiRNA-mediated knockdown of
IL-8 expression led to a concomitant reduction of IL-6 mRNA
levels by 40% compared with the non-targeting control (Fig.
FIGURE 3. Long-term stableMMP-8 overexpression also causes an up-regulation of IL-6 and IL-6 protein andmRNA expression that is dependent on
the catalytic activity of MMP-8. Two independent clones of MDA-MB-231 cells stably transfected with pcDNA4 empty vector, wild-type MMP-8, and E198A
mutant MMP-8 were analyzed. Top panel, ELISA measurements of IL-6 and IL-8 protein levels in serum-free conditioned media collected 24 h after serum
starvation. Lower panel, RNA quantification by real-time TaqMan RT-PCR of IL-6 and IL-8 mRNAs in the same cells. Both wild-type MMP-8 clones 1 and 2
were different compared with all other cells by at least p 0.05 or p 0.01 unless shown otherwise *, p 0.05; **, p 0.01; ***, p 0.001. EA, E198A
mutant MMP-8.
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5A). In contrast, knockdown of IL-6 had no effect on IL-8
mRNA expression compared with the non-targeting control
siRNA (Fig. 5B). In separate experiments, human recombinant
IL-6 and IL-8 were added to parental MDA-MB-231 cells for
24 h, and the expression level of MMP8 determined by RT-
PCR. Addition of IL-8 alone did not affect expression of IL6
(data not shown) or MMP8 mRNAs, but recombinant IL-6
induced endogenous MMP8 expression by 20% (Fig. 5C).
Taken together, these data suggest that MMP-8, IL-6, and IL-8
may constitute a self-reinforcing loop. MMP-8 can induce
expression of IL-6 and IL-8 in short-term exposure to the pro-
tease, and IL-8 reinforces IL-6 expression, whereas the induced
IL-6 may augment MMP8 expression. In the long-term WT
MMP-8 clones, where IL-6 and IL-8 production is no longer
dependent uponMMP-8, IL-8may help to sustain elevated IL-6
expression.
IL-6 and IL-8 Expression in Long-term MMP-8-expressing
Cells Is Dependent on NF-B Signaling and PAR2 Is Linked to
IL-6 Expression—We explored the effects of pharmacological
inhibition of major cell signaling pathways to determine the
relevance of the particular pathways to the increased expres-
sion of IL-6 and IL-8 in the long-termWTMMP-8-expressing
MDA-MB-231 cells. The inhibitors used and their target
pathways were as follows: PD0325901 and U0126 (MAPK-Erk
pathway), SB203580 (p38), wortmannin and PI-103 (PI-3K),
bisindolylmaleimide 1 (PKC), SP600125 (JNK), BAY 11-7082
(NF-B), and SB431542 (TGFR1).Of the inhibitors examined,
only the NF-B inhibitor BAY 11-7082 reduced secretion of
both IL-6 and IL-8 by 60% compared with the vehicle control in
the cells overexpressing wild-type MMP-8 (Fig. 6A). The
TGFR1 inhibitor SB431542 had no effect onMMP-8-induced
IL-6 levels, but IL-8 levels were increased by 100% in the WT
MMP-8 overexpressing cells, and the control EV and E198A
mutantMMP-8-expressing cells also showed a slight induction,
showing that TGF signaling is inhibitory to IL-8 production in
MDA-MB-231 cells (Fig. 6B).
We also considered the possible involvement of protease-
activated receptor (PAR) signaling becauseMMP-1 is known to
cleave and activate PAR-1 (26–28). However, PAR-1 was not
expressed by the parental MDA-MB-231 cells or the WT
FIGURE 4. Wild-type MMP-8 reduces colony formation of MDA-MB-231 cells, and expression is shut down by cells. A, colonies visible by 20 days
post-transfection stained with methylene blue. The control well consisted of cells that were untransfected and so died under zeocin selection as a control for
cell death. EA, E198Amutant. B, Western blot analysis using an anti-MMP-8 antibody on 20 concentrated serum-free conditionedmedia, tracking the loss of
expressionofwild-typeMMP-8 fromstably transfectedMDA-MB-231 cells. Threepools ofwild-typeMMP-8 stables (1–3), were culturedalongside apool of cells
transfected with the control vector, and E198A mutant MMP-8 were maintained with () or without (-) zeocin selection. Top panel, cells 7 weeks post-
transfection. Bottompanel, cells 11weeks post-transfection. The positive control usedwas conditionedmedia fromHEK-293T cells transiently transfectedwith
WT MMP-8. *, p 0.05; **, p 0.01; ***, p 0.001.
FIGURE5.MMP-8, IL-6, and IL-8exist aspart of an interconnected regulatory circuit.A, RNAquantificationby real-timeTaqManRT-PCRof IL-6mRNA levels
inWTMMP-8 overexpressingMDA-MB-231 cells after siRNA knockdownof IL-6 or IL-8 for 48 h. B, RNAquantification by real-time TaqMan RT-PCR of IL-8mRNA
levels in WT MMP-8 overexpressing MDA-MB-231 cells after siRNA knockdown of IL-6 or IL-8 for 48 h. C, RNA quantification by real-time TaqMan RT-PCR of
endogenousMMP-8 in naïve, non-transfectedMDA-MB-231 cells treatedwith recombinant human IL-6 and IL-8 for 24 h. *, p 0.05; **, p 0.01;***, p 0.001;
ns, not significant.
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MMP-8-expressing clones (data not shown). The G protein-
coupled receptor PAR-2 was considered because it is expressed
by epithelial cells (29) and neutrophils (30), has a role in neu-
trophil migration (31), and has reported involvement in IL-6
and IL-8 up-regulation and secretion (31–33). We observed
that PAR-2 expression was consistently up-regulated in the
long-term WT MMP8-expressing MDA-MB-231 cells (Fig.
6C). Knockdown of PAR-2 by siRNA reduced IL-6 protein and
mRNA expression by 90 and 60%, respectively, in the WT
MMP-8 expressing cells but had the reverse effect on IL-8
expression, causing an approximate 80% increase in both RNA
and protein levels (Fig. 6D). The schematic in Fig. 6E summa-
rizes the relationships between MMP-8, IL-6, and IL-8 under
acute and long-term exposure of breast cancer cells to catalyt-
ically active MMP-8 and to PAR-2 and TGF- signaling.
DISCUSSION
Matrix metalloproteinase 8 was the first member of the
MMP family that was revealed to be tumor- or metastasis-sup-
pressive in vivo (6, 7, 13). Subsequently,MMP-8 expressionwas
found to be amarker of a lower incidence of lymph nodemetas-
tasis and, consequently, to confer a better prognosis in human
breast carcinoma (9). It has also been found to be protective in
cancer of the tongue (10). In human melanoma, function-inac-
tivating mutations in MMP8 have been found at high fre-
quency, and wild-type but not mutant forms suppressed tumor
formation in soft agar assays, supporting its role as a tumor
suppressor (34). This study extends these findings using a series
of human mammary carcinoma cell lines, where we demon-
strate that transient expression of catalytically active WT
MMP-8, but not an inactive E198A mutant form, induced the
expression of IL-6 and IL-8. However, sustained expression of
WT MMP-8 was deleterious to breast cancer cell growth in
colony formation assays, and, upon extended culture, the exog-
enous MMP8 expression cassette was silenced in most cell
pools, accompanied by a coordinate reduction in IL-6 and IL-8
expression. In a few instances, stable WT MMP-8-expressing
FIGURE 6. Both IL-6 and IL-8 up-regulation occurs via NF-B, but IL-8 is
also negatively regulated by TGF and PAR-2. A, ELISA measurements of
IL-6 and IL-8 protein levels after incubation of MDA-MB-231 clonal isolates
stably transfected with pcDNA4 empty vector, wild-type MMP-8, and E198A
mutant (EA) MMP-8 after incubationwith 10MBAY 11-7082, anNF-B inhib-
itor, for 48 h. DMSO, dimethyl sulfoxide. B, ELISA measurements of IL-6 and
IL-8 protein levels after incubation of MDA-MB-231 clonal isolates stably
transfectedwith pcDNA4 empty vector, wild-typeMMP-8, and E198Amutant
MMP-8 after incubation with 10 M SB431542, a TGFR1 inhibitor, for 48 h.
C, RNA quantification by real-time TaqMan RT-PCR of PAR-2 in MDA-MB-231
clonal isolates stably transfected with pcDNA4 empty vector, wild-type
MMP-8, and E198A mutant MMP-8. D, top panel, Western blot analysis and
RNA quantification by real-time TaqMan RT-PCR of PAR2 to confirm the
knockdown of PAR-2 after siRNA knockdown for 48 h in wild-type MMP-8
overexpressing MDA-MB-231 clonal isolate 1. Center panel, RNA quantifica-
tion by real-time TaqMan RT-PCR of IL-6 and IL-8 in cells after PAR-2 siRNA
knockdown. Bottom panel, ELISA measurement on serum-free conditioned
media of IL-6 and IL-8protein levels after PAR-2 siRNAknockdown. *,p0.05;
**, p  0.01, ***, p  0.001; ns, not significant. E, schematic showing the
relationships between MMP-8, IL-6, and IL-8 in a self-reinforcing loop and
pathways that may contribute to this system in breast cancer cells. On acute
exposure to catalytically activeWTMMP-8, breast cancer cells up-regulate the
expression of IL-6 and IL-8 (black lines and arrows). IL-6 is also able to induce
MMP-8 expression. Red lines and arrows show the pathways that are evident
in breast cancer cells that adapt to long-term expression of WT MMP-8. Not
shown on the diagram is that IL-6 and IL-8 expression is also dependent on
NF-B signaling, which may be activated by PAR-2 as well as other signaling
pathways, including autocrine loops resulting from IL-6 and IL-8 induction.
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clones ofMDA-MB-231 cells were obtained, and these retained
elevated IL-6 and IL-8 production, although we infer that addi-
tional genetic or epigenetic changes had likely occurred in these
cells because their IL-6/IL-8 expression levels were no longer
dependent upon MMP-8. Instead, increased IL-6 levels may in
part be due to the action of IL-8 acting in an autocrine fashion
and also to PAR-2, which was found to be up-regulated in the
long-termWTMMP-8-expressing cells.
We detected increased levels of IL-6 and IL-8 proteins by
ELISA in conditioned media of MCF-7, MDA-MB-231, and
SK-BR-3 breast carcinoma cells transfected transiently with
WTMMP-8, indicating that the response is likely a general one
and not restricted to cancer cells that have a particular estrogen
receptor status or amplified HER2. The effects on IL-6 and IL-8
were specific because we saw no increases in several other
inflammatory mediators, including TNF, IL1, IL-10, and
IL-12p70. It is known that MMP-8 carries out N-terminal pro-
cessing of IL-8 and its murine ortholog LIX, leading to activa-
tion of the chemokines and increasing their neutrophil che-
moattractant activity in vivo (19). We considered that MMP-8
might thus have led to increased detection of IL-6 and IL-8
proteins in cell-conditioned media through proteolytic cleav-
age of precursor or cell-associated forms of these molecules.
We cannot rule this out as a contributory factor, but because
the increased protein levels were reflected in increased IL6 and
IL-8 mRNA abundance in WT MMP-8-transfected cells, we
conclude that the principal effect of the protease is at the level
of induction of gene transcription. A normal immortalized
mammary epithelial cell line (HMT-3522 S1) showed no effect
of WT or E198A mutant MMP-8 on the production of the
interleukins, indicating that malignant transformation is a pre-
requisite for induction.
Interleukins 6 and 8 are well established as tumor-promot-
ing, proinflammatory factors in numerous cancer scenarios (35,
36). Interleukin 6 acts via the membrane-bound or soluble IL-6
receptor, which binds the cytokine and then interacts with the
gp130 signaling receptor, leading to activation of downstream
pathways, including the JAK-1-STAT-3pathway,MAPkinases,
and NF-B (37). Activation of IL-6 secretion, for instance via
HER2 amplification, creates an autocrine signaling loop involv-
ing JAK-1/STAT-3-mediated IL-6 expression (38). Also, Src-
mediated transformation of mammary epithelial cells has been
shown to involve IL-6 acting in a positive feedback loop via
activation of NF-B (39). The IL-8 chemokine activates multi-
ple pathways following its engagement with two G protein
receptors (CXCR1 and CXCR2), leading to the promotion of
the proliferation, survival, and migration of cancer cells (36).
Recently, both IL-6 and IL-8 have also been shown to regulate
breast cancer stem cell renewal (40, 41). Therefore, it appeared
paradoxical to us that MMP-8, on the basis of its history as an
antitumorigenic protease, would elicit the production of factors
that have profoundly protumorigenic actions. Two points are
critical for consideration, however, the first being the impact of
MMP-8 on innate immunity and the role of the innate immune
response in tumor progression and the second being the dis-
tinction between early, acute effects of catalytically active
MMP-8 upon breast cancer cells and how cells cope with sus-
tained production of the protease.
Neutrophils are the first wave of innate immune cells that are
recruited to sites of acute inflammation. These triggered neu-
trophils release and autoactivate pro-MMP-8 from the specific
granules, which then acts upon LIX (mouse) and IL-8 (human),
enhancing further neutrophil chemotaxis in a feed-forward
mechanism (19). The systemic absence ofMMP-8 inMmp8/
mice has profound effects on inflammation, the outcomes of
which depend on the tissue site and the nature of the inflam-
mation. In carcinogen-induced skin tumors or in skin wounds
there is a delay in neutrophil infiltration at early times in
Mmp8-null versuswild-type mice, but this eventually leads to a
persistent accumulation at later time points, which exacerbates
tumor development (6) and impairs wound repair (20). This is
also evident in the more severe alveolar bone loss inMmp8/
mice comparedwith thewild type inPorphyromonas gingivalis-
induced periodontitis (16, 42) and in LPS-induced corneal
inflammation (43). In all of these situations,MMP-8 is required
to promote both the initial onset and the subsequent clearance
of the inflammatory neutrophilic response. In some tissues,
such as the lung and the liver, the absence of MMP-8 and the
attendant initial reduction in neutrophil influx and reduced
chemokine activation can be protective, as has been observed in
models of ventilator-induced injury in the lung (15), bleomy-
cin-induced lung fibrosis (14), and TNF-induced lethal hepa-
titis (44). All of these situations are accompanied by alteration
of the levels of numerous chemokines and cytokines, including
reduced levels of LIX (15, 42, 44). Thus, the induction of IL-6
and IL-8 expression attributable to the catalytic activity of
MMP-8 in breast cancer cells is consistent with a role for
MMP-8 in the initial triggering of an acute inflammatory
response. Within the microenvironments of emerging tumors,
this activation may set in motion subsequent macrophage-de-
pendent and adaptive immune system responses that act to
resolve inflammation and suppress tumor progression (45).
One of the most important points to emerge from this study
is that sustained, elevated expression of MMP-8 by breast can-
cer cells eventually impaired their growth. This did not occur as
an acute response toWTMMP-8 because we saw no apprecia-
ble effects on cell growth or apoptosis over the 3–4 days during
which cells were expressing the proteins following transient
transfection (although subtle effects may be hard to detect in
transient assays). Instead, the growth-suppressive effect ofWT
MMP-8 was apparent in longer-term colony formation assays.
Palavalli and colleagues (34) also saw no effect on short-term
growth of culturedMel-STRmelanocytes following expression
of human WT MMP-8, but there was substantial inhibition of
colony growth in soft agar. These effects on growth were not
apparent in an earlier study that had transfected a mouse
Mmp8 expression vector into murine B16-F10 cells, so it is
possible that the growth effects may be species-specific (9). In
our experiments, serial passage of transfected breast MDA-
MB-231 carcinoma cells expressingWTMMP-8 led, over time,
to a progressive loss of expression of the protease. This was not
observed for cells expressing the E198A catalytically dead
mutant, indicating that it was a result ofMMP-8 protease activ-
ity. The suppression occurred even when the cells were main-
tained under continuously enforced zeocin selection. We con-
firmed that the fullMMP8 expression cassette was retained in
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these cells, indicating that expression was likely lost through
epigenetic silencing. A comprehensive analysis of the transcrip-
tional status of the entire MMP family in relation to their epi-
genetic parameters (DNA methylation, histone modifications,
and microRNAs) identified MMP8 as displaying strict epige-
netic silencing in multiple cancer cell lines, consistent with its
antitumorigenic role (46). In our long-term MDA-MB-231
transfected cell cultures, loss of expression of WT MMP-8
coincided with a return to base-line levels for the expression of
IL-6 and IL-8, which further supports a causal connection
between MMP-8 and the elevated expression of the inflamma-
tory mediators.
In the rareMDA-MB-231 clones that gave sustained elevated
expression of WT MMP-8, although IL-6 and IL-8 levels were
also maintained, the expression of the interleukins was no lon-
ger dependent on the presence of MMP-8 because neither
siRNA-mediated knockdown of MMP-8 nor treatment with
DL-111, an MMP-8-selective inhibitor, attenuated their
expression.We infer from these data that IL-6 and IL-8may act
to overcome the growth-suppressive effects of WT MMP-8.
However, these factors possibly act togetherwith other growth-
regulatory factors whose expression is sensitive toWTMMP-8
because their combined knockdown did not decrease cell
growth in short-term assays (data not shown). We do not yet
know the identities of the molecules that confer the continued
ability of breast cancer cells to grow while expressing catalyti-
cally active MMP-8. It is clear from our knockdown experi-
ments that IL-8 is, at least in part, responsible for the sustained
expression of IL-6. Data from other groups support an auto-
crine feedback loop for IL-6 in breast cancer cells involving
NF-B signaling linked to control of IL-6 expression through
the microRNAs let-7 (39) and miR-200c (47). Consistent with
this we see a dependence of both IL-6 and IL-8 production on
NF-B signaling. We therefore speculate that IL-6 and IL-8
create a self-reinforcing loop that allows the MDA-MB-231
cells to continue growth independently of the inhibitory action
of MMP-8.
It has been observed previously that the delayed wound heal-
ing seen in Mmp8/ mice correlated with reduced levels of
active TGF-1 (20). Altered TGF signaling could contribute
to the WTMMP-8-mediated up-regulation of IL-8 expression
we have observed because IL-8 levels were enhanced in MDA-
MB-231 cells by pharmacological inhibition of TGF signaling.
Another potential contributory mechanism for the sustained
growth of WTMMP-8-expressing MDA-MB-231 cells may be
the increased expression of PAR-2 that we observed in these
cells compared with cells expressing the E198A mutant
MMP-8. Protease-activated receptor 2 is a widely expressed
member of the PAR family of G-protein-coupled receptors that
is known to be activated by several serine proteases, including
trypsin andmatriptase, leading to activation ofNF-B signaling
(48, 49). Knockdown of PAR-2 expression in the WTMMP-8-
expressing cells led to a reduction of IL-6 production, but, in
contrast, this led to a further augmentation of IL-8 expression.
Although MMP-1 (collagenase 1) is known to cleave and acti-
vate PAR-1 (26–28), we have no evidence to suggest that
MMP-8 is acting directly through PAR-2. Indeed, as discussed
above, in the long-term WT MMP-8-expressing clones, IL-6/
IL-8 are decoupled fromMMP-8 action. It is possible, however,
that among the genetic/epigenetic changes during clonal evo-
lution that have allowed MDA-MB-231 cells to tolerate WT
MMP-8 may be the increased production of proteases that act
through PAR-2. However, this likely contributes only to the
IL-6 expression status because PAR-2 negatively regulates IL-8
expression (Fig. 6E).
In conclusion, therefore, our experiments reveal a novel
action of catalytically active MMP-8 in breast cancer cells that
results in increased production of key regulators of tumor
growth and inflammation, IL-6, and IL-8. These effects occur
upon acute expression of the enzyme and are not apparent in
non-transformed mammary epithelial cells, suggesting that
theymay be linked with tumor progression. Although the iden-
tities of the MMP-8 substrates that are the direct mediators of
its effects on growth and the expression of the inflammatory
mediators remain to be firmly established, our data implicate
the involvement of bothTGF- and PAR-2-mediated signaling.
We suggest that the induction of proinflammatory mediators
such as IL-6 and IL-8 is relevant to the mechanisms by which
MMP-8 orchestrates the onset and resolution of inflammation
in vivo in tumors and during tissue repair.
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